



THE ARTHRITIS RESEARCH CANADA
BOARD MEETING – SEPTEMBER 19, 2024
ANNUAL REPORT OF THE SCIENTIFIC DIRECTOR

TRAINEES

New Trainees

Manuel Ester (Supervisor: **Claire Barber**) joined Arthritis Research Canada Calgary as a new Post-Doctoral fellow. Dr. Ester has a PhD in Kinesiology from University of Calgary and his initial project is focusing on evaluating a new model of care consisting of patient-initiated follow-up for rheumatology care. He is also working on another exercise-related study.

Maribeth Anne (Fortune) Gelisanga, (Supervisor: **Linda Li**) joined Arthritis Research Canada Vancouver as a new Master's student in the Department of Physical Therapy at UBC.

Racheal Githumbi (Supervisor: **Claire Barber**) started as a new PhD student in epidemiology at the University of Calgary. She is a current research associate and is leading the learning health system work at the University of Calgary.

Derin Karacabeyli (Supervisor: **Diane Lacaille**) started his Clinician Investigator Program in July 2024 after completing his Rheumatology clinical training and is enrolled in a Master's program in Experimental Medicine at UBC starting in September 2024, with plans to transfer to a PhD. His research interest focuses on obesity management in people with arthritis.

Judith Jade (Supervisors: **Antonio Avina-Zubieta**, **Kun Huang**, Fergus To) joined Arthritis Research Canada Vancouver from the UK to pursue a Clinical and Research Fellowship in Myositis in the UBC Division of Rheumatology.

Tosin Ogunleye (Supervisor: **Claire Barber**, Co-supervisor: Stephanie Garner) started as a new PhD student in Epidemiology at University of Calgary. Her thesis research will focus on Giant Cell Arteritis, a type of vasculitis.

Trainees who completed their degrees

Lulu Guo (Supervisor: **Hui Xie**) successfully defended her PhD thesis entitled, "*Complier Average Causal Effect Estimation in Randomized Controlled Trials with Multiple Endpoints and Treatment Noncompliance*". In August 2024, Dr Guo started a Postdoctoral Fellowship in the Data Science Program at Harvard University and the

Dana-Farber Cancer Institute. Building on her doctoral work, she will apply adaptive clinical trial designs for biomarker validation studies.

Alyssa Howren (Supervisor: **Mary De Vera**) successfully defended her PhD thesis on December 12, 2023. Her thesis was entitled *“Exploring Health Care Encounters and Treatments for Mental Disorders in Individuals with Inflammatory Arthritis: Epidemiologic and Health Services Research Studies”*. She is now pursuing a post-doctoral fellowship in epidemiology at Stanford University with Dr Julia Simard.

Bocheng Jing (Supervisor: **Hui Xie**) successfully defended his PhD thesis in January 2024. His thesis was entitled *“Local Sensitivity to Nonignorable Missingness in the Overdispersed Count Outcome Using Negative Binomial Model”*.

Gloria Li (Co-Supervisors: **Antonio Avina-Zubieta** and Mahyar Etminan) successfully defended her PhD thesis on March 25, 2024. Her thesis was entitled *“Evaluating the association between anti-TNF-alpha treatment and multiple sclerosis in autoimmune conditions: insights from health administrative data and methodological challenges”*. She will be pursuing a post-doctoral fellowship at the university of California in San Francisco (UCSF) with Dr. Jinoos Yazdany to further develop skills applying artificial intelligence to epidemiology studies. She received a 3-year CIHR Postdoctoral fellowship for her project *“Liver Toxicity Monitoring in Users of Disease-Modifying Antirheumatic Drugs: Use of Real-World Data to Examine Patient Safety Errors and Predict Adverse Events”*.

Darren Mazzei (Supervisor: **Deborah Marshall**) successfully defended his PhD thesis on December 12, 2023. His thesis was entitled *“The Need, Value and Affordability of First-line Treatments for Hip and Knee Osteoarthritis in Alberta”*.

Maureen O’Brien (Supervisor: Ranita Manocha, Co-supervisor **Cheryl Barnabe**), successfully defended her Master’s thesis on July 26, 2024. Her thesis was entitled *“The Feasibility and Usability of a Novel Tool for Learning and Reviewing Walking Aid Skills: A Multi-Method Study”*.

Thalia Otamendi (Supervisor: **Linda Li**) successfully defended her PhD thesis in November 2023 Her thesis title was *“The Role of Illness Perceptions in Mental Health Treatment-seeking and Outcomes After Mild Traumatic Brain Injury”*.

Tita Szlachetka (Supervisor: **Diane Lacaille**), successfully defended her Master’s thesis on August 15, 2024. Her thesis was entitled *“Cognitive Function in People with Rheumatoid Arthritis.”*

Linda Truong (Supervisor: **Jackie Whittaker**) successfully defended her PhD thesis, on September 28, 2023. The title of her thesis was *“It Takes a Village: The Role of Social Support During Recovery from Sport-related Knee Injuries”*. She is pursuing a Post-Doctoral Fellowship in the Department of Physical Therapy at UBC.

Summer Students

Zanir Bhanji (Supervisor: **Cheryl Barnabe**) was a summer student at Arthritis Research Canada Calgary, His project title was *“Acuity of Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: A Population-Based Study”*.

Gracie Burns (Supervisor: **Alex Legge**) was a CRA summer student at Arthritis Research Canada Halifax. She is a medical student at Dalhousie University entering her second year. Her project was entitled *“Developing and Evaluating a Laboratory-based Frailty Index (FI-Lab) for the Prediction of Long-Term Health Outcomes in Systemic Lupus Erythematosus”*.

Laurie Champagne and **Lisa Hannane** (Supervisor: **Laëtitia Michou**) were summer students at l’Université Laval working on a project entitled *“Study of cardiovascular events and vascular calcifications in Paget’s disease of bones.”*

Timothy Cheng (Supervisor: **Diane Lacaille**) was a Summer Coop student at Arthritis Research Canada Vancouver. He was involved in conducting a *survey to people with rheumatoid arthritis to understand risk factors for complications of inflammation in people with rheumatoid arthritis, as part of the PRECISION study.*

Ciana Sudheer (Supervisor: **Cheryl Barnabe**) was a summer student at Arthritis Research Canada Calgary. Her project title was *“Specific-Cause Hospitalizations for Psoriatic Arthritis, Ankylosing Spondylitis, and Gout Patients: A Systematic Review”*.

Alandra Ward (Supervisor: **Cheryl Barnabe**) was a summer student at Arthritis Research Canada Calgary. Her project title was *“A Systematic Review of the Proportions and Rates of Specific Cause Hospitalizations in People with Rheumatoid Arthritis”*. She was awarded the 1st place prize for her poster presented at the McCaig Institute Summer Student Symposium, Aug. 14th, 2024.

Michael Wu (Supervisor: **Diane Lacaille**) is an internal medicine resident who worked on research project over the summer at Arthritis Research Canada Vancouver. He is conducting a *scoping review on the use of virtual care in rheumatology.*

Trainee Salary Awards

Nicole Andersen (Supervisor: **Deborah Da Costa**) was awarded \$21,875 from the Canadian Institutes of Health Research for her Master’s in Clinical Counselling, Psychology. Her Master’s thesis project will evaluate *“the adaptation of an online program to improve sleep for people living with arthritis”*.

Vienna Cheng (Supervisor: **Mary De Vera**) received a MITACS Accelerate award of \$45,000 over 12 months for her Master's in Pharmaceutical Sciences. The title of her project is *"Targeted synthetic and biosimilar disease modifying antirheumatic drugs in pregnancy: Patterns of use among females with rheumatic diseases and outcomes"*.

Kasra Moolooghy (Supervisor: **Diane Lacaille**) received a MITACS Accelerate award of \$45,000 over 12 months for his Master's in Experimental Medicine. The title of his thesis project is *"Comparing the risk of adverse events across different classes of biologics prescribed for inflammatory arthritis"*.

Codie Primeau (Supervisor: **Linda Li**) was awarded a three-year, \$150,000 the Arthritis Society Postdoctoral Fellowship Salary Award for his project *"Exploring the Lived Experiences of Sexual and Gender Minority Populations Living with Arthritis: A Patient Engagement Centered Approach"*.

Codie Primeau (Supervisor: **Linda Li**) was selected for a prestigious two-year \$140,000 Canadian Institutes of Health Research Banting Post-Doctoral Fellowship for his research entitled, *"Leveraging Citizen Science for Inclusive Pain Research: Maximizing Public Engagement for Co-Developing Research Questions with Sexual and Gender Minority Communities"*.

Nevena Rebic (Supervisor: **Mary De Vera**) received the UBC Andrew Nord Fellowship in Rheumatology Masters Award of \$14,666.67 for the 2023 academic year.

Jocelyn Thomas (Supervisor: **Glen Hazlewood**) received a trio of salary awards to support her PhD for her project: *"Moving towards the personalization of treatment choices in rheumatoid arthritis: Combining clinical modelling strategies to personalize risk estimates"*.

- 1) A three-year, \$52,500 PhD Salary Award from the Arthritis Society;
- 2) A one-year, \$12,000 University of Calgary Alberta Graduate Excellence Scholarship Award. The award "recognizes outstanding academic achievement of students pursuing graduate studies in Alberta";
- 3) A one-year \$35,000. CANTRAIN-CTTP Doctoral Studentship 2023 Award. CANTRAIN is a new CIHR-funded clinical trials training program.

Trainee Other Award and Honours

Deniz Bayraktar (Supervisor: **Linda Li**), who completed his visiting professorship at UBC in June 2024, was promoted to Associate Professor at his home university, Izmir Katip Celebi University in Izmir, Turkey, in April 2024.

Derin Karacabeyli (Supervisor: **Diane Lacaille**) received the 2024 Experimental Medicine Entrance Award of \$5,000 from the UBC Faculty of Medicine.

Derin Karacabeyli (Supervisor: **Diane Lacaille**) received the Phil Rosen Award for the Best Abstract on Clinical or Epidemiology Research by a Trainee at the Canadian Rheumatology Association Annual Meeting.

Natalie McCormick (Supervisor: **Hyon Choi**) was awarded the new ACR Emerging Investigator Excellence Award for the Metabolic & Crystal Arthropathies – Basic & Clinical Science category, for her abstract on premature mortality in gout.

FACULTY

New Appointments

Deniz Bayraktar was appointed an Arthritis Research Canada Affiliate Scientist in June 2024. His research focuses on improving rehabilitation outcomes in patients with juvenile idiopathic arthritis and adult-onset inflammatory arthritis.

Kun Huang was appointed an Arthritis Research Canada Clinician Investigator in September 2023. Her clinical expertise and research is in a group of diseases of the muscles called auto-immune inflammatory myositis.

Hyein Kim was appointed an Arthritis Research Canada Clinician Investigator in June 2024. Her clinical expertise and research interest is in scleroderma and interstitial lung diseases associated with connective tissue diseases.

Valerie Leclair was appointed an Arthritis Research Canada Research Scientist in March 2024. She specializes in research into autoimmune inflammatory myopathies.

Wei Zhang was appointed an Arthritis Research Canada Research Scientist in October 2024. Her research focuses on the measurement and valuation of productivity loss, as well as the economic evaluation of health care interventions and health policy related to pharmaceuticals.

Scientific Awards

Cheryl Barnabe is the Principal Investigator on a two-year \$25,000 University of Calgary Cumming School of Medicine Clinical Research Fund (CRF) Grant entitled *“Implementation and Evaluation of Shared Decision-Making Strategies with Indigenous Peoples for Rheumatoid Arthritis Treatment”*.

May Choi was awarded a three-year \$375,000 The Arthritis Society Stars Career Development Award for her project *“CLIMB: Complement activation Levels and Interferon activity as novel Myositis Biomarkers”*.

Mary De Vera is the Principal Investigator on a one-year \$69,094 Canadian Institutes of Health Research Catalyst Grant that will analyse survey data from the Canadian Longitudinal Study of Aging (CLSA) for a study entitled “*Applying an equity and intersectionality lens to understanding the burden of arthritis on aging Canadians (APPROACH)*”. Co-Investigators include **Cheryl Barnabe**, **Antonio Avina-Zubieta**, Niloofar Gheshlaghi, **Mark Harrison**, Preet Kang, and **Megan Thomas**.

Marie Hudson is a Co-Applicant along with Anna Naumova and Carolyn Brown on a three-year \$376,610, Strategic Operating Grant from The Arthritis Society entitled “*X-inactivation in rheumatoid arthritis and impact on sex-specific disease risks*”. Celia Greenwood is the Principal Investigator. **Ines Colmegna**, Sasha Bernatsky, Kathleen Oros Klein and Liam O’Neil are Collaborators on the project.

Marie Hudson is the Principal Investigator on a three-year, \$450,000 Strategic Operating Grant from The Arthritis Society entitled “*Identification of immune signatures of rheumatic immune-related adverse events secondary to immune checkpoint inhibitors*”. Co-Investigators include **Sabrina Hoa**, Wilson Miller, Réjean Lapointe, Sonia Del Rincon and Khashayar Esfahani.

Linda Li is a Co-Principal Investigator and **Alison Hoens** is a Co-investigator on a one-year Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis (CIHR-IMHA) Inclusive Research Excellence Prize – for the Patient Engagement category, entitled “*Listening to Patient Partners - From developing evidence-based tools for advancing meaningful patient engagement in research to now implementing them at an international organization for rheumatology research*”. Clayton Hamilton, a prior Arthritis Research Canada trainee, is the Nominated Principal Investigator and Peter Tugwell another PI. Other Co-investigators include Dorcas Beaton, Catherine Hofstetter, Lara Maxwell and APAB members **Annette McKinnon**, and **Shanon McQuitty**.

Linda Li is a Co-Principal Investigator along with Cindy Bartha and Liisa Galea on a one-year, \$100,000 Priority Announcement from the Institute of Aging of The Canadian Institutes of Health Research for her project grant entitled “*EPIC Health: Exercise in Perimenopause to Improve Cognitive Health*”. Teresa Liu-Ambrose is the Nominated Principal Investigator. Co-Investigators include Jennifer Davis, Louis Bherer, Joel Singer and others.

Linda Li is a Co-Investigator on a one-year \$70,000 Canadian Institutes of Health Research Catalyst Grant entitled “*Health or wealth? Socioeconomic status as a moderator of the associations between healthy activity behaviours and cognitive function*”. Teresa Liu-Ambrose is the Principal Investigator.

Linda Li is a Co-Principal Investigator with twelve others on a one-year \$1,380,000 Canadian Institutes of Health Research Operating Grant “*Strategy for Patient-Oriented*

Research (SPOR) Evidence Alliance, Canadian Institutes of Health Research (CIHR),: SPOR – Guidelines and Systematic Reviews”. Andrea Tricco is the Nominated Principal Applicant. There are over 50 Co-Investigators, Collaborators and Knowledge Users on the project.

Linda Li is a Co-Investigator with seven others on a five-years \$489,600 Canadian Institutes of Health Research Grant *“Implementation research to improve scale-up of the delivery of evidence-based community exercise programs for strokes”*.

Jackie Whittaker is Co-Principal Investigator with Lara Boyd on a one-year \$20,000 University of British Columbia Faculty of Medicine, Department of Physical Therapy Research Seed Grant for her project *“How does knee osteoarthritis alter the sensorimotor cortex”*. Master’s student **Chris Lamb** (Supervisor: **Jackie Whittaker**) is a Co-investigator.

Jackie Whittaker is the Principal Investigator on a three-year, \$450,000 Strategic Operating Grant from The Arthritis Society entitled *“Self-managing knee health in young people at high-risk of early-onset osteoarthritis: The MyKnee randomized controlled trial”*. **Linda Li, Hui Xie, Alison Hoens, Jennifer Davis, Amber Mosewich, Maxi Miciak** and **Ewa Roos** are Co-Investigators. **Trish Silvester-Lee** and **Angelina Ko** are Patient Collaborators on the project.

Jackie Whittaker is the Principal Investigator on two applications that received Priority Announcement Funding from the Canadian Institutes of Health Research (CIHR) in the amount of \$100,000 each, for one year, for her project entitled *“The Stop Osteoarthritis (SOAR) Hybrid Effectiveness-Implementation Type 1 Randomized Controlled Trial for Young People at-High-Risk of Early Onset Knee Osteoarthritis”*.

- The first priority announcement funding was from the Institute of Gender and Health + Sports Canada, for her Project Grant. Co-Investigators include Jennifer Davis, **Alison Hoens**, Michael Hunt, **Linda Li, Justin Losciale**, Maxi Miciak, Amber Mosewich, Ewa Roos, Adnan Sheikh, Linda Truong, David Wilson and **Hui Xie**. **Trish Silvester-Lee** is a patient collaborator.
- The second was from the Priority Announcement Funding for Female Athlete Health. Co-Investigators include **Linda Li**, Michael Hunt, David Wilson, Jennifer Davis, **Hui Xie, Linda Truong, Justin Losciale** and **Alison Hoens**.

Jackie Whittaker is a Co-Investigator on a one-year \$28,925 (NZLD) Health Delivery Research Application Grant from the Health Research Council of New Zealand entitled *“Community of practice co-creation of a life-span approach to managing ACL injury*. The Principal Investigator is Richard Ellis.

Hui Xie is the Principal Investigator on a five-year \$105,000 NSERC Discovery Grant entitled *“Knowledge Discovery Using Nonrandom Data Samples”*.

Wei Zhang is the Principal Investigator on a one-year \$70,000 Canadian Institutes of Health Research Catalyst Grant entitled *“Trajectories of work productivity loss: Working from home and insights during COVID-19”*. Co-Investigators include: Monique Gignac, Gary Johns, **Diane Lacaille** and Christopher McLeod. Lin Chen is a Collaborator.

Honours and Appointments

Antonio Avina-Zubieta was presented with the Charles L Christian award for significant advances in understanding lupus at the Lupus 21st Century Meeting in Naples Florida in September 2023. The award goes to an “investigator who has made significant advances in understanding the pathogenesis, impact, or treatment of lupus”.

Catherine Backman was awarded a 2023 Association of Rheumatology Professionals ARP Master award at the American College of Rheumatology meeting in November. The ARP Master Award is one of the highest honors the College bestows. This award is presented to ARP members who have made outstanding contributions to the field of rheumatology through service to the ACR/ARP and advancements in research, practice, education, and/or advocacy.

Megan Barber was awarded the 2023 Future Leader Award by the Alberta Medical Association Section of Rheumatology.

Susan Bartlett was the recipient of the 2024 AHPA Carolyn Thomas Award for an abstract entitled "Specific Symptom Clusters at Diagnosis Signal a Poorer Early RA Prognosis on Methotrexate Treatment: Results from The Canadian Early Arthritis Cohort". This work was also recognized as a podium presentation at the CRA meeting.

Ann Clarke was awarded the 2024 Distinguished Investigator Award at the CRA AHPA Annual Scientific meeting in February 2024. The award is in Recognition of a Distinguished Investigator who has made an outstanding contribution to rheumatology research internationally.

John Esdaile was awarded the 2024 Distinguished Rheumatologist Award at the CRA AHPA Annual Scientific meeting in February. This is the highest-ranking award provided by the Canadian Rheumatology Association. It is given to an accomplished Canadian Rheumatologist of high professional calibre, who has significantly furthered rheumatology in Canada.

Diane Lacaille was awarded the 2024 University of British Columbia Faculty of Medicine Distinguished Achievement Award for Advancement of Equity, Diversity and Inclusiveness in recognition of her contributions to the faculty in this area.

Diane Lacaille was awarded the 2024 University of British Columbia Department of Medicine Martin M. Hoffman Award for Excellence in Research. This honour is awarded to faculty members in recognition of outstanding research and scholarly contributions.

Jackie Whittaker was awarded the 2024 University of British Columbia Faculty of Medicine Distinguished Achievement Award for Overall Excellence – Mid-Career Recipients, in recognition of her research and scholarly contributions to the faculty.

Arthritis Research Canada Trainees Day and Scientific Retreat

May 1 – 3, 2024

In total 18 Researchers and 24 trainees from Halifax, Laval, Calgary and Vancouver attended the Annual Trainee Day and Scientific Retreat, with several more participating online. The Trainee’s Day included an Arthritis Patient Advisory Board panel on *“Patient involvement in research”* with other workshops focused on obtaining research funding. **Linda Li** presented on *“Answering your 7 questions about grant writing”* and **Mary De Vera** facilitated an interactive workshop on *“All about peer review”*.

May Choi kicked off the first day of the Retreat with her Keynote presentation *“AI-Powered Precision Medicine as an Approach to Autoimmune Diseases”*. Other highlights were an interactive workshop with **Monika Szpunar** on *“Creating an infographic”* for disseminating research results, and the inaugural ‘Three-Minute-Thesis’ competition with **Chris Lamb** (Supervisor: **Jackie Whittaker**) receiving the audience favourite award for his 3MT presentation *“Brain sensorimotor changes associated with symptomatic knee osteoarthritis”*

The retreat closed with the Distinguished Guest Lecture by **Pauline Hadley-Beauregard** at the Friday luncheon, *“Leading with ‘Why’: Why brand matters”*.

Signed:



Diane Lacaille, MD, MHSc, FRCPC
Mary Pack Chair in Rheumatology Research,
Scientific Director, Arthritis Research Canada/Arthrite-recherche Canada
Professor of Medicine, University of British Columbia

Appendix I

FUNDING FROM JULY 1, 2023 TO JUNE 30, 2024

AIHS - Alberta Innovates Health Solutions; CAN - Canadian Arthritis Network; CIORA - Canadian Initiative for Outcomes in Rheumatoid Arthritis; CIHR - Canadian Institutes of Health Research; CRA - Canadian Rheumatology Association; CHHM - Centre for Hip Health and Mobility; HSFC - Heart and Stroke Foundation of Canada; EULAR - European League Against Rheumatism; MSFHR - Michael Smith Foundation for Health Research; NCI - National Cancer Institute; NIH - National Institutes of Health; NCE - Networks of Centres of Excellence; TAS - The Arthritis Society;; UBC - University of British Columbia; SPARTAN - Spondyloarthritis research and treatment network ; SRCC - Spondyloarthritis Research Consortium of Canada

SCIENTIST FUNDING - Operating Grants

| PI(s) | Co-I(s) | Title | Funding Agency | Annual Amount | Total Awarded | Start Date | End Date |
|------------------------------------|---|--|----------------|---------------|---------------|------------|----------|
| Abrahamowicz M | JA Aviña-Zubieta , S Bernatsky, A Bérard, W Dixon, M. Durand, L Eder, S Ferreira Guerra, D Lacaille , S Perreault, L Pilote, R Sapir-Pichhadze, R Tamblyn, J Widdifield, G Yi | New statistical methods for population-based studies of time-varying drug exposures: Development, validation, and real-world analyses of drug safety and effectiveness | CIHR | \$160,650 | \$481,950 | Apr-22 | Mar-25 |
| Bernatsky S, Smargiassi A | M Abrahamowicz, J Aviña-Zubieta , P Awadalla, H Chen, T Dummer, M Goldberg, S Jean, M Johnson, D Levy, J Spinelli, S Weichenthal, J Widdifield | Air pollution and systemic autoimmune rheumatic diseases | CIHR | \$154,530 | \$772,650 | Oct-18 | Sep-23 |
| Tamblyn R, Totino L | Abrahamowicz A, Bartlett S , Buckeridge D, Lee T, McDonald E, Motusky A, Pupo R, Thavon K, Weir D | Evaluating the effectiveness of Smart About Meds (SAM), a mobile app to improve medication management following hospital discharge | CIHR | \$46,139 | \$184,556 | Apr-22 | Mar-26 |
| Aviña-Zubieta A, Esdaile JM | H Choi , M Dawes, M Etminan, D Lacaille, LC Li , D Maberley, K Shojanian, H Xie | Risk of Retinal Toxicity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Long-term Hydroxychloroquine Therapy | CIHR | \$141,525 | \$707,625 | Mar-19 | Feb-24 |

| | | | | | | | |
|---|---|---|--|--------------|-------------|--------|--------|
| Bernatsky S, Smargiassi A | M Abrahamowicz, J Aviña-Zubieta , P Awadalla, H Chen, T Dummer, M Goldberg, S Jean, M Johnson, D Levy, J Spinelli, S Weichenthal, J Widdifield | Air pollution and systemic autoimmune rheumatic diseases | CIHR | \$128,775 | \$772,650 | Oct-18 | Sep-24 |
| Gomez-Puerta J | R Sanmarti, M G Magaña, JA Aviña-Zubieta , C Carbonell Abella, D Martinez | Disease Burden of Inflammatory Rheumatic Diseases in Cataluña | Spanish Minister of Science and Innovation | \$33,268 | \$66,535 | Apr-22 | Mar-24 |
| MacDermid J, Backman C , Birmingham T, Bouer L, Marshall D , Moyer R, Ronsky J, Roy JS, Thomas A | Knowledge User: K Hofstetter, M Hunt, J Whittaker | Canadian Musculoskeletal (MSK) Rehab Research Network | CIHR | \$399,398 | \$1,996,990 | Jan-20 | Dec-24 |
| Bansback N , Harrison M | Anis A, De Vera M , Clement F, Law M, Beall R | Evaluating the impact of a mandatory switching policy for biosimilars | CIHR | \$33,150 | \$99,450 | Apr-21 | Mar-24 |
| van der Veer S, Dixon W | N Bansback | Transforming outpatient consultations by integrating regular symptom tracking into clinical care: the Remote Monitoring of Rheumatoid Arthritis (REMORA2) study | VERSUS Arthritis UK & NIHR | \$925,000 | \$3,700,000 | Oct-21 | Nov-25 |
| Barber C | Jones CA, Barnabe C, Lacaille D, Hazlewood G , Widdifield J, Wallace Y (pt) | Implementation of the Alberta Rheumatology Provincial Learning Health System | CIHR | \$104,549.67 | \$313,649 | Apr-23 | Mar-26 |

| | | | | | | | |
|--|--|---|-------|--------------|-------------|--------|--------|
| Barber C , Crump T | C Barnabe , E Dempsey, G Hazlewood , A Hoens , S. Katz, J Kopec , D Lacaille , P MacMullan, D Mosher, J Rankin, J Sutherland, K Then | Psychometric evaluation of a measure of care complexity in rheumatoid arthritis | CIHR | \$99,195 | \$297,584 | Sep-22 | Aug-25 |
| Barber C | Hoens A , Manske S, Hazlewood G , Ward R, Lacaille D , Lopatina E , Barber M , MacMullan P, Mosher D, Fifif Ma A, Jung M, Phillips L, Twilt M, Luca N, Then K, Crump T, Osinski K, Job B, Dhiman K, Zafar S, Bhangu G, Subdar S | Development and pilot of a shared-care model for rheumatoid arthritis leveraging an “on-demand” follow-up strategy | CIORA | \$54,898 | \$109,796 | Jul-22 | Jun-24 |
| Barber C | Jones CA , Barnabe C , Lacaille D , Hazlewood G , Widdifield J, Wallace Y (pt) | Implementation of the Alberta Rheumatology Provincial Learning Health System | CIHR | \$104,550 | \$313,649 | Apr-23 | Mar-26 |
| Ahluwalia V, Apple T, Eder L, Laur C, Thorne C, Widdifield J | C Barber , S Bernatsky, G Hawker, C Hofstetter, N Ivers, B Kuriya, L Passalent, P Rochon, L Soever, A Steiman | The Ontario Rheumatology Learning Health System for Transforming Integrated Care for Patients with Rheumatic and Musculoskeletal Disorders | CIHR | \$391,303 | \$1,956,515 | Apr-23 | Mar-28 |
| Beaupre L, Finseth E, Eubank B, Ferguson-Pell M, Sheps D | E Armstrong, C Barber , A Charlton, A Kania-Richmond, J Martyn, P Paul, A Ramadi, J Robert, J Round, C Smith | Using Digital Health to Better Serve Rural Albertans living with Shoulder Pathology: Alberta's Remote Management of ShoUlders Program (ARMS UP) | CIHR | \$264,643.80 | \$1,323,219 | Apr-23 | Mar-28 |

| | | | | | | | |
|---|--|--|---------------------------------------|--------------|-------------|--------|--------|
| Tugwell PS, Welch V | S Ali, C Barber , C Barnabe , A Darzi, O Dewidar, G Hazlewood , A Lee, LC Li, O Magwood, L Maxwell, J Petkovic, B Shea, E Tomlinson, K Toupin-April | Reducing inequitable differences in health outcomes in the treatment of Arthritis | CIHR | \$138,974.67 | \$416,924 | Oct-23 | Sep-26 |
| Barber M | C Barber , A Clarke , L Skieth | Healthcare access and quality of care in Albertan patients with systemic lupus erythematosus and antiphospholipid antibodies/antiphospholipid syndrome | Cumming School of Medicine Seed Grant | \$12,500 | \$25,000 | Apr-23 | May-24 |
| Barnabe C , Healy B, Tailfeathers E, Crowshoe L, Currie C, Fellner K, Henry R, Voyageur C | R Weasel Fat, J Baker, B Bastien, S Chisan, A Greenshaw, R Henderson, A Kennedy, S Kutz, A Loyola-Sanchez, L ManyGuns, T Oosterbroek, M Rock, W Shotyk | Alberta Indigenous Mentorship in Health Innovation Network (AIM-HI Network) | CIHR | \$200,000 | \$1,000,000 | Oct-19 | Sep-24 |
| Barnabe C , Crowshoe L, Bablitz C, Green M, Henderson R, Kennedy A, Montesanti S, Murry A, Roach P, Tailfeathers E | Auger C, Auger J, Baker J, Chowdhury C, Crowshoe T et al | Indigenous Primary Health Care and Policy Research (IPH CPR) Network in Alberta | CIHR | \$700,000 | \$3,500,000 | Oct-19 | Sep-24 |
| Barnabe C | C Barber , C Shukalek | Avoidable Acute Care Use for Inflammatory Arthritis Conditions: Groundwork to Improve Inflammatory Arthritis Health Service and System Quality | CIHR | \$313,649 | \$313,649 | Mar-23 | Feb-24 |

| | | | | | | | |
|---|---|---|---|-----------|-------------|--------|--------|
| Barnabe C | | Implementation and Evaluation of Shared Decision-Making Strategies with Indigenous Peoples for Rheumatoid Arthritis Treatment | University of Calgary Cumming School of Medicine Clinical Research Fund (CRF) | \$12,500 | \$25,000 | Apr-24 | Mar-26 |
| TBA | C Barnabe | Quality of Care for Metis in Alberta Emergency Departments: Co-Creating Understandings and Definitions” | Metis Nation of Alberta | \$104,437 | \$313,310 | Apr-23 | Mar-26 |
| Austen Wiebe VJ, Bill, Kashuba S, MMcLane P, Tailfeathers E | C Barnabe , R Bartel, R Henderson, B Holroyd, A James, K Janvier, J Khangura, M Landry, E Lang, E Louis, R Oster, K Rittenbach, P Roach, T Big Plume, K Foudy | Advancing Anti-Racist and Equity-Oriented Care in the Emergency Department with First Nations Partners | CIHR | \$437,963 | \$1,751,852 | Apr-23 | Mar-27 |
| Boyd S, Cheung A, Morin S | Alexander T, Alos N, Andronowski J, Barnabe C et al (+50) | OsNET: The Canadian Bone Health Research Network | CIHR | \$400,000 | \$1,200,000 | Jul-23 | Jun-26 |
| Emery C | C Barnabe , K Belton, L Benson, A Black, P Elson, R Ferber, P Fuselli, C Goulet, E Brent, M Jordon, S Kenny G Kuntze, C Lebrun, K MacDonald, A Macpherson, DA Marshall, J Whittaker et al | SHRed Injuries: Preventing Injuries and their consequences in youth sport and recreation | CIHR | \$148,493 | \$1,039,450 | Jul-18 | Jun-25 |
| Manske S | C Barnabe, G Hazlewood , P Salat, D Mosher, C Barber , S Barr, R Deardon | Advanced multi-modal imaging to predict early inflammatory arthritis progression | The Arthritis Society | \$124,843 | \$374,530 | 22-Mar | Feb-24 |

| | | | | | | | |
|--|--|---|--|-----------|-----------|--------|--------|
| Benseler S, Haddad E, Yeung R | Morris QD | Precision Decisions in MIS-C: Towards improving outcomes in children with COVID-19 | CIHR | \$229,500 | \$459,000 | Mar-23 | Feb-24 |
| Benseler S, Miettunen P, Esser M | | Efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in juvenile and adult-onset Still's disease and Systemic lupus erythematosus | Swedish Orphan Biovitrum (SOBI) AG | \$119,430 | \$238,859 | Apr-22 | Mar-24 |
| Benseler S, Marshall DA, Wilson J | Celluci T, Currie G, Page S, Stringer E, Swart J, Wulfraat N, Yeung R | Producing an Arthritis Value- framework with economic Evidence - Paving the Way for Rare Childhood Diseases | CIHR | \$150,000 | \$300,000 | Jan-22 | Dec-24 |
| Andrade B, Archibald M, Benchimol E, Birkin C, Chafe R, Chaillet N et al | S Ali, S Anthony, D Beal, A Beaudoin, M Beggs, R Bell, S Benseler et al | Empowering Next-generation Researchers in perinatal and Child Health (ENRICH) | CIHR | \$125,000 | \$500,000 | Jan-22 | Dec-27 |
| Bernatsky S, Smargiassi A | M Abrahamowicz, J Avina- Zubieta, P Awadalla, H Chen, T Dummer, M Goldberg, S Jean, M Johnson, D Levy, J Spinelli, S Weichenthal, J Widdifield | Air pollution and systemic autoimmune rheumatic diseases | CIHR | \$154,530 | \$772,650 | Oct-18 | Sep-24 |

| | | | | | | | |
|---|--|---|---------------------------------------|-----------|-----------|--------|--------|
| Choi M | Clarke AE , Costenbader K, Elliott S, Skeith L | SLE-CALCULATOR: Systemic Lupus Erythematosus CardiovascuLar Disease Event Risk PrediCtion Using Machine LeArning Techniques and NOvel ThRombotic Autoantibodies | CIHR | 91,800 | \$183,600 | Oct-21 | Sep-23 |
| Choi M | | CLIMB: Complement activation Levels and Interferon activity as novel Myositis Biomarkers | The Arthritis Society | 119,000 | 357,000 | Apr-24 | Mar-27 |
| Cibere J | J Esdaile , B Forster, J Kopec , L Li , D Wilson, H Wong, | Population-based longitudinal cohort study of femoroacetabular impingement of the hip using magnetic resonance imaging outcomes | CIHR | \$177,225 | \$531,674 | Oct-20 | Sep-25 |
| Vinet E | S Bernatsky, AE Clark , PR Fortin , J Hanly, C Peschken, Z Touma | Risk stratification and personalized therapy in lupus pregnancies | CIHR | \$151,470 | \$757,350 | Oct-22 | Sep-27 |
| Colmegna I , Fortin PR | Bernatsky S, Ward B, Flamand L, Dionne M | COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases | Province of Quebec Ministry of Health | \$800,000 | \$800,000 | Dec-21 | Nov-22 |
| Colmegna I , Nijnik A, Langlais D | | Hematopoietic stem and progenitor cells as mediators of trained immunity in rheumatoid arthritis | CIHR | \$199,800 | \$999,000 | Oct-20 | Sep-25 |
| Colmegna I , Costiniuk C, Pelaez S | Legare J, Merry L, Ruppenthal L | COVID-19 Vaccine Confidence Among At-Risk and Under-Vaccinated Groups Within HIV and Rheumatic diseases (CONFIDENCE) | CIHR | \$74,750 | \$149,500 | Oct-21 | Sep-23 |

| | | | | | | | |
|--------------------|--|---|--|--------------|-----------|--------|--------|
| Colmegna I, | | Circulating extracellular vesicles in rheumatoid arthritis: Novel biomarkers of methotrexate treatment response | TAS | \$50,000 | \$100,000 | Feb-22 | Jan-24 |
| Greenwood C | I Colmegna, M Hudson | X-inactivation in rheumatoid arthritis and impact on sex-specific disease risks | TAS | \$125,536.67 | \$376,610 | Apr-24 | Mar-27 |
| Da Costa D | M De Vera, PR Fortin, E Rahme, E Vinet, F de Montigny | Mental Health in Individuals with Autoimmune Rheumatic Diseases During the Transition to Parenthood: A Mixed Methods Study to Identify Associated Factors and Support | CIHR | \$79,560 | \$198,900 | Apr-23 | Sep-25 |
| De Vera M | N Amiri, E Sayre, S Ensworth, C Baldwin, N Rebic | Following maternal, neonatal, and childhood outcomes associated with use of arthritis medications perinatally (FAMILY) | The Arthritis Society | \$140,000 | \$420,000 | Apr-23 | Mar-26 |
| De Vera M | C Barnabe, A Avina-Zubieta, N Gheshlaghi, M Harrison, P Kang, M Thomas | Applying an equity and intersectionality lens to understanding the burden of arthritis on aging Canadians (APPROACH) | CIHR | \$69,094 | \$69,094 | Jul-24 | Jun-25 |
| Dutz J | | Inhibition of tissue resident memory T-cells as a therapy for contact hypersensitivity | CIHR - Operating Grant: Canadian Dermatology | \$25,000 | \$50,000 | Sep-22 | Aug-24 |

| | | | | | | | |
|--|--|--|-----------------------|-----------|-----------|--------|--------|
| Boilard, E | Droit A, Fortin PR | Role of megakaryocytes in Systemic Lupus Erythematosus | CIHR | \$146,880 | \$734,400 | Apr-23 | Mar-28 |
| Boilard, E | P Fortin , C Belleannee, S Lacroix | Platelets and neutrophils: The two culprits mediating pain in inflammatory arthritis | CIHR | \$96,390 | \$910,350 | Apr-20 | Mar-25 |
| Bourgoin S | Fortin P | Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases | The Arthritis Society | \$150,000 | \$450,000 | Apr-23 | Mar-26 |
| Dieudé M | P Fortin , E Boillard, H Cardinal, | Impact of Vascular Injury Derived Exosomes on Lupus Nephritis | CIHR | \$115,515 | \$577,575 | Apr-22 | Mar-27 |
| Hazlewood G , Tugwell P, Wells G | Bansback N, Barber CE , Elliott J, Kamso M , Kelly S, Maxwell M | Living systematic reviews of pharmacological treatments for Rheumatoid Arthritis | CIHR | \$46,279 | \$185,114 | Oct-21 | Sep-25 |
| Hazlewood G , Wells G | N Bansback, C Barber, C Barnabe , C Bombardier, V Bykerk, P Charlton, A Scott, D Choquette, R Deardon, J Elliott, MM Kamso , S Kelly, L Proulx, L Richards, O Schieir, J Thomas | Personalizing the choice of therapy in rheumatoid arthritis | CIHR | \$420,752 | \$420,752 | Apr-22 | Mar-26 |
| Graham MM, James MT, Sajobi T, Wilton SB | O Awosoga, B Har, G Hazlewood , L Lix, A McRae, C Norris, MJ Parilla Lopez, H Quan, RD Turgeon, T Wilson, M Wang | Characterizing patient preferences and personalizing risk information for optimal patient-centered management of coronary artery disease | CIHR | \$127,181 | \$508,724 | Apr-23 | Mar-27 |

| | | | | | | | |
|---|--|--|------|--------------|--------------|--------|--------|
| Tugwell PS, Welch V | S Ali, C Barber, C Barnabe , A Darzi, O Dewidar, G Hazlewood, A Lee, LC Li, O Magwood, L Maxwell, J Petkovic, B Shea, E Tomlinson, K Toupin-April | Reducing inequitable differences in health outcomes in the treatment of Arthritis | CIHR | \$138,974.67 | \$416,924 | Oct-23 | Sep-26 |
| Hutton B, Moher D, Straus SE, Tricco AC, Wells G | AM Abou-Setta, G Hazlewood , B Hemmelgarn, A Hossain, Z Jordan, S Kelly, E Langlois, J Presseau, A Proctor, B Reeves, A Stevens, K Thavorn, M Tunis, J Watt | Drug Safety and Effectiveness Network Methods and Applications Group in Indirect Comparisons (DSEN MAGIC) Team | CIHR | \$272,174 | \$816,522 | Apr-20 | Mar-25 |
| Hoa S | D Assayag, M Baron, S Golch, M Hambly, M Hudson , M Larche, JL Senecal | Randomized Double-Blind Placebo-Controlled Clinical Trial to Assess the Efficacy of Mycophenolate Mofetil in Subclinical Interstitial Lung Disease Associated with Systemic Sclerosis: a Feasibility Study | CIHR | \$92,437 | \$346,640 | Oct-22 | Jun-26 |
| Archambault P, Awadalla P et al | Allin S, Arino J, Hoens A et al +50 | Long COVID Web: Pan-Canadian Post-COVID Condition Research Network | CIHR | \$3,999,923 | \$19,999,614 | Nov-22 | Oct-27 |
| Bostick G, Bussieres A, Cooper L, McNiven N, Wideman T, et al | Bement M, Bhanji F, Fishman S, Hudon A, Hoens A (Collaborator) et al | Improving pain education across entry-level physiotherapy programs in Canada: An integrated knowledge translation study | CIHR | \$120,870 | \$604,350 | Apr-21 | Mar-26 |

| | | | | | | | |
|--------------------------------------|---|---|-----------------------|-----------|-----------|--------|--------|
| Hudson M, Colmegna I, Farge D | Hoa SA, Laneuville P, Peltier L, Resche-Rigon M, Schnitzer M | Phase I/II randomized controlled clinical trial of umbilical cord-derived mesenchymal stromal cells in refractory systemic sclerosis | CIHR | \$140,000 | \$420,000 | Apr-19 | Mar-24 |
| Hudson M, Johnson S, Denton C | Hoa SA, Stern E | Multicriteria decision analysis with 1000 Minds for developing scleroderma renal crisis classification criteria | CIORA | \$60,000 | \$60,000 | Oct-23 | Sep-24 |
| Hudson M | Hoa S, Miller W, Lapointe R, Del Rincon S, Esfahani K | Identification of immune signatures of rheumatic immune-related adverse events secondary to immune checkpoint inhibitors | TAS | \$150,000 | \$450,000 | Apr-24 | Mar-27 |
| Leask A, Philip A | M Hudson | Characterization of a novel anti-fibrotic peptide for the treatment of scleroderma | CIHR | \$97,308 | \$486,540 | Apr-21 | Mar-26 |
| Jamal S, Appleton T | C Ye, J Pope, M Hudson | Early Adalimumab Induction for Treatment of Steroid-Dependent Checkpoint Inhibitor Associated Inflammatory Arthritis: A Pragmatic Randomized Clinical Trial | CIORA | \$58,200 | \$116,400 | Oct-23 | Sep-25 |
| Jones CA, Drummond N | Barnabe C, Barber CEB | Rheumatoid Arthritis in Canadian Primary Care Settings: Epidemiology, Management of Care and Patient Experience | The Arthritis Society | \$99,884 | \$299,652 | Apr-21 | Mar-24 |

| | | | | | | | |
|--|--|---|----------------------------------|-----------|-----------|--------|--------|
| Lacaille D | Bansback N, Barber C, Barnabe C, Bartlett S, Colmegna I, Da Costa D, Fortin P, Hazlewood G, Hoens A, Koehn C, Li L, Michou L, Oelke N | FlexCAre: Co-developing a Flexible Care Delivery Model for Inflammatory Arthritis | The Arthritis Society | \$112,500 | \$450,000 | Dec-22 | Mar-26 |
| Morton L, Lacaille D | GJ Macfarlane, R Hollick, K Walker-Bone | Supporting people with musculoskeletal disorders in Scotland to remain in work: adapting the Making it Work™ intervention developed for people with inflammatory arthritis in Canada. | Government of Scotland, £232,840 | \$402,500 | \$402,500 | Jan-22 | Dec-23 |
| Li LC , Liu Ambrose T | C Bartha, J Brubacher, J Davis, T Dignum, R Falck, C Hsu, M Kho, T Manyango, L Nagamatsu, N Parmar, D Skelton, O Theou, H Wong | ACTIVE: Adding Life to Years in Cognitive Frailty by Preventing Falls | CIHR | \$163,710 | \$818,550 | Apr-23 | Mar-28 |
| Kho ME, Chan TMY, Marshall JC, Murthy S, Muscedere J, Park S | Archambault P, Ball I, Boyd J, Brooks D, Burns K, Choong K, Carayannopoulos K, Caron C, Cook D, D'Aragon F, Duan E, Fowler R, Li LC , Fox-Robichaud A, Herridge M, Karachi T, Reeve B, Lamontagne F, Lee L, Lewis K, Mehta S, Reid J, Rochweg B, Rudkowski J, Seely A, Semrau J, Thabane L, Tsang J, Williamson D | CYCLE RCT: Process evaluation, end-of-grant knowledge translation, and planning for future ICU survivorship rehabilitation interventions | CIHR | \$100,000 | \$100,000 | Apr-23 | Mar-24 |

| | | | | | | | |
|--|--|--|---|-------------|-------------|--------|--------|
| Hamilton C, Tugwell P, Li L | A Hoens , D Beaton, C Hofstetter, L Maxwell, A McKinnon , S McQuitty | Listening to Patient Partners - From developing evidence-based tools for advancing meaningful patient engagement in research to now implementing them at an international organization for rheumatology research | CIHR- Research Excellence Prize, Patient Engagement | \$25,000 | \$25,000 | Sep-23 | Aug-24 |
| Li LC , Liu-Ambrose T, Davis J | R Falk, K Madden, R Rhodes, M Sadatsafavi, HC Wong | SuPA Mobility: Supporting Physical Activity to Promote Mobility in Mobility-Limited Older Adults | CIHR | \$105,188 | \$631,128 | Apr-21 | Mar-27 |
| Li LC , Liu-Ambrose T | Bartha C, Davis J, Falck R, Feehan L, Hoens A , Holmes B, Kho M, Leese J , Ma J , Mackay-Lyons M, Madden K, Mayo N, Theou O, Wong H, Xie H | Moving More: Supporting uptake of evidence for physical activity in older adults with complex health care needs | CIHR | \$129,094 | \$516,376 | Apr-22 | Sep-25 |
| Tricco A, Straus S, Abou-Setta AM, Barker K, Clement F, Clifford TJ, Colquhoun H, Curran J, Godfrey C, Isaranuwachai W, LeBlanc A, Li LC , Moffitt P, Moher D, Teare GF | Barnabe C , Graham I, Ivers N, Klassen T, Legare F, Mitton C, Morin S, Scott S, Sibely K, Snelgrove-Clarke E, Squires J, plus > 100 investigators | SPOR Evidence Alliance | CIHR | \$2,630,000 | \$2,630,000 | Jul-22 | Dec-23 |

| | | | | | | | |
|--|---|---|-------|--------------|-------------|--------|--------|
| Li LC | T Liu-Ambrose, S Murphy, F Feldman, M Oakey, J Davis, J Ma , C Koehn, L Dian, D Jehu, H Xie | Implementing an evidence-based exercise program to reduce falls in community-dwelling seniors | MSFHR | \$166,667 | \$500,000 | Apr-18 | Mar-24 |
| Jung ME, Alexander A, Casmey S, Coes C, Compton S, Cullen L, Hartley-Folz S, Hughes CL, Kyle JL, Logan SM, Paterson K, Squires S, Bean C, Fuller DL, Li LC , Martin Ginis KA, Sherifali DT, Witteman HM | Davis JC, McGavock JM, Ndjaboue R, Singer J, Strachan SM | Small steps for big changes: Implementing an evidence-based diabetes prevention program into diverse urban communities | CIHR | \$493,117.17 | \$2,958,703 | Oct-22 | Sep-28 |
| Black A, Bosma R, Fernandez N, Goldwitz D, Kent A, King M, Leblanc A, McCormick R, Poitras ME, Robinson-Settee | Abou-Setta A, Atherton P, Aubin D, Bacon S, Li LC , Tricco A et al | Innovative National Strategies for Patient-Oriented Research Education / Stratégies Nationales Innovantes pour l'Éducation en Recherche axée sur le Patient (INSPIRE) | CIHR | \$875,000 | \$5,250,000 | Mar-21 | Feb-27 |

| | | | | | | | |
|--|---|--|------|-------------|--------------|--------|--------|
| Bourbeau J, Anderson DR, Batist G, Bell EC, Benoit BL, Collister D, Dasgupta K, Fahim C, Fergusson DA, Fillion KB, Gahagan JC, Goos L, Khan NA, King M, Li LC , Mitra S, Morin SN, Pilote L, Reiman T, Richer LP, Saleh RR, Sapp JL, Tomblin Murphy GG, Yeh, AE | Lacaille D, Bansback N and 58 co-investigators | Canadian Consortium of Clinical Trial Training (CANTRAIN) platform: enhancing career preparedness in RCT research targeting different audiences across the continuum | CIHR | \$3,772,441 | \$11,317,324 | Sep-22 | Aug-25 |
| Crizzle A, Elzohairy Y, Vrkljan B | J Dow, G Equakun, LC Li, S Marshall , N Meger, E Mychael et al | Medically at-risk drivers: The road to developing evidence-based fitness to drive guidelines | CIHR | \$133,875 | \$803,250 | Apr-18 | Mar-24 |
| Guzman, J | Cabral D, Feldman B, Li LC , Loughin T, Stringer E, Toupin-April K, Tucker L | Treating children with arthritis according to their individual probability of outcomes and response to treatments - The PERSON-JIA Trial | CIHR | \$91,035 | \$455,175 | Apr-21 | Mar-26 |

| | | | | | | | |
|---|--|---|-----------------------|-------------|-----------|--------|--------|
| J Robinson, S Singh | L Battersby, T Bubela, P Casari, L Funnell, A Godfreyson, S Hajazi, R Kherani, LC Li , J Matheson, I Mathes, T O'Callaghan, S Smith, M Tecson, D Whitehurst | Preventing the next fracture: Spreading Fracture Liaison Service across British Columbia | CIHR | \$150,000 | \$150,000 | Mar-23 | Feb-24 |
| Tucker L | Guzman J, Cabral D, Feldman B, Li LC , Loughin T, Stringer E, Toupin-April K, Tucker L | PERSON-JIA: the Personalized Estimates of Response and Severity Outcomes in Newly-diagnosed Juvenile Idiopathic Arthritis trial | The Arthritis Society | \$98,026.67 | \$294,080 | Apr-21 | Mar-26 |
| Marshall DA , Johnson J | Wozniak L, Ademola I, Smith C | Effectiveness of an individualized decision aid for total knee arthroplasty implemented in routine clinical practice | EUROQOL | \$134,946 | \$269,891 | Apr-23 | Mar-25 |
| Baumgart D, Bercik P, Bernstein C, Calliou S, D'Silva A, Daley K, De Nino A, De Souza R, Marshall DA , Nguyen G, Otley A et al | | IMAGINE (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects) SPOR Chronic Disease Network - Knowledge Mobilization & Implementation Science Phase 2 | CIHR | \$183,438 | \$733,750 | Apr-22 | Mar-26 |

| | | | | | | | |
|--|--|---|--|-----------|-----------|--------|--------|
| Bryan S, Doupe M, Gallant N, Lopatina E , Manhas K, Jot P, McGrail K, Noseworthy T, Singal D, Wasylak T, Zelinsky S, Marshall DA | Bielska I, Bruce M, Hamilton C et al | Enhancing a Community of Practice for the Health System Impact Fellowship Program: Advancing Capacity for Sustainable & Patient-Centred Learning Health Systems across Canada | CIHR | \$140,000 | \$350,000 | Jul-22 | Dec-24 |
| Westby M | Marshall DA, Backman C, Barber C, Koehn C, Kerr S | Moving towards equity in hip and knee replacement rehabilitation: A feasibility study to test implementation of online quality indicator toolkits | The Arthritis Society | \$100,000 | \$200,000 | Apr-22 | Mar-24 |
| Gagliardi A | Marshall D, Hazlewood G | Co-generating strategies to support equitable person-centred early diagnosis and management of osteoarthritis | The Arthritis Society | \$115,167 | \$345,500 | Apr-21 | Mar-24 |
| Michou L | | the study of SUPT20H in the pathogenesis of rheumatoid arthritis | French Rheumatology Association | \$13,500 | \$27,000 | Apr-22 | Mar-24 |
| Prlic H | L Li, H Xie, D Lacaille, A Aviña-Zubieta | Osteoarthritis and cognitive function: A population-based cross-sectional study | Arthritis Health Professions Association | \$11,500 | \$11,500 | Apr-23 | Mar-24 |
| J Whittaker | E Roos | OPTIKNEE: An international consensus to optimize knee health after knee injury | CIHR | \$25,000 | \$25,000 | Jul-23 | Jun-24 |

| | | | | | | | |
|------------------------------|--|--|---|-----------|-----------|--------|--------|
| J Whittaker, K Kausky | | Navigating the maze: Supporting family physicians in rapid, accurate diagnosis, management, and referral of acute knee trauma | SharedCare - Government of British Columbia and Doctors of BC | \$15,000 | \$15,000 | Jul-22 | Jun-24 |
| J Whittaker | A Hoens, H Xie, LC Li, J Davis, A Mosewich, M Miciak, E Roos, Patient Collaborators: T Silvester-Lee, A Ko | Self-managing knee health in young people at high-risk of early-onset osteoarthritis: The MyKnee randomized controlled trial | TAS | \$150,000 | \$450,000 | Apr-24 | Mar-27 |
| J Whittaker | J Davis, A Hoens , M Hunt, L Li, J Losciale , M Miciak, A Mosewich, E Roos, A Sheikh, L Truon, D Wilson, H Xie, Collaborator: T Silvester-Lee | The Stop Osteoarthritis (SOAR) Hybrid Effectiveness-Implementation Type 1 Randomized Controlled Trial for Young People at-High-Risk of Early Onset Knee Osteoarthritis | CIHR | \$100,000 | \$100,000 | Apr-24 | Mar-25 |
| Ellis R | J Whittaker | Community of practice co-creation of a life-span approach to managing ACL injury | Health Research Council of New Zealand | \$24,118 | \$24,118 | Apr-24 | Mar-25 |
| D O'Brien | J Whittaker , Reid, R Ellis, T Wilson-Uluinayau | Exploring the medium to long term well-being of people with post-traumatic knee osteoarthritis following ACL tear in Aotearoa (New Zealand) | Arthritis New Zealand | \$45,630 | \$45,630 | Jul-22 | Jun-25 |

| | | | | | | | |
|-------------------------------|---|--|---|---------------------|-----------|--------|------------|
| Xie, H | | Knowledge Discovery Using Nonrandom Data Samples | Natural Sciences & Engineering Research Council (NSERC) | \$21,000 | \$105,000 | Apr-24 | 2029--3-31 |
| W Zhang | M Gignac, G Johnd, D Lacaille , C McLeod | Trajectories of work productivity loss: Working from home and insights during COVID-19 | CIHR | \$70,000 | \$70,000 | Apr-24 | Mar-25 |
| Annual Total 2023-2024 | | | | \$25,446,846 | | | |

| SCIENTIST FUNDING - Salary Grants | | | | | |
|--|--|------------------|-----------------------|----------------------|----------------------|
| Peer Review | | | | | |
| Funding Agency | Title | Faculty | Start/End Date | Annual Amount | Total Awarded |
| BC Lupus | Lupus Scholar Award | Aviña A | 2010 - 2023 | \$50,000 | \$650,000 |
| CIHR | Canada Research Chair in Rheumatoid Arthritis and Autoimmune Diseases (Tier 2) | Barnabe C | Oct 19 - Sep 24 | \$100,000 | \$500,000 |
| CIHR | Canada Research Chair in Health Outcomes & Treatment Adherence (Tier 2) | De Vera M | Apr 22 - Mar 27 | \$100,000 | \$500,000 |
| CIHR | Canada Research Chair in Systematic Autoimmune Rheumatic Diseases (Tier I) - Renewal | P Fortin | Jul 12 - Mar 26 | \$200,000 | \$1,950,000 |
| Canada Research Chair Program | Canada Research Chair in Patient-Oriented Knowledge Translation | Li L | Apr-19 - Mar 24 | \$100,000 | \$500,000 |

| | | | | | |
|---------------------|---|--------------------|-----------------|------------------|-----------|
| UBC | Knowledge Exchange and Mobilization (KxM) Scholar Award | Ma J | Apr 23 - Mar 25 | \$10,000 | \$20,000 |
| MSFHR | MSFHR Salary Award | Whittaker J | Jul 20 - Jun 25 | \$90,000 | \$450,000 |
| Annual Total | | | | \$650,000 | |
| 2023-2024 | | | | | |

Endowed Chairs

| | | | | | |
|------|---|-------------------|-----------|--|--|
| UBC | Mary Pack Chair | Lacaille D | Sep 11 - | | |
| UofC | Arthur J.E. Child Chair in Rheumatology Outcomes Research | Barnabe C | July 22 - | | |
| UBC | Harold Robinson-Arthritis Society Chair in Rehabilitation Sciences | Li L | Jul 16 - | | |
| SFU | Maureen and Milan Illich Chair in Statistics and Information Sciences for Arthritis and Musculoskeletal Disease | Xie H | Sep15 - | | |

TRAINEE AWARDS

| Funding Agency | Award Type and/or Research Title | Trainee | Supervisor | Start/End Date | Annual Amount | Total Awarded |
|---|--|--------------------|-------------|-----------------|---------------|---------------|
| The Scientific and Technological Research Council of Turkey | Postdoctoral Research Fellowship award | Bayraktar D | Li L | Jul 23 - Jun 24 | \$46,120 | \$46,120 |

| | | | | | | |
|--------------------------------|---|--------------------|-------------------------|-----------------|----------|-----------|
| MITACS | Targeted synthetic and biosimilar disease modifying antirheumatic drugs in pregnancy: Patterns of use among females with rheumatic diseases and outcomes | Cheng V | De Vera M | Jan 24 - Feb 25 | \$45,000 | \$45,000 |
| University of British Columbia | Andrew Nord Fellowship in Rheumatology | Daftarian N | Aviña-Zubieta JA | Jul 22 - Jun 26 | \$22,000 | \$88,000 |
| CIHR | Doctoral Research Award - RetINal Toxicity And hydroxyChloroquine Therapy (INTACT) | N Daftarian | Aviña-Zubieta JA | Jun 23 - May 26 | \$35,000 | \$105,000 |
| UBC | University of British Columbia 4-year Fellowship | Losciale, J | Whittaker J | Jul 22 - Jun 26 | \$18,200 | \$72,800 |
| | PhD Salary Award for The Stop OsteoARthritis (SOAR) Proof-of-Concept Delayed Control Randomized Trial: Can We Mitigate A Key Risk Factor for Osteoarthritis following Sport-related Knee Trauma?" | Losciale, J | Whittaker J | Sep 21 - Aug 25 | \$10,500 | \$31,500 |
| MITACS | Comparing the risk of adverse events across different classes of biologics prescribed for inflammatory arthritis | Moolooghy K | Lacaille D | Jan 24 - Feb 25 | \$45,000 | \$45,000 |
| MITACS | Data linkage and Artificial Intelligence approaches to improving rheumatoid arthritis data quality and case detection using health administrative data and primary care data in Alberta, Canada | Pham A | Jones CA | Feb 22 - Feb 24 | \$60,000 | \$120,000 |

| | | | | | | |
|---|--|------------------|------------------|-----------------|----------|-----------|
| Michael Smith Health Research BC Research | Trainee Award - Exploring the Lived Experiences of Sexual and Gender Minority Populations Living with Arthritis: A Patient Engagement Centered Approach | Primeau C | Li L | Apr 23 - Mar 26 | \$49,500 | \$148,500 |
| The Arthritis Society | Postdoctoral Research Fellowship award - Exploring the Lived Experiences of Sexual and Gender Minority Populations Living with Arthritis: A Patient Engagement Centered Approach | Primeau C | Li L | Oct 23 - Sep 26 | \$50,000 | \$150,000 |
| CIHR Banting Post-doctoral Fellowship | Leveraging Citizen Science for Inclusive Pain Research: Maximizing Public Engagement for Co-Developing Research Questions with Sexual and Gender Minority Communities | Primeau C | Li L | May 24 - Apr 26 | \$70,000 | \$140,000 |
| CIHR | Postdoctoral Research fellowship - Proureicemic diets, microbial composition and functional potential, and plasma uric acid | Rai S | Choi H | Oct 22 - Sep 25 | \$50,000 | \$150,000 |
| UBC | School of Graduate and Postdoctoral Studies Friedman Award | Rebic N | De Vera M | Oct 22 - Sep 23 | \$37,500 | \$37,500 |

| | | | | | | |
|-----------------------|---|------------------------|--------------------|-----------------|----------|-----------|
| CIHR | Doctoral Research Award - Optimizing medication and vaccination adherence in rheumatoid arthritis in the COVID-19 era: Development of a patient-centred intervention | Ta V | Bartlett S | Jun 23 - May 26 | \$35,000 | \$105,000 |
| UBC | Killam Doctoral Scholarship | Thomas M | De Vera M | Apr 22 - Mar 24 | \$32,000 | \$64,000 |
| CIHR | Doctoral Research Award - Assessing equity considerations in the research and care of patients with inflammatory arthritis (ACCESS)". | Thomas M | De Vera M | Jun 23 - May 26 | \$35,000 | \$105,000 |
| The Arthritis Society | PhD Salary Award - Differences in health for patients with inflammatory arthritis: Are they preventable? | Thomas M | De Vera M | Oct 21 - Sep 24 | \$10,500 | \$31,500 |
| The Arthritis Society | PhD Salary award - Moving towards the personalization of treatment choices in rheumatoid arthritis: Combining clinical modelling strategies to personalize risk estimates | Thomas-Purdue J | Hazlewood G | Oct 23 - Sep 26 | \$17,500 | \$52,500 |
| University of Calgary | Alberta Graduate Excellence Scholarship Award. | Thomas-Purdue J | Hazlewood G | Sep 23 - Aug 24 | \$12,000 | \$12,000 |
| CIHR/CANTRAIN | CANTRAIN-CTTP Doctoral Studentship | Thomas-Purdue J | Hazlewood G | Sep 23 - Aug 24 | \$35,000 | \$35,000 |

| | | | | | | |
|-------------------------------|---|----------------------|-----------------------------------|-----------------|------------------|-----------|
| UBC | 4-Year Fellowship Award - The role of psychological, social, and contextual factors in recovery and return to sport after a sport-related knee injury | Truong L | Whittaker J | Sep 20 - Aug 24 | \$72,000 | \$288,000 |
| CIHR | Fellowship Award - Reducing the risk of osteoarthritis after a sport knee injury: Proof-of Concept of the SOAR (Stop OsteoARthritis) program | Truong L | Whittaker J | Jun 21 - May 24 | \$55,000 | \$165,000 |
| CIHR | Doctoral Research Award - Access to outpatient physiotherapy in British Columbia following anterior cruciate ligament injury | Worthington H | Li L | Apr 23 - Mar 25 | \$35,000 | \$105,000 |
| CIHR | Canada Graduate Scholarship award for her project "A Better Match: Transforming rheumatoid arthritis care using text-based messaging | Zafar S | Barber C & Hazlewood G | Apr 22 - Mar 24 | \$17,500 | \$17,500 |
| Annual Total 2023-2024 | | | | | \$895,320 | |

Appendix II – Publications & Abstracts, July 1, 2023 – June 30, 2024

Names in bold indicate Arthritis Research Canada/Arthrite-recherche Canada Scientists, trainees and Patient Advisory Board Members

PUBLICATIONS

1. Abbaticchio A, Theodorlis M, **Marshall D**, MacKay C, Borkhoff CM, **Hazlewood GS**, Battistella M, Lofters A, Ahluwalia V, Gagliardi AR. Policies in Canada fail to address disparities in access to person-centred osteoarthritis care: a content analysis. *BMC Health Serv Res*. 2024 Apr 25;24(1):522. doi: 10.1186/s12913-024-10966-5.
2. Abhishek A, Tedeschi SK, Pascart T, Latourte A, Dalbeth N, Neogi T, Fuller A, Rosenthal A, Becce F, Bardin T, Ea HK, Filippou G, Fitzgerald J, Iagnocco A, Lioté F, McCarthy GM, Ramonda R, Richette P, Sivera F, Andrés M, Cipolletta E, Doherty M, Pascual E, Perez-Ruiz F, So A, Jansen TL, Kohler MJ, Stamp LK, Vinh J, Adinolfi A, Arad U, Aung T, Benillouche E, Bortoluzzi A, Dau J, Maningding E, Fang MA, Figus FA, Filippucci E, Haslett J, Janssen M, Kaldas M, Kimoto M, Leamy K, Navarro GM, Sarzi-Puttini P, Scirè C, Silvagni E, Sirotti S, Stack JR, Truong L, Xie C, Yokose C, Hendry AM, Terkeltaub R, Taylor WJ, **Choi HK**. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. *Ann Rheum Dis*. 2023 Oct;82(10):1248-1257. doi: 10.1136/ard-2023-224575. Epub 2023 Jul 26. See also *Arthritis Rheumatol*. 2023 Oct;75(10):1703-1713. doi: 10.1002/art.42619. Epub 2023 Jul 26.
3. **Abrahamowicz M**. Assessing cumulative effects of medication use: New insights and new challenges. *Pharmacoepidemiol Drug Saf*. 2024 Jan;33(1):e5746. doi: 10.1002/pds.5746. Epub 2023 Dec 27.
4. Abuwa C, Abbaticchio A, Theodorlis M, **Marshall DA**, MacKay C, Borkhoff CM, **Hazlewood GS**, Battistella M, Lofters A, Ahluwalia V, Gagliardi AR. Identifying strategies that support equitable person-centred osteoarthritis care for diverse women: content analysis of guidelines. *BMC Musculoskelet Disord*. 2023 Sep 14;24(1):734. doi: 10.1186/s12891-023-06877-x.
5. Ahmadian S, Johnson KM, Ho JK, Sin DD, Lynd LD, **Harrison M**, Sadatsafavi A. Cost-Effectiveness Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc*. 2023 Dec;20(12):1735-1742. doi: 10.1513/AnnalsATS.202304-301OC.
6. Ahmed S, Gupta L, Kuwana M, Pauling JD, Day J, Ravichandran N, Joshi M, Parodis I, Sen P, Jagtap K, Nikiphorou E, Saha S, Agarwal V, Chatterjee T, Lilleker JB, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Tan AL, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Distler O, Wibowo SAK; COVAD Study Group; Incl **Hudson M**, Chinoy H, Aggarwal R, Agarwal V, Makol A. Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey. *Rheumatol Int*. 2023 Sep 5. doi: 10.1007/s00296-023-05433-z. Online ahead of print.

7. Ahmed S, Parks-Vernizzi E, Perez B, Arnold B, Boucher A, Hossenbaccus M, Correia H, **Bartlett SJ**. Translation and linguistic validation of 24 PROMIS item banks into French. *Qual Life Res*. 2024 Jun 12. doi: 10.1007/s11136-024-03690-4. Online ahead of print.
8. Ali E, Neufeld ME, Howard L, Masri BA, **Greidanus NV, Garbuz DS**. Clinical Outcomes and Risk Factors for Re-Revision Due to Trunnion Corrosion in Primary Metal-on-Polyethylene Total Hip Arthroplasty. *J Arthroplasty*. 2024 Feb 7:S0883-5403(24)00080-9. doi: 10.1016/j.arth.2024.01.057. Online ahead of print.
9. Alkan A, Carrier ME, Henry RS, Kwakkenbos L, **Bartlett SJ**, Gietzen A, Gottesman K, Guillot G, Lawrie-Jones A, **Hudson M**, Hummers LK, Malcarne VL, Mayes MD, Mouthon L, Richard M, Wojcek RK, Worrone-Sauvé M, Benedetti A, Thombs BD, **Fortin P**; SPIN Investigators. Minimal Detectable Changes of the HAQ-DI, PROMIS-29v2.0 Domains, and PHQ-8 in Systemic Sclerosis: A SPIN Cohort Cross-Sectional Study. *Arthritis Care Res (Hoboken)*. 2024 Jun 26. doi: 10.1002/acr.25397. Online ahead of print.
10. Alothman R, Yeung J, Waterman E, Lepik C, **Amiri N**. Leflunomide exposure through second trimester of pregnancy: A case report. *Birth Defects Res*. 2023 Oct 1;115(16):1566-1569. doi: 10.1002/bdr2.2221. Epub 2023 Jul 18. print.
11. Ambasta A, Holroyd-Leduc JM, Pokharel S, Mathura P, Shih AW, Stelfox HT, Ma I, **Harrison M**, Manns B, Faris P, Williamson T, Shukalek C, Santana M, Omodon O, McCaughey D, Kassam N, Naugler C. Re-Purposing the Ordering of Routine Laboratory Tests in Hospitalized Medical Patients (RePORT): protocol for a multicenter stepped-wedge cluster randomised trial to evaluate the impact of a multicomponent intervention bundle to reduce laboratory test over-utilization. *Implement Sci*. 2024 Jul 2;19(1):45. doi: 10.1186/s13012-024-01376-6.
12. Andreoli L, Lini D, Schreiber K, Parodis I, Sen P, Naveen R, Day J, Joshi M, Jagtap K, Nune A, Nikiphorou E, Agarwal V, Saha S, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Edgar Gracia-Ramos A, Cavagna L, Kuwana M, Knitza J, Makol A, Patel A, Pauling JD, Wincup C, Barman B, Zamora Tehozol EA, Serrano JR, García-De La Torre I, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Akarawatcharangura Goo P, Shumnalieva R, Chen YM, Hoff LS, El Kibbi L, Halabi H, Vaidya B, Sazliyana Shaharir S, Hasan ATMT, Dey D, Gutiérrez CET, Caballero-Urbe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Saavedra MA, Distler O; COVAD study group; Incl. **Hudson M**, Chinoy GAH, Agarwal V, Aggarwal R, Gupta L. COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study. *Rheumatology (Oxford)*. 2023 Jul 28;kead382. doi: 10.1093/rheumatology/kead382. Online ahead of print.
13. Atay EJ, Murry AT, **Barnabe C**, Sawyer O, Bednar MA. Indigenous Mentorship for the Health Sciences: An Appraisal of a Contemporary Model by Indigenous Stakeholders. *Teach Learn Med*. 2023 Jul 11:1-17. doi: 10.1080/10401334.2023.2230577. Online ahead of print.
14. Baraf HSB, Khanna PP, Kivitz AJ, Strand V, **Choi HK**, Terkeltaub R, Dalbeth N, DeHaan W, Azeem R, Traber PG, Keenan RT. The COMPARE head-to-head,

- randomised-controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout. *Rheumatology (Oxford)*. 2023 Jul 14;kead333. doi: 10.1093/rheumatology/kead333. Online ahead of print.
15. **Barber CEH**, Lethebe BC, Szostakiwskyj JH, **Barnabe C**, **Barber MRW**, Katz S, England BR, **Hazlewood GS**. A population-based analysis of rheumatology care patterns for inflammatory arthritis during COVID-19 in Alberta, Canada. *Semin Arthritis Rheum*. 2024 Jan 11;65:152364. doi: 10.1016/j.semarthrit.2024.152364. Online ahead of print.
 16. **Barber MRW**, Ugarte-Gil MF, Hanly JG, Urowitz MB, St-Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, **Fortin PR**, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Pons-Estel BA, Cardwell FS, Alarcón GS, **Clarke AE**. Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. *Ann Rheum Dis*. 2024 May 16;ard-2024-225613. doi: 10.1136/ard-2024-225613. Online ahead of print.
 17. Barclay R, Webber SC, Hahn F, **Jones CA**, Mayo NE, Sivakumaran S, Liu Y, Chilibeck PD, Salbach NM. A park-based group mobility program for older adults with difficulty walking outdoors: a quantitative process evaluation of the Getting Older Adults Outdoors (GO-OUT) randomized controlled trial. *BMC Geriatr*. 2023 Dec 11;23(1):833. doi: 10.1186/s12877-023-04524-7.
 18. **Bartlett SJ**, Bykerk VP, Schieir O, Valois MF, Pope JE, Boire G, Hitchon C, **Hazlewood G**, Bessette L, Keystone E, Thorne C, Tin D, Bingham CO, 3rd, Investigators C. "From Where I Stand": using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare questionnaire (RA-FQ). *Quality of life research*. 2023;32(5):1307-18. Epub 20220908. doi: 10.1007/s11136-022-03227-7.
 19. Beckett M, **Dutz J**, Huang K. Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients. *RMD Open*. 2024 Jan 18;10(1):e003837. doi: 10.1136/rmdopen-2023-003837.
 20. Beckett M, Tan J, Bonnardeaux E, **Dutz J**, **Shojania K**, To F, **Obrzut A**, **Avina-Zubieta JA**. Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients. *Rheumatology (Oxford)*. 2024 May 2;63(5):1432-1436. doi: 10.1093/rheumatology/kead404.
 21. Bengoa FJ, Howard LC, Neufeld ME, **Garbuz DS**. Malseating of Modular Dual Mobility Liners: High Prevalence in Revision Total Hip Arthroplasty. *J Arthroplasty*. 2023 Jul;38(7S):S211-S216. doi: 10.1016/j.arth.2023.03.094. Epub 2023 Apr 5.
 22. Bergeron A, Nessim C, Kleiner O, Manion R, **Dutz J**, Philip A, Chan AW; Skin Investigation Network of Canada Priority Setting Collaborative. Skin Investigation Network of Canada (SKIN Canada) Priority Setting Initiative ranks the top 10

- evidence uncertainties for Merkel cell carcinoma. *Br J Dermatol*. 2024 Jan 23;190(2):281-282. doi: 10.1093/bjd/ljad398.
23. Berthelsen DB, Simon LS, Ioannidis JPA, Voshaar M, Richards P, Goel N, Strand V, Nielsen SM, Shea BJ, Tugwell P, **Bartlett SJ, Hazlewood GS**, March L, Singh JA, Suarez-Almazor ME, Boers M, Stevens RM, Furst DE, Woodworth T, Leong A, Brooks PM, Flurey C, Christensen R; OMERACT Safety Working Group. Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group. *Semin Arthritis Rheum*. 2023 Oct 26;63:152288. doi: 10.1016/j.semarthrit.2023.152288. Online ahead of print.
 24. Berthelsen DB, Nielsen SM, Rasmussen MU, Voshaar M, Richards P, **Bartlett SJ, Hazlewood GS**, Shea BJ, Tugwell P, Ellingsen T, Jørgensen TS, Kristensen S, Simon LS, Christensen R, Flurey CA; OMERACT Safety Working Group. "I couldn't carry on taking a drug like that": A qualitative study of patient perspectives on side effects from rheumatology drugs. *Rheumatology (Oxford)*. 2024 Apr 13:keae223. doi: 10.1093/rheumatology/keae223. Epub ahead of print. PMID: 38613847.
 25. Bhuiya AR, Sutherland J, Boateng R, Bain T, Skidmore B, Perrier L, Makarski J, Munce S, Lewis I, Graham ID, Holroyd-Leduc J, Straus SE, Stelfox HT, Striffler L, Lokker C, **Li LC**, Leung FH, Dobbins M, Puchalski Ritchie LM, Squires JE, Rac VE, Fahim C, Kastner M. A scoping review reveals candidate quality indicators of Knowledge Translation and Implementation Science practice tools. *J Clin Epidemiol*. 2023 Nov 6:S0895-4356(23)00281-0. doi: 10.1016/j.jclinepi.2023.10.021. Online ahead of print.
 26. Biln NK, Guh D, **Bansback N, Shojania K, Harrison M**. The Association of Rheumatologist Supply and Multidisciplinary Care With Timely Patient Access to Rheumatologists: Evidence From British Columbia, Canada. *Arthritis Care Res (Hoboken)*. 2024 Apr;76(4):444-453. doi: 10.1002/acr.25274. Epub 2024 Feb 11. Online ahead of print.
 27. Blaess J, Geneton S, Goepfert T, Appenzeller S, Bordier G, Davergne T, Fuentes Y, Haglo H, Hambly K, Kinnett-Hopkins D, Su KY, **Legge A, Li L**, Mak A, Padjen I, Sciascia S, Sheikh SZ, Soriano-Maldonado A, Ugarte-Gil MF, Md Yusof MY, Parodis I, Arnaud L. Recommendations for physical activity and exercise in persons living with Systemic Lupus Erythematosus (SLE): consensus by an international task force. *RMD Open*. 2024 Apr 4;10(2):e004171. doi: 10.1136/rmdopen-2024-004171.
 28. Blazey P, Scott A, Ardern CL, Davis JC, **Whittaker JL, Losciale JM**, Khan KM. (2024). Consensus methods in patellofemoral pain. How rigorous are they? A scoping review. *Br J Sports Med*. 2024 Jun 20;58(13):733-744. doi: 10.1136/bjsports-2023-107552.
 29. Bowdish DME, Chandran V, Hitchon CA, Kaplan GG, **Avina-Zubieta JA, Fortin PR**, Larché MJ, Boire G, Gingras AC, Dayam RM, **Colmegna I**, Lukusa L, Lee JLF, Richards DP, Pereira D, Watts TH, Silverberg MS, Bernstein CN, **Lacaille D**, Benoit J, Kim J, Lalonde N, Gunderson J, Allard-Chamard H, Roux S, Quan J, Hracs L,

- Turnbull E, Valerio V, Bernatsky S, SUCCEED investigative team. When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study. *J Rheum*. March 2024. *J Rheumatol*. 2024 Jul 1;51(7):721-727. doi: 10.3899/jrheum.2023-1214.
30. Bruce M, Yogaratnam K, Suryaprakash N, Barker KL, **Marshall DA**. Key ingredients for successful collaboration in health research: perspectives of patient research partners. *Res Involv Engagem*. 2024 Jun 5;10(1):52. doi: 10.1186/s40900-024-00590-2.
 31. Cardwell FS, Elliott SJ, **Barber MRW**, Cheema K, George S, Boucher A, **Clarke AE**. Canadian patient experiences of lupus nephritis: a qualitative analysis. *Lupus Sci Med*. 2023 Dec 9;10(2):e000982. doi: 10.1136/lupus-2023-000982.
 32. **Choi MY**, Satoh M, Fritzler MJ. Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies. *Curr Opin Rheumatol*. 2023 Nov 1;35(6):383-394. doi: 10.1097/BOR.0000000000000957. Epub 2023 Jul 27.
 33. **Choi HK**, Zhang Y. Not Only Excruciating Pain: Might a Gout Flare Episode Lead to Pulmonary Embolism? *Arthritis Rheumatol*. Sep 2023;75(9):1506-1508. doi:10.1002/art.42511.
 34. **Choi MY**, Chen I, **Clarke AE**, Fritzler MJ, Buhler KA, Urowitz M, Hanly J, St-Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, **Fortin PR**, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Buyon JP, Sontag D, Costenbader KH. Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes. *Ann Rheum Dis*. 2023 Jul;82(7):927-936. doi: 10.1136/ard-2022-223808. Epub 2023 Apr 21.
 35. **Choi MY**, Satoh M, Fritzler MJ. Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies. *Curr Opin Rheumatol*. 2023 Nov 1;35(6):383-394. doi: 10.1097/BOR.0000000000000957. Epub 2023 Jul 27.
 36. Coll JC, Turcotte AF, Leslie WD, **Michou L**, Weisnagel SJ, Mac-Way F, Albert C, Berger C, Morin SN, Rabasa-Lhoret R, Gagnon C. Advanced glycation end products are not associated with bone mineral density, trabecular bone score, and bone turnover markers in adults with and without type 1 diabetes: a cross-sectional study. *JBMR Plus*. 2024 Jan 4;8(3):ziad018. doi: 10.1093/jbmrpl/ziad018. eCollection 2024 Feb.
 37. **Colmegna I**, Valerio V, Amiable N, Useche M, Rampakakis E, Flamand L, Rollet-Labelle E, Bessette L, Fitzcharles MA, Hazel E, McCormack D, **Michou L**, Panopalis P, Langlois MA, Bernatsky S, **Fortin PR**. COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna

- Spikevax primary series. *RMD Open*. 2023 Nov 29;9(4):e003400. doi: 10.1136/rmdopen-2023-003400.
38. **Contreras DG**, McLane P, **Barber CEH**, Lin K, Elliott MJ, **Chomistek K**, **McQuitty S**, **Davidson E**, Hildebrandt C, Katz S, Lang E, Holroyd BR, **Barnabe C**. Emergency department utilization by persons with rheumatoid arthritis: a population-based cohort study. *Rheumatol Int*. 2024 Jun 8. doi: 10.1007/s00296-024-05627-z. Online ahead of print.
 39. Coward S, Benchimol EI, Bernstein CN, **Avina-Zubieta A**, Bitton A, Carroll MW, Cui Y, Hoentjen F, Hracs L, Jacobson K, Jones JL, King J, Kuenzig ME, Lu N, El-Matary W, Murthy SK, Nugent Z, Otley AR, Panaccione R, Peña-Sánchez JN, Singh H, Targownik LE, White D, Windsor JW, Kaplan GG; Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian nationwide analysis. *Am J Gastroenterol*. 2024 Feb 1. doi: 10.14309/ajg.0000000000002687. Online ahead of print.
 40. Currie GR, Kennedy BL, **Benseler S**, Yeung R, Swart J, Vastert S, Wulffraat NM, Kip MMA, MacKean G, **Marshall DA**. Managing juvenile idiopathic arthritis within the context of their life: What we learnt from children and youth living with juvenile idiopathic arthritis and their parents. *Musculoskeletal Care*. July, 2023;1–13. doi:10.1002/msc.1805.
 41. Dal Santo T, Rice DB, Carrier ME, Virgili-Gervais G, Levis B, Kwakkenbos L, Golberg M, **Bartlett SJ**, Gietzen A, Gottesman K, Guillot G, **Hudson M**, Hummers LK, Malcarne VL, Mayes MD, Mouthon L, Richard M, Sauvé M, Wojeck RK, Geoffroy MC, Benedetti A, Thombs BD; SPIN investigators. Factors associated with physical function among people with systemic sclerosis: a SPIN cohort cross-sectional study. *Rheumatology (Oxford)*. 2024 Mar 12:keae162. doi: 10.1093/rheumatology/keae162. Epub ahead of print. PMID: 38471107.
 42. Dal Santo T, Golberg M, Nassar EL, Carrier ME, Hu S, Kwakkenbos L, **Bartlett SJ**, Fox RS, Lee YC, Varga J, Benedetti A, Thombs BD; Scleroderma Patient-centered Intervention Network Pain Patient Advisory Team. Protocol for the development of a tool to map systemic sclerosis pain sources, patterns, and management experiences: a Scleroderma Patient-centered Intervention Network patient-researcher partnership. *BMC Rheumatol*. 2024 Jun 21;8(1):28. doi: 10.1186/s41927-024-00398-3.
 43. Dal Santo T, Rice D, Carrier ME, Virgili-Gervais G, Levis B, Kwakkenbos L, **Bartlett SJ**, Gietzen A, Gottesman K, Guillot G, Hudson M, Hummers LK, Malcarne V, Mayes M, Mouthon L, Richard M, Sauve M, Wojeck R, Geoffroy MC, Benedetti A, Thombs B; SPIN investigators. Factors associated with satisfaction with social roles and activities among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort cross-sectional study. *RMD Open*. 2024 Feb 29;10(1):e003876. doi: 10.1136/rmdopen-2023-003876.
 44. Damer A, Chaudry E, Eftekhari D, **Benseler SM**, Safi F, Aviv RI, Tyrrell PN. Neuroimaging Scoring Tools to Differentiate Inflammatory Central Nervous System Small-Vessel Vasculitis: A Need for Artificial Intelligence/Machine Learning?-A

Scoping Review. Tomography. 2023 Oct 2;9(5):1811-1828. doi: 10.3390/tomography9050144.

45. Dano S, Hussain J, Edwards N, Sun YI, Li M, Howell D, Peipert JD, Novak M, **Bartlett SJ**, Mucsi I. Assessing Fatigue in Patients Receiving Kidney Replacement Therapy Using PROMIS Computer Adaptive Testing. *Am J Kidney Dis*. 2023. Epub 20230309. doi: 10.1053/j.ajkd.2022.12.018.
46. Décarry S, de Wit M, Naye F, Barton JL, Fraenkel L, **Li LC**, Brooks P, Stacey D, Maxwell LJ, Campbell W, Hofstetter C, Voshaar M, Meara A, Christensen R, Boonen A, Suarez-Almazor ME, Meade T, March L, Jull JE, Alten R, Morgan EM, Stewart **Hazlewood G**, **Barber CEH**, Guillemin F, El-Miedany Y, Mittoo S, Robertson TW, **Bartlett SJ**, Singh JA, Mannion M, Nasef SI, Boel A, Adebajo A, Arnaud L, Gill TK, Moholt E, Burt J, Jayatilleke A, Hmamouchi I, Berthelsen DB, Blanco FJ, Mather K, Maharaj A, Sharma S, Caso F, Beaton D, Shea B, Fong C, Fernandez AP, Mackie S, Nikiphorou E, Jones A, Greer-Smith R, Sloan VS, Akpabio A, Strand V, Lee RR, Umaefulam V, Monti S, Abaza N, Schultz G, Stones S, Gossec L, Nielsen SM, Cavallo S, Srinivasalu H, Constien D, Evans V, Tugwell P, Toupin-April K. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials. *Semin Arthritis Rheum*. 2024 Apr;65:152381. doi: 10.1016/j.semarthrit.2024.152381. Online ahead of print.
47. Dewidar O, Pardo Pardo J, Welch V, **Hazlewood GS**, Darzi AJ, **Barnabe C**, Pottie K, Petkovic J, Kuria S, Sha Z, Allam S, Busse JW, Schunemann HJ, Tugwell P. Operationalizing the GRADE-Equity criterion to inform guideline recommendations: Application to a Medical Cannabis guideline. *J Clin Epidemiology*. 2024 Jan;165:111185. doi: 10.1016/j.jclinepi.2023.10.001. Epub 2023 Nov 11.
48. Dhiman K, Hall M, Crump T, **Hoens AM**, **Lacaille D**, Rankin JA, Then KL, **Hazlewood G**, **Barnabe C**, Katz S, Sutherland J, Dempsey E, **Barber CEH**. Content validity testing of the INTERMED Self-Assessment in a sample of adults with rheumatoid arthritis and rheumatology healthcare providers. *Health Expect*. Feb;27(1):e13978. doi: 10.1111/hex.13978.
49. D'Silva A, Islam Z, **Marshall DA**, Vallance JK, Nasser Y, Rajagopalan V, MacKean G, Raman M. Experiences of Irritable Bowel Syndrome Patients in a Virtual Yoga Program: Qualitative Findings from a Clinical Trial. *Dig Dis Sci*. 2024 Jan;69(1):169-179. doi: 10.1007/s10620-023-08125-7. Epub 2023 Nov 1.
50. El Kamouni H, Jalaledin D, Albert A, **Hoa S**, Vo C, Bourré-Tessier J, Rich É, Goulet JR, Koenig M, Pérez G, **Choi MY**, Troyanov Y, Satoh M, Fritzler MJ, Sénécal JL, Landon-Cardinal O. Anti-SMN autoantibodies in mixed connective tissue disease are associated with a severe systemic sclerosis phenotype. *RMD Open*. 2023 Oct;9(4):e003431. doi: 10.1136/rmdopen-2023-003431.
51. El Tal T, Morin MP, Morris SK, Farrar DS, Berard RA, Kakkar F, Moore Hepburn C, Baerg K, Beaufils C, Bennett TL, **Benseler SM**, Beaudoin-Bussièrès G, Chan K, Cyr C, Dahdah N, Donner EJ, Drouin O, Edjoc R, Eljaouhari M, Embree JE, Farrell C, Finzi A, Forgie S, Giroux R, Kang KT, King M, Laffin Thibodeau M, Lang B, Laxer

- RM, Luu TM, McCrindle BW, Orkin J, Papenburg J, Pound CM, Price VE, Proulx-Gauthier JP, Purewal R, Sadarangani M, Salvadori MI, Thibeault R, Top KA, Viel-Thériault I, Haddad E, Scuccimarri R, Yeung RSM. Paediatric inflammatory multisystem syndrome in Canada: population-based surveillance and role of SARS-CoV-2 linkage. *Pediatr Res*. 2023 Jun 5:1-10. doi: 10.1038/s41390-023-02668-1. Online ahead of print.
52. Falck RS, Sorte Silva NCB, Balbim GM, **Li LC**, Barha CK, Liu-Ambrose T. Addressing the elephant in the room: the need to examine the role of social determinants of health in the relationship of the 24-hour activity cycle and adult cognitive health. *Br J Sports Med*. 2023 Nov;57(22):1416-1418. doi: 10.1136/bjsports-2023-106893. Epub 2023 Oct 5.
 53. Falck RS, Hsu CL, Best JR, Boa Sorte Silva NC, Hall PA, **Li LC**, Liu-Ambrose T. Cross-sectional and longitudinal neural predictors of physical activity and sedentary behaviour from a 6-month randomized controlled trial. *Sci Rep*. 2024 Jan 9;14(1):919. doi: 10.1038/s41598-023-48715-z.
 54. Farrar D, Hepburn CM, Drouin O, El Tal T, Morin MP, Berard R, King M, Thibodeau ML, Baerg K, Beaudoin-Bussièrès G, Beaufile C, Bennett TL, Benseler S, Chan K, Cyr C, Dahdah N, Donner E, Embree J, Farrell C, Finzi A, Forgie S, Giroux R, Kang K, Lang B, Laxer R, McCrindle B, Orkin J, Papenburg J, Pound C, Price V, Proulx-Gauthier JP, Purewal R, Sadarangani M, Salvadori M, Thibeault R, Top K, Viel-Thériault I, Haddad E, Scuccimarri R, Yeung R, Kakkar F, Morris S. Resource use and disease severity of children hospitalized for COVID-19 versus multisystem inflammatory syndrome in children (MIS-C) in Canada. *Can Commun Dis Rep*. 2023 Apr 1;49(4):103-112. doi: 10.14745/ccdr.v49i04a03. eCollection 2023 Apr 1.
 55. Fazal ZA, **Avina-Galindo M**, **Marozoff S**, Kwan J, **Lu N**, **Avina-Zubieta JA**. Risk of venous thromboembolism in patients with rheumatoid arthritis: a meta-analysis of observational studies. *BMC Rheumatology*. 2024; <https://doi.org/10.1186/s41927-024-00376-9>
 56. Florax AA, Doeleman MJH, de Roock S, van der Linden N, Schatorjé E, Currie G, **Marshall DA**, IJzerman MJ, Yeung RSM, **Benseler SM**, Vastert SJ, Wulffraat NM, Swart JF, Kip MMA; for UCAN-CAN DU and UCAN CURE consortia. Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing tumour necrosis factor-alfa inhibitors in juvenile idiopathic arthritis. *Rheumatology (Oxford)*. 2023 Dec 20:kead688. doi: 10.1093/rheumatology/kead688. Online ahead of print.
 57. Gagliardi AR, Abbatichio A, Theodorlis M, **Marshall DA**, MacKay C, Borkhoff CM, **Hazlewood GS**, Battistella M, Lofters A, Ahluwalia V. Multi-level strategies to improve equitable timely person-centred osteoarthritis care for diverse women: qualitative interviews with women and healthcare professionals. *Int J Equity Health*. 2023 Oct 7;22(1):207. doi: 10.1186/s12939-023-02026-x.
 58. Gattorno M, Obici L, Penadés IC, Kallinich T, **Benseler S**, Dekker E, Lévy J, De Benedetti F, Lachmann H. Long-term efficacy/safety of canakinumab in patients with tumor necrosis factor receptor-associated periodic syndrome: results from a

- phase III trial. *Arthritis Rheumatol.* 2023 Sep 5. doi: 10.1002/art.42695. Online ahead of print.
59. Gavin JP, Rossiter L, Fenerty V, **Leese J**, Adams J, Hammond A, **Davidson E**, **Backman CL**. The Impact of Occupational Therapy on the Self-Management of Rheumatoid Arthritis: A Mixed Methods Systematic Review. *ACR Open Rheumatol.* 2024 Feb 8. doi: 10.1002/acr2.11650. Online ahead of print.
 60. GBD 2021 Osteoarthritis Collaborators incl. **Kopec J**. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Rheumatol.* 2023 Aug 21;5(9):e508-e522. doi: 10.1016/S2665-9913(23)00163-7. eCollection 2023 Sep.
 61. GBD 2021 Osteoarthritis Collaborators incl. **Kopec J**. Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. *Lancet Rheumatol.* 2023 Sep 25;5(10):e594-e610. doi: 10.1016/S2665-9913(23)00211-4. eCollection 2023.
 62. Ghaseminejad F, Rich KE, Rosenbaum D, Rydz E, Palepu A, Dodek P, Salmon A, Leitch HA, Townson A, **Lacaille D**, Varshney VP, Khan NA. Differences in Physician Burnout by Specialty: A Cross-Sectional Survey. *Perm J.* 2024 Jun 25:1-11. doi: 10.7812/TPP/24.040. Online ahead of print.
 63. Gheshlaghi N, **Thomas M**, **Trehan N**, **Harrison M**, **De Vera MA**. Reporting of determinants of health inequities and participant characteristics in randomized controlled trials of juvenile idiopathic arthritis in Canada: a scoping review. *Pediatr Rheumatol Online J.* 2023 Nov 6;21(1):134. doi: 10.1186/s12969-023-00917-5.
 64. Gladman DD, Chandran V, Rosen CF, Rohekar S, Boyd T, Eder L, Rahman P, **Dutz J**, **Chan J**, Haydey RP, Barac S, Laliberté MC, Girard T, Fournier PA, Sutton M, Pereira D, Chim T, Coupal L, Choquette D. Residual Disease Activity In Canadian Patients With Psoriatic Arthritis (PsA) Treated With Advanced Therapies: Results From A Multi-Registry Analysis (UNISON-PsA). *J Rheumatol.* 2024 May 1;51(5):479-487. doi: 10.3899/jrheum.2023-0716. Online ahead of print.
 65. Grignaschi S, Kim M, Zanframundo G, Ravichandran N, Lilleker JB, Sen P, Joshi M, Agarwal V, Kardes S, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Chatterjee T, Tan AL, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Nune A, Distler O, Chinoy H, Cavagna L, Agarwal V, Aggarwal R, Gupta L; COVAD study group. High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey. *Rheumatol Int.* 2023 Sep;43(9):1637-1649. doi: 10.1007/s00296-023-05344-z. Epub 2023 Jun 14.
 66. Gulcernal MO, Sarac DC, Alp G, Duran G, Gucenmez S, Solmaz D, Akar S, **Bayraktar D**. Effects of video-based cervical stabilization home exercises in patients with rheumatoid arthritis: a randomized controlled pilot study. *Z Rheumatol.* 2024 Jul 1. doi: 10.1007/s00393-024-01543-6. Online ahead of print.
 67. Gupta A, **De Vera MA**, **Rebic N**, **Amiri N**. Pre-pregnancy planning for female patients seen at a pregnancy and rheumatic diseases clinic: a retrospective analysis

- of patients with rheumatic diseases seeking pregnancy-related care. *Rheumatology Int.* 2024 Feb;44(2):283-289. doi: 10.1007/s00296-023-05398-z. Epub 2023 Aug 3.
68. Hadwen B, Stranges S, Pope JE, **Bartlett S**, Boire G, Bessette L, Hitchon CA, **Hazlewood G**, Keystone EC, Schieir O, Thorne C, Tin D, Valois MF, Bykerk V, Barra L; CATCH Investigators. Risk factors for prevalent and incident hypertension in rheumatoid arthritis: data from the Canadian Early Arthritis Cohort. *Rheumatol Adv Pract.* 2024 May 22;8(2):rkae066. doi: 10.1093/rap/rkae066. eCollection 2024.
69. Hamilton M, Christine Lin CW, Arora S, **Harrison M**, Tracy M, Nickel B, Shaheed CA, Gnjjidic D, Mathieson S. Understanding general practitioners' prescribing choices to patients with chronic low back pain: a discrete choice experiment. *Int J Clin Pharm.* 2024 Feb;46(1):111-121. doi: 10.1007/s11096-023-01649-y. Epub 2023 Oct 26.
70. **Harrison M**. Sex in the Time of COVID-19. *J Rheumatol.* 2023 Oct;50(10):1208-1210. doi: 10.3899/jrheum.2023-0444. Epub 2023 Jul 15.
71. Hart HF, Birmingham TB, Sritharan P, **Primeau CA**, King MG, Fischer LK. Sex-related differences in gait characteristics and their associations with symptoms in individuals with patellofemoral osteoarthritis. *Gait & Posture.* 2024 Jan;107:35-41. doi: 10.1016/j.gaitpost.2023.09.009. Epub 2023 Sep 17.
72. Hart HF, Crossley KM, Culvenor AG, Khan MCM, West TJ, Kennedy JB, **Couch JL**, **Whittaker JL**. Knee confidence, fear of movement and psychological readiness for sport in individuals with knee conditions: A systematic review and meta-analysis. *Journal of Orthopaedic and Sports Physical Therapy* Jan 29:1-35 doi: 10.2519/jospt.2024.12070 PMID 38284344
73. Henry RS, Kwakkenbos L, Carrier ME, Patten S, **Bartlett SJ**, Mouthon L, Varga J, Benedetti A, Thombs BD. Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study. *Clin Exp Rheumatol.* 2023 Aug;41(8):1639-1643. doi: 10.55563/clinexprheumato/cca0xv.
74. Hitchon C, Islam S, Fung D, Liu Q, Lac L, **Bartlett S**, Bessette L, Boire G, **Hazlewood G**, Keystone E, Pope J, Schieir O, Thorne C, Tin D, Valois MF, Bykerk V; CATCH Canadian Early Arthritis Cohort (CATCH) Investigators, van der Heijde D, O'Neil L, Hu P. Artificial Intelligence Models for Computer-Assisted Joint Detection and Sharp-Van Der Heijde Score Prediction in Hand Radiographs from Patients with Rheumatoid Arthritis. *J Rheumatol.* In Press.
75. Holm PM, Simonö C, Brydegaard NK, Høgsgaard D, Thorborg K, Møller M, **Whittaker JL**, Roos EM, Skou ST. An early care void: The injury experience and perceptions of treatment among knee-injured individuals and healthcare providers – a qualitative interview study. *Phys Ther Sport* 64:32-40. doi: [10.1016/j.pts.2023.08.006](https://doi.org/10.1016/j.pts.2023.08.006).
76. **Hoque R**, **Avina-Zubieta JA**, **Lacaille D**, **De Vera MA**, Qian Y, McCandless L, **Esdale J**, **Xie H**. Antimalarial Adherence and Risk of Cardiovascular Events in Rheumatoid Arthritis and Systemic Lupus Erythematosus patients: A Population-

- based Study. (Hoboken). 2023 Sep 10. doi: 10.1002/acr.25233. Online ahead of print.
77. **Howren A**, Sayre E, **Avina-Zubieta JA**, Puyat J, **Da costa D**, **Xie H**, **Davidson E**, **De Vera M**. "What came first?" Population-based evaluation of health care encounters for depression and anxiety before and after inflammatory arthritis diagnosis. *Arthritis Care & Research*. December 2024 Jan 8. doi: 10.1002/acr.25294. Online ahead of print.
 78. Huang A, **Wang E**, Sanger S, Papaioannou A, Rodrigues IB. 2023. Comparison of national and international sedentary behaviour and physical activity guidelines for older adults: A systematic review and quality appraisal with AGREE II. *PLOS ONE*. 2023 Nov 27;18(11):e0294784. doi: 10.1371/journal.pone.0294784. eCollection 2023.
 79. Huot S, **Fortin PR**, Godbout A, Laflamme C, Pouliot M. A tool to assist rheumatologists to engage their lupus patients: the Purple Butterfly. *Rheumatol Adv Pract*. 2024 Jun 12;8(3):rkae075. doi: 10.1093/rap/rkae075. eCollection 2024.
 80. Iziduh S, Abenoja A, Theodorlis M, Ahluwalia V, Battistella M, Borkhoff CM, **Hazlewood GS**, Lofters A, MacKay C, **Marshall DA**, Gagliardi AR. Priority strategies to reduce socio-gendered inequities in access to person-centred osteoarthritis care: Delphi survey. *BMJ Open*. 2024 Feb 19;14(2):e080301. doi: 10.1136/bmjopen-2023-080301.
 81. Jinks C, Botto-van Bemden A, Bowden J, Bunzli S, Eyles J, Egerton T, Foster NE, Healey EL, Maddison J, O'Brien D, Parry E, Quicke JG, Schiphof D, Thomas MJ, Holden MA and Change OA Narrative Initiative (Allen KD, Babatunde OO, Bennell KL, Berry A, Bierma-Zeinstra S, Callahan LF, Campbell L, Dziedzic KS, Finney A, French HP, Haber T, Hadley-Barrows T, Hall M, Hawker G, Henriksen M, Hinman RS, Ho-Pham L, Hunter DJ, Lawford BJ, Mallen C, McHugh GA, Kopkow C, Neogi T, Nicholls E, Nicolson PJA, Østerås N, Paskins Z, Protheroe J, Roos EM, Runhaar J, Skou ST, Simkins J, Swaithe L, Thomas G, van der Esch M, **Whittaker JL**, Zhang W). Changing the Narrative on Osteoarthritis: A call for global action. *Osteoarthritis and Cartilage*. 32(4):414-420 doi: 10.1016/j.joca.2024.02.004.
 82. **Jones CA**, Jessiman-Perreault G, Kania-Richmond A, Metcalfe A, Hart DA, Beaupre LA: The effect of geographic location and payor type on provincial-wide delivery of the GLA:D program for hip and knee osteoarthritis in Alberta, Canada. *Osteoarthritis and Cartilage Open* 2023, 5(4):100398.
 83. Jorge AM, Melles RB, Marmor MF, Zhou B, Zhang Y, **Choi HK**. Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes. *JAMA Netw Open*. 2024 May 1;7(5):e2410677. doi: 10.1001/jamanetworkopen.2024.10677.
 84. Joshi AD, **McCormick N**, Yokose C, Yu B, Tin A, Terkeltaub R, Merriman T, Eliassen AH, Curhan GC, Raffield LM, **Choi HK**. Pre-Diagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk, Accounting for Serum Urate Levels: A Population-Based, Prospective Study and Mendelian Randomization Analysis. *Arthritis & Rheumatology*. 2023 Sep;75(9):1648-1657.

85. Kang EH, Shin A, Park CS, Lee EB, Lee YJ, Curhan G, **Choi HK**. Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study. *Rheumatology (Oxford)*. 2024 May 11:keae262. doi: 10.1093/rheumatology/keae262. Online ahead of print.
86. Kania-Richmond A, Beaupre LA, Jessiman-Perreault G, Tribo D, Martyn J, Hart DA, Robert J, Slomp M, **Jones CA**. 'I do hope more people can benefit from it.': The qualitative experience of individuals living with osteoarthritis who participated in the GLA:D™ program in Alberta, Canada. *PLoS One*. 2024 Feb 21;19(2):e0298618. doi: 10.1371/journal.pone.0298618. eCollection 2024.
87. Kania-Richmond A, **Jones CA**, Martyn J, Hastings S, Ellis K, Jessiman-Perreault G, Hart DA, Robert J, Slomp M, Beaupre LA. Implementing a guideline-based education and exercise program for people with knee and hip osteoarthritis-Practical experiences of providers and clinic leaders: A qualitative study. *Musculoskeletal Care*. 2023 Aug 7. doi: 10.1002/msc.1801.
88. Kania-Richmond A, Beaupre LA, Jessiman-Perreault G, Tribo D, Martyn J, Hart DA, Robert J, Slomp M, **Jones CA**. Participants' perceived benefits from the GLA:D™ program for individuals living with hip and knee osteoarthritis: a qualitative study. *J Patient Rep Outcomes*. 2024 Jun 26;8(1):62. doi: 10.1186/s41687-024-00740-w.
89. Karam SG, Zhang Y, Pardo-Hernandez H, Siebert U, Koopman L, Noyes J, Tarride JE, Stevens AL, Welch V, Saz-Parkinson Z, Ens B, Devji T, Xie F, **Hazlewood G**, Mbuagbaw L, Alonso-Coello P, Brozek JL, Schünemann HJ. ROBVALU: a tool for assessing risk of bias in studies about people's values, utilities, or importance of health outcomes. *BMJ*. 2024 Jun 12;385:e079890. doi: 10.1136/bmj-2024-079890.
90. Katz PP, **Barber CEH**, Duarte-García A, Garg S, Machua W, Rodgers W, Santiago-Casas Y, Suter L, Bartels CM, Yazdany J. Development of the American College of Rheumatology's Patient-reported Outcome Quality Measures for Systemic Lupus Erythematosus. *Arthritis Care Res (Hoboken)*. 2024 Jan 15. doi: 10.1002/acr.25301. Online ahead of print.
91. Kayani B, Howard LC, Neufeld ME, **Garbuz DS**, Masri BA. Cannabis and Pain Control After Total Hip and Knee Arthroplasty. *Orthop Clin North Am*. 2023 Oct;54(4):407-415. doi: 10.1016/j.jocl.2023.04.002. Epub 2023 Jun 5.
92. Kheirkhah H, Hartfeld N, Widdifield J, Kulhawy-Wibe S, **Roberts J**, Yacyshyn E, Lee J, Jilkin K, Jerome D, Kwok T, Burt J, **Barber CEH**. An Overview of Reviews to Inform Organization-level Interventions to Address Burnout in Rheumatologists. *J Rheumatol*. November 2023, 50 (11) 1488-1502; DOI: <https://doi.org/10.3899/jrheum.2023-0437>.
93. Khorshidi HA, **Marshall DA**, Goranitis I, Schroeder B, IJzerman M. System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model. *Expert Rev Pharmacoecon Outcomes Res*. 2024 Jan;24(1):37-47. doi: 10.1080/14737167.2023.2267764. Epub 2024 Jan 18.
94. Krustev E, Hanly JG, Chin R, Buhler KA, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sánchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg D, Rahman A,

Merrill JT, **Fortin PR**, Gladman DD, Bruce IN, Petri MA, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askenase A, Buyon J, Fritzler MJ, **Clarke AE**, **Choi MY**. Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus. *Lupus Sci Med*. 2024 Apr 9;11(1):e001139. doi: 10.1136/lupus-2023-001139.

95. Kwakkenbos L, Thombs BD, Khanna D, Carrier ME, Baron M, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudou S, Riggs R, Sauve M, Wigley F, **Hudson M**, **Bartlett SJ**. Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. *Rheumatology*. 2023;62(11):3771. doi: 10.1093/rheumatology/kez234.
96. **Leclair V**, Notarnicola A, Kryštůfková O, Mann H, Andersson H, Diederichsen LP, Vencovský J, Holmqvist M, Lundberg IE, Steele RJ, **Hudson M**. Effect modification of cancer on the association between dysphagia and mortality in early idiopathic inflammatory myopathies. *Semin Arthritis Rheum*. 2024 Feb 2;65:152408. doi: 10.1016/j.semarthrit.2024.152408. Online ahead of print.
97. **Leese J**, **Therrien S**, **Ramachandran S**, **Backman CL**, **Ma JK**, Koehn CL, **Hoens AM**, **English K**, **Davidson E**, **McQuitty S**, Gavin J, Adams J, **Li LC**. Decision-Making around COVID-19 Public Health Measures and Implications for Self-Care Activities: Experiences of Persons with Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2023 Oct 23. doi: 10.1002/acr.25262. Online ahead of print.

A narrated graphical abstract for the paper (developed with Monika) is also available on YouTube at https://www.youtube.com/watch?v=JxkL8w_buAo

98. Lefrançois P, Doueidari Z, Kleiner O, Manion R, **Dutz J**, Philip A, Chan AW; Skin Investigation Network of Canada Priority Setting Collaborative. Top 10 research priorities for cutaneous squamous cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative. *Br J Dermatol*. 2024 Feb 16;190(3):431-432. doi: 10.1093/bjd/ljad387.
99. Leung Soo C, Bhatnagar S, **Bartlett SJ**, Esmail A, Dheda K, Pant Pai N. Development and Evaluation of a Digital HIV Risk Assessment Tool Incorporated Within an App-Based Self-Testing Program. *Journal of acquired immune deficiency syndromes*. 2023;93(5):387-94. doi: 10.1097/QAI.0000000000003210.
100. Leung Soo C, Pant Pai N, **Bartlett SJ**, Esmail A, Dheda K, Bhatnagar S. Socioeconomic factors impact the risk of HIV acquisition in the township population of South Africa: A Bayesian analysis. *PLOS Glob Public Health*. 2023;3(1):e0001502. Epub 20230126. doi: 10.1371/journal.pgph.0001502.
101. **Li LC**, **Xie H**, Feehan LM, Shaw C, **Lu N**, **Ramachandran S**, **Wang E**, **Therrien S**, **Mucha J**, **Hoens AM**, **English K**, **Davidson E**, Liu-Ambrose T, **Backman CL**, **Esdaile JM**, Miller KJ, **Lacaille D**. Effect of digital monitoring and counselling on self-management ability in patients with rheumatoid arthritis: a randomised

- controlled trial. *Rheumatology (Oxford)*. 2023 Dec 28;kead709. doi: 10.1093/rheumatology/kead709. Online ahead of print.
102. **Li L**, Etminan M, Kaplan GG, Tremlett H, **Xie H**, **Aviña-Zubieta JA**. Multiple Sclerosis Risk Among Anti-tumor Necrosis Factor Alpha Users: A Methodological Review of Observational Studies Based on Real-world Data. *Curr Drug Saf*. 2024;19(2):200-207. doi: 10.2174/1574886318666230726162245.
 103. Lieber SB, Nahid M, **Legge A**, Rajan M, Lipschultz RA, Lin M, Reid MC, Mandl LA. Comparison of two frailty definitions in women with systemic lupus erythematosus. *Rheumatology (Oxford)*. 2024 May 2;63(5):1384-1390. doi: 10.1093/rheumatology/kead393.
 104. Loganathan A, Zanframundo G, Yoshida A, Faghihi-Kashani S, Bauer Ventura I, Dourado E, Bozan F, Sambataro G, Yamano Y, Bae SS, Lim D, Ceribelli A, Isailovic N, Selmi C, Fertig N, Bravi E, Kaneko Y, Saraiva AP, Jovani V, Bachiller-Corral J, Cifrian J, Mera-Varela A, Moghadam-Kia S, Wolff V, Campagne J, Meyer A, Giannini M, Triantafyllias K, Knitza J, Gupta L, Molad Y, Iannone F, Cavazzana I, Piga M, De Luca G, Tansley S, Bozzalla-Cassione E, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, **Hudson M**, Kuwana M, Lundberg IE, Mammen AL, McHugh NJ, Miller FW, Montecucco C, Oddis CV, Rojas-Serrano J, Schmidt J, Scirè CA, Selva-O'Callaghan A, Werth VP, Alpini C, Bozzini S, Cavagna L, Aggarwal R; CLASS Project. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank. *Clin Exp Rheumatol*. 2024 Feb;42(2):277-287. doi: 10.55563/clinexprheumatol/s14zq8. Epub 2024 Mar 14.
 105. **Losciale JM**, **Truong LK**, Zhang K, Scarr T, **Xie H**, **Li LC**, Mitchell C, Hunt MA, **Whittaker JL**. The association between knee muscle performance and clinical outcomes of knee function 1-4 years after a sport-related knee joint injury. *Phys Ther Sport*. 64:147-55 doi: 10.1016/j.ptsp.2023.10.003.
 106. **Losciale JM**, **Truong LK**, **Zhang K**, **Silvester-Lee T**, Miciak M, Pajkic A, **Le CY**, **Xie H**, **Hoens AM**, Mosewich AD, Hunt MA, **Li LC**, Roos EM, **Whittaker JL**. Assessing the efficacy of the Stop OsteoARthritis (SOAR) program: A randomized delayed-controlled trial in persons at increased risk of early onset post-traumatic knee osteoarthritis. *Osteoarthritis Cartilage*. 2024 Apr 12:S1063-4584(24)01151-8. doi: 10.1016/j.joca.2024.04.003. Online ahead of print.
 107. **Macdonald GG**, **Leese J**, **Hoens AM**, **Kerr S**, **Lum W**, **Gulka L**, Nimmon L, **Li LC**. A patienthood that transcends the patient: An analysis of patient research partners' narratives of involvement in a Canadian arthritis patient advisory board. *J Health Serv Res Policy*. 2024 Jan;29(1):22-30. doi: 10.1177/13558196231197288. Epub 2023 Aug 26.
 108. Mandal AK, Merriman TR, **Choi HK**, Mount DB. Caffeine inhibits both basal and insulin-activated urate transport. *Arthritis Rheumatol*. 2024 Jun 26. doi: 10.1002/art.42940. Online ahead of print.
 109. Mann SK, Bone JN, Bosman ES, Cabral DA, Morishita KA, Brown KL; PedVas Investigator Network (incl. **Benseler S**).. Predictive utility of ANCA positivity and

- antigen specificity in the assessment of kidney disease in paediatric-onset small vessel vasculitis. *RMD Open*. 2024 Jun 17;10(2):e004315. doi: 10.1136/rmdopen-2024-004315.
110. Marozoff S, **Tan J, Lu N**, Loree JM, **Xie H, Lacaille D, Kopec JA, Esdaile JM**, Corradetti B, Malone P, Koehn C, **Mennell P, Hoens AM, A Avina-Zubieta JA, Lacaille D**. Effect of immunosuppressive or immunomodulatory agents on severe COVID-19 outcomes: A population-based cohort study. *ACR Open Rheumatol*. 2023 Dec;5(12):685-693. doi: 10.1002/acr.2.11620. Epub 2023 Oct 11.
 111. **Marshall DA**, Tagimacruz T, **Barber CEH**, Cepoiu-Martin M, Lopatina E, Robert J, Lupton T, Patel J, Mosher DP. Intended and unintended consequences of strategies to meet performance benchmarks for rheumatologist referrals in a centralized intake system. *J Eval Clin Pract*. 2023 Sep 18. doi: 10.1111/jep.13926. Online ahead of print.
 112. **Marshall DA**, Veldwijk J, Janssen EM, Reed SD. Stated-Preference Survey Design and Testing in Health Applications. *Patient*. 2024 Jan 31. doi: 10.1007/s40271-023-00671-6. Online ahead of print.
 113. **Marshall DA**, Gerber B, Lorenzetti DL, MacDonald KV, Bohach RJ, Currie GR. Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies. *Pharmacoeconomics*. 2023 Dec;41(12):1563-1588. doi: 10.1007/s40273-023-01308-0. Epub 2023 Aug 18.
 114. Maxwell L, Wright G, Schultz G, Grosskleg S, Barton J, Campbell W, Guillemin F, Hofstetter C, Petkovic J, Simon L, Shea B, Adebajo A, **Barnabe C**, Goel N, Hurley P, Nikiphorou E, Tugwell P. Embracing Unity at OMERACT: Valuing Equity, Promoting Diversity, Fostering Inclusivity. *Semin Arthritis Rheum*. 2024 Jun;66:152422. doi: 10.1016/j.semarthrit.2024.152422. Epub 2024 Feb 29.
 115. McLane P, Bill L, Healy B, **Barnabe C**, Plume TB, Bird A, Colquhoun A, Holroyd BR, Janvier K, Louis E, Rittenbach K, Curtin KD, Fitzpatrick KM, Mackey L, MacLean D, Rosychuk RJ. Leaving emergency departments without completing treatment among First Nations and non-First Nations patients in Alberta: a mixed-methods study. *CMAJ*. 2024 Apr 21;196(15):E510-E523. doi: 10.1503/cmaj.231019.
 116. **McCormick N**, Lin K, Yokose C, **Lu N**, Zhang Y, **Choi HK**. Unclosing Premature Mortality Gap Among Patients With Gout in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors. *Arthritis Care Res (Hoboken)*. 2024 Jan 8. doi: 10.1002/acr.25292. Online ahead of print.
 117. **McCormick N**, Yokose C, Wei J, **Lu N**, Wexler DJ, **Aviña-Zubieta JA, De Vera M**, Zhang Y, **Choi HK**. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent gout flares and gout-primary emergency department visits and hospitalizations: a general population cohort study. *Ann Intern Med*. 2023 Aug;176(8):1067-1080. doi: 10.7326/M23-0724. Epub 2023 Jul 25.

118. **McCormick N**, Yokose C, Challener GJ, Joshi AD, Tanikella S, **Choi HK**. Serum Urate and Recurrent Gout. *JAMA*. 2024 Feb 6;331(5):417-424. doi: 10.1001/jama.2023.26640.
119. **McCormick N**, Yokose C, Lu N, Wexler DJ, **Aviña-Zubieta JA**, **De Vera MA**, McCoy RG, **Choi HK**. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin. *JAMA Intern Med*. 2024 Jun 1;184(6):650-660. doi: 10.1001/jamainternmed.2024.0376.
120. McGrath T, Guzman J, Tucker L, Shiff NJ, Yaskina M, Tupper S, Rumsey DG; Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh-Out) Investigators; Incl **Benseler S**. Predictors of persisting pain in children with Juvenile Idiopathic Arthritis: a case control study nested in the ReACCh-Out cohort. *Pediatr Rheumatol Online J*. 2023 Sep 16;21(1):102. doi: 10.1186/s12969-023-00885-w.
121. Melles RB, Jorge AM, Marmor MF, Zhou B, Conell C, Niu J, **McCormick N**, Zhang Y, **Choi HK**. Hydroxychloroquine Dose and Risk for Incident Retinopathy: A Cohort Study. *Ann Intern Med*. 2023 Feb;176(2):166-173. doi: 10.7326/M22-2453. Epub 2023 Jan 17.
122. Meng CF, Lee YC, Schieir O, Valois MF, Butler MA, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Bessette L, Pope J, **Bartlett SJ**, Bykerk VP; Canadian Early Arthritis Cohort Investigators. Having More Tender Than Swollen Joints Is Associated With Worse Patient-Reported Outcomes in Patients With Early RA. *J Clin Rheumatol*. 2024 May 1. doi: 10.1097/RHU.0000000000002091. Epub ahead of print. PMID: 38689390.
123. **Merry K**, MacPherson MM, Blazey P, Fearon A, Hunt M, Morrissey D, Napier C, Reid D, **Whittaker JL**, Willy RW, Scott A. 2024. Current practice, guideline adherence, and barriers to implementation for Achilles tendinopathy rehabilitation: a survey of physical therapists and patients. *BMJ Open Sport and Exercise Medicine*, 2024;10:e001678. doi: [10.1136/bmjsem-2023-001678](https://doi.org/10.1136/bmjsem-2023-001678).
124. **Merry K**, MacPherson M, Vis-Dunbar M, **Whittaker JL**, Grävare Silbernagel K, Scott A. Identifying characteristics of resistance-based therapeutic exercise interventions for Achilles tendinopathy: A scoping review. *Phys Ther Sport*. 2023 Sep;63:73-94. doi: 10.1016/j.ptsp.2023.06.002. Epub 2023 Jul 1.
125. **Michou L**, Gamache P, Guertin JR, Tarride JE, Brown JP, Jean S. Prevalence and incidence of Paget's Disease of Bone: Temporal Trend Over 20 years in Quebec, Canada. *Bone*. 2023 Nov;176:116895. doi: 10.1016/j.bone.2023.116895. Epub 2023 Sep 6.
126. Morozan A, Joy S, Fujii U, Fraser R, Watters K, Martin JG, **Colmegna I**. Superiority of systemic bleomycin to intradermal HOCl for the study of interstitial lung disease. *Sci Rep*. 2023 Nov 23;13(1):20577. doi: 10.1038/s41598-023-47083-y.
127. Mucsi I, Siddiqui M, Wang J, Kalaher J, Baltazar V, Kerr L, Sampathu A, Peipert J, **Bartlett SJ**, Li M, Howell D, Novak M. Social Participation in Kidney Transplant Recipients (KT) Compared to Patients on Hemodialysis (HD). *American Journal of Transplantation*. 2023;23(6):S1094-S.

128. Munce SEP, Wong E, Luong D, Rao J, Cunningham J, Bailey K, John T, **Barber C**, Batthish M, Chambers K, Cleverley K, Crabtree M, Diaz S, Dimitropoulos G, Gorter JW, Grahovac D, Grimes R, Guttman B, Hébert ML, Henze M, Higgins A, Khodyakov D, Li E, Lo L, Macgregor L, Mooney S, Severino SM, Mukerji G, Penner M, Pidduck J, Shulman R, Stromquist L, Trbovich P, Wan M, Williams L, Yates D, Toulany A. Patient, caregiver and other knowledge user engagement in consensus-building healthcare initiatives: a scoping review protocol. *BMJ Open*. 2024 May 8;14(5):e080822. doi: 10.1136/bmjopen-2023-080822.
129. Muñoz-Grajales C, Barraclough ML, Diaz-Martinez JP, Su J, Bingham K, Kakvan M, Kretzmann RP, Tartaglia MC, Ruttan L, **Choi MY**, Appenzeller S, Marzouk S, Bonilla D, Katz P, Beaton D, Green R, Gladman DD, Wither J, Touma Z. Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment. *Front Immunol*. 2024 Jan 25;14:1326751. doi: 10.3389/fimmu.2023.1326751. eCollection 2023.
130. Nash P, **Dutz JP**, Peterson S, Patel BP, Eaton K, Shawi M, Zazzetti F, Wei JC. Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes. *BMJ Open*. 2023 Nov 8;13(11):e062306. doi: 10.1136/bmjopen-2022-062306.
131. Naye F, Toupin-April K, de Wit M, LeBlanc A, Dubois O, Boonen A, Barton JL, Fraenkel L, Li LC, Stacey D, March L, **Barber CEH**, **Hazlewood GS**, Guillemain F, **Bartlett SJ**, Berthelsen DB, Mather K, Arnaud L, Akpabio A, Adebajo A, Schultz G, Sloan VS, Gill TK, Sharma S, Scholte-Voshaar M, Caso F, Nikiphorou E, Nasef SI, Campbell W, Meara A, Christensen R, Suarez-Almazor ME, Jull JE, Alten R, Morgan EM, El-Miedany Y, Singh JA, Burt J, Jayatilleke A, Hmamouchi I, Blanco FJ, Fernandez AP, Mackie S, **Jones A**, Strand V, Monti S, Stones SR, Lee RR, Nielsen SM, Evans V, Srinivasalu H, Gerard T, Demers JL, Bouchard R, Stefan T, Dugas M, Bergeron F, Beaton D, Maxwell LJ, Tugwell P, Decary S. OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments. *Semin Arthritis rheum*. 2023;65:152344. doi: 10.1016/j.semarthrit.2023.152344.
132. Neyer MA, Henry RS, Carrier ME, Kwakkenbos L, Wojeck RK, Gietzen A, Gottesman K, Guillot G, Lawrie-Jones A, Mayes MD, Mouthon L, Nielson WR, Richard M, Worrón-Sauvé M, Harel D, Malcarne VL, **Bartlett SJ**, Thombs BD. Validity, Reliability, and Differential Item Functioning of English and French Versions of the 10-Item Connor-Davidson Resilience Scale in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *Arthritis Care Res (Hoboken)*. 2023 Nov;75(11):2369-2378. doi: 10.1002/acr.25139. Epub 2023 Jun 7.
133. Neyer MA, Henry RS, Carrier ME, Kwakkenbos L, Virgili-Gervais G, Wojeck RK, Wurz A, Gietzen A, Gottesman K, Guillot G, Lawrie-Jones A, Mayes MD, Mouthon L, Nielson WR, Richard M, Sauvé M, Harel D, Malcarne VL, **Bartlett SJ**, Benedetti A, Thombs BD; SPIN Investigators. The association of resilience and positive mental health in systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) cohort cross-sectional study. *J Psychosom Res*. 2024

Apr;179:111648. doi: 10.1016/j.jpsychores.2024.111648. Epub 2024 Mar 11. PMID: 38507968.

134. Nguyen K, Barsalou J, Basodan D, Batthish M, **Benseler SM**, Berard RA, Blanchette N, Boire G, Bolaria R, Bruns A, Cabral DA, Cameron B, Campillo S, Cellucci T, Chan M, Chédeville G, Chetaille AL, Chhabra A, Couture J, Dancey P, De Bruycker JJ, Demirkaya E, Dhalla M, Duffy CM, Feldman BM, Feldman DE, Gerschman T, Haddad E, Heale L, Herrington J, Houghton K, Huber AM, Human A, Johnson N, Jurencak R, Lang B, Larché M, Laxer RM, LeBlanc CM, Lee JJY, Levy DM, Lim L, Lim LSH, Luca N, McGrath T, McMillan T, Miettunen PM, Morishita KA, Ng HY, Oen K, Park J, Petty RE, Proulx-Gauthier JP, Ramsey S, Roth J, Rosenberg AM, Rozenblyum E, Rumsey DG, Schmeling H, Schneider R, Scuccimarrì R, Shiff NJ, Silverman E, Soon G, Spiegel L, Stringer E, Tam H, Tse SM, Tucker L, Turvey S, Twilt M, Duffy KW, Yeung RSM, Guzman J; ReACCh-Out and CAPRI Registry Investigators. A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry. *Rheumatology (Oxford)*. 2023 Oct 18:kead560. doi: 10.1093/rheumatology/kead560. Online ahead of print.
135. Nguyen Y, Blanchet B, Urowitz MB, Hanly JG, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, **Clarke AE**, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, Van Vollenhoven RF, Aranow C, Le Guern V, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Buyon J, Costedoat-Chalumeau N. Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort. *Arthritis Rheumatol*. 2023 Dec;75(12):2195-2206. doi: 10.1002/art.42645. Epub 2023 Nov 13.
136. Oldroyd AGS, Callen JP, Chinoy H, Chung L, Fiorentino D, Gordon P, Machado PM, McHugh N, Selva-O'Callaghan A, Schmidt J, Tansley SL, Vleugels RA, Werth VP; International Myositis Assessment and Clinical Studies Group Cancer Screening Expert Group;(Incl **Hudson M**). Aggarwal R. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. *Nat Rev Rheumatol*. 2023 Dec;19(12):805-817. doi: 10.1038/s41584-023-01045-w. Epub 2023 Nov 9.
137. Olson J, Brophy H, Turk T, **Jones A**, Yamamoto S, Yacyshyn E, Sadowski C, Paul P. Perceptions of Cannabis Use: A Qualitative Descriptive Study of Rheumatology Patients. *Journal of Primary Care and Community Health* 2023 14;1-6 <https://doi.org/10.1177/21501319231194974>.
138. Onwuka DC, Chen LYC, Zhan SH, Seidman MA, Cartagena L, Killow V, Abou-tak H, Mattman A, **Carruthers M**. Mass spectrometry in IgG4-related disease diagnosis. *Scientific Reports*. 2024 Jan13;14(1):2584.
139. Panchawagh S, Ravichandran N, Barman B, Nune A, Javaid M, Gracia-Ramos AE, Day J, Joshi M, Kuwana M, Saha S, Pande AR, Caballero-Urbe CV, Velikova T, Parodis I, Knitza J, Kadam E, Tan AL, Shinjo SK, Boro H; COVAD Study Group;

- (Incl. **Hudson M**) Aggarwal R, Agarwal V, Chatterjee T, Gupta L. COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group. *Rheumatol Int.* 2024 Jan;44(1):73-80. doi: 10.1007/s00296-023-05496-y. Epub 2023 Dec 7.
140. Parkinson JF, Ospina PA, Round J, McNeely ML, **Jones CA**. Generic Health Utility Measures in Exercise Oncology: A Scoping Review and Future Directions. *Curr Oncol.* 2023 Sep 28;30(10):8888-8901. doi: 10.3390/currenol30100642.
141. Pham Q, Wong D, Pfisterer KJ, Aleman D, **Bansback N**, Cafazzo JA, Casson AJ, Chan B, Dixon W, Kakaroumpas G, Lindner C, Peek N, Potts HW, Ribeiro B, Seto E, Stockton-Powdrell C, Thompson A, van der Veer S. The Complexity of Transferring Remote Monitoring and Virtual Care Technology Between Countries: Lessons From an International Workshop. *J Med Internet Res.* 2023 Aug 1;25:e46873. doi: 10.2196/46873.
142. Pijnenburg L, Giannini M, Bouchard-Marmen M, Arnaud L, Barsotti S, Bellando-Randone S, Bernardi L, Bini P, Blagojevic J, Codullo V, Couderc M, De Moreuil C, Dernis E, Diamanti L, Dubost JJ, Duval F, Emmi G, Galempoix JM, Geny B, Gottenberg JE, Groza M, Guffroy A, Guichard I, Guilpain P, Hervier B, **Hudson M**, Iaccarino L, Iannone F, Lebrun D, Marchioni E, Mariampillai K, Maurier F, Mosca M, Nadaj-Pakleza A, Nannini C, Piot JM, Prieto-González S, Poursac N, Rouanet E, Sellam J, Selva-O'Callaghan A, Séverac F, Sibilia J, Sole G, Soulages A, Terrier B, Tournadre A, Troyanov Y, Vernier N, Vesperini V, Viillard JF, Ziane R, Cavagna L, Meyer A. In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case-control study. *RMD Open.* 2023 Sep;9(3):e003081. doi: 10.1136/rmdopen-2023-003081.
143. Polley DJ, Latham P, **Choi MY**, Buhler KA, Fritzier MJ, Fritzier ML. Identification of novel clusters of co-expressing cytokines in a diagnostic cytokine multiplex test. *Front Immunol.* 2023 Jul 31;14:1223817. doi: 10.3389/fimmu.2023.1223817. eCollection 2023.
144. Predmore Z, Chen EK, Concannon TW, Schrandt S, **Bartlett SJ**, Bingham CO, Xie RZ, Chapman RH, Frank L. Treatment goals for rheumatoid arthritis: patient engagement and goal collection. *J Comp Eff Res.* 2023;12(5):e220097. Epub 20230328. doi: 10.57264/ceer-2022-0097.
145. Price E, Shirtcliffe A, Fisher T, Chadwick M, **Marra CA**. A systematic review of economic evaluations of pharmacist services. *Int J Pharm Pract.* 2023 Sep 30;31(5):459-471. doi: 10.1093/ijpp/riad052.
146. **Primeau CA**, Philpott HT, Vader K, Unger J, **Le CY**, Birmingham TB, MacDermid JC. Students' attitudes, beliefs and perceptions surrounding 2SLGBTQIA + health education and inclusiveness in Canadian physiotherapy programs. *BMC Public Health.* 2023 Aug 30;23(1):1661. doi: 10.1186/s12889-023-16554-2.
147. **Primeau CA**, Philpott HT, Vader K, Unger J, **Le CY**, Birmingham TB, MacDermid JC. Knowledge, behaviours, and training related to 2SLGBTQIA+ health education amongst entry-level physiotherapy students in Canada: results of a nationwide,

- cross-sectional survey. *BMC Med Educ.* 2023 Jul 19;23(1):519. doi: 10.1186/s12909-023-04499-4.
148. Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, Barnes H, Adegunsoye A, Azuma A, Chung L, Gardner GC, Highland KB, **Hudson M**, Kaner RJ, Kolb M, Scholand MB, Steen V, Thomson CC, Volkmann ER, Wigley FM, Burlile D, Kemper KA, Knight SL, Ghazipura M. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med.* 2023 Sep 29. doi: 10.1164/rccm.202306-1113ST. Online ahead of print.
 149. Rahmanzadeh Koucheh E, Voaklander D, **Jones CA**. Farming and the risk of developing osteoarthritis in Alberta, Canada. *Rural Remote Health.* 2024 May;24(2):8383. doi: 10.22605/RRH8383. Epub 2024 May 24.
 150. **Rai SK**, Wang S, Hu Y, Hu FB, Wang M, **Choi HK**, Sun Q. Adherence to Healthy and Unhealthy Plant-Based Diets and the Risk of Gout. *JAMA Netw Open.* 2024 May 1;7(5):e2411707. doi: 10.1001/jamanetworkopen.2024.11707.
 151. Räisänen AM, Benson LC, **Whittaker JL**, Emery CA. Evaluating a wearable solution for measuring lower extremity asymmetry during landing. *Physiother Can* 75(3):271-75 doi: 10.3138/ptc-2021-0086.
 152. Rapoport CS, Choi AK, Kwakkenbos L, Carrier ME, Henry RS, Levis B, **Bartlett SJ**, Gietzen A, Gottesman K, Guillot G, Lawrie-Jones A, Mayes MD, Mouthon L, Richard M, Worroneau-Sauvé M, Benedetti A, Roesch SC, Thombs BD, Malcarne VL; SPIN COVID-19 Patient Advisory Team; SPIN Investigators (incl. **Fortin P**). Moderators of Loneliness Trajectories in People with Systemic Sclerosis During the COVID-19 Pandemic: A SPIN COVID-19 Cohort Longitudinal Study. *Int J Behav Med.* 2024 Jan 18. doi: 10.1007/s12529-023-10248-0. Online ahead of print.
 153. **Rebić N**, Munro S, Garg R, **Hazlewood G**, **Amiri N**, Baldwin C, Ensworth S, Proulx L, **De Vera MA**. "The medications are the decision-makers..." Making reproductive and medication use decisions among female patients with rheumatoid arthritis: a constructivist grounded theory. *Arthritis Res Ther.* 2022 Jan 22;24(1):31. doi: 10.1186/s13075-021-02704-7.
 154. **Rebić N**, Law MR, Brotto LA, Cragg JJ, **De Vera MA**. The Intersectional Impact of Cost-Related Non-Adherence and Depression: A Cross-Sectional Analysis of the Canadian Community Health Survey by Sex, Race, and Indigeneity. *Community Ment Health J.* 2023 Nov 6. doi: 10.1007/s10597-023-01202-1. Online ahead of print.
 155. **Rebić N**, **De Vera MA**, Gupta A, **Amiri N**. Perinatal Use and Discontinuation of Disease-Modifying Antirheumatic Drugs: Outcomes of Patients Seen at a Pregnancy and Rheumatic Diseases Clinic. *J Clin Rheumatol.* 2024 May 16. doi: 10.1097/RHU.0000000000002090. Online ahead of print.
 156. Renson T, Kelly MM, Benediktsson H, Grundhoefer N, Luca N, Miettunen P, Twilt M, Grisaru S, Wade A, Banks A, Fifi-Mah A, Hamiwka L, **Benseler S**. Non-invasive biomarkers of disease activity and organ damage in ANCA-associated vasculitis: a

- systematic review. *RMD Open*. 2024 Feb 9;10(1):e003579. doi: 10.1136/rmdopen-2023-003579.
157. Rice J, **Li LC**, Davis JC, Pahor M, Madden K, Wei N, Wong H, Skelton DA, McCormick S, Falck RS, Barha CK, Rhodes RE, Loomba S, Sadatsafavi M, Liu-Ambrose T. Supporting physical activity for mobility in older adults with mobility limitations (SuPA Mobility): study protocol for a randomized controlled trial. *Trials*. 2023 Nov 28;24(1):769. doi: 10.1186/s13063-023-07798-9.
 158. Riganti P, **McKinnon AM**. Plain language summaries: enhancing patient-centred care and improving accessibility of health research. *BMJ Evid Based Med*. 2023 Oct;28(5):299-302. doi: 10.1136/bmjebm-2022-112200. Epub 2023 May 31.
 159. Rio EK, Rabusin CL, Munteanu SE, Docking SI, Perrott M, **Couch J**, Murphy MC, Girdwood M. Where is Your Pain? Achilles Tendinopathy Pain Location on Loading Is Different to Palpation, Imaging and Recall Location. *J Orthop Sports Phys Ther*. 2024 Jan;54(1):1-9. doi: 10.2519/jospt.2023.12131.
 160. Roach P, Ruzycki SM, Lithgow KC, McFadden CR, Chikwanha A, Holroyd-Leduc J, **Barnabe C**. A logic framework for addressing medical racism in academic medicine: an analysis of qualitative data. *BMC Med Ethics*. 2024 Apr 15;25(1):45. doi: 10.1186/s12910-024-01045-9.
 161. Roach P, Campbell P, Ody M, Scott M, **Barnabe C**, Montesanti S, Kennedy A, Murry A, Tailfeathers E, Crowshoe L. Access, Relationships, Quality and Safety (ARQS): a qualitative study to cocreate an Indigenous patient experience tool for virtual primary care. *BMJ Open Qual*. 2023 Dec 7;12(4):e002365. doi: 10.1136/bmjopen-2023-002365.
 162. **Roberts JH**, Gunn C, Mackinnon JE, Parlee S, Bakowsky V, Taylor T, **Barber CEH**, Hanly JG. Feasibility of Physiotherapist-Led Rheumatology Triage: A Randomized Study. *J Rheumatol*. 2024 May 15;jrheum.2023-1071. doi: 10.3899/jrheum.2023-1071. Online ahead of print.
 163. **Roberts JH**, Gun C, Mackinnon JE, Parlee S, Bakowsky V, Taylor T, **Barber CEH**, Hanly JG. Feasibility of physiotherapist-led rheumatology triage: A randomized study. *J Rheumatol*. 2024 Apr 15;jrheum.2023-1071. doi: 10.3899/jrheum.2023-1071. Epub ahead of print. PMID: 38621798.
 164. Rodrigues IB, Fahim C, Garad Y, Presseau J, **Hoens AM**, Braimoh J, Duncan D, Bruyn-Martin L, Straus SE. Developing the intersectionality supplemented Consolidated Framework for Implementation Research (CFIR) and tools for intersectionality considerations. *BMC Med Res Methodol* 2023 Nov 9;23(1):262. doi: 10.1186/s12874-023-02083-4.
 165. Roos M, Bertrand-Charette M, Dubé MO, Tittley J, Brisson M, Chau L, **Whittaker JL**, Desmeules F, Mercier C, Roy JS. A cross-sectional observational study comparing individuals with a symptomatic full-thickness rotator cuff tear with age-matched controls. *J Shoulder Elbow Surg*. 2023 Nov 21;8(1):58-66. doi: 10.1016/j.jseint.2023.10.006. eCollection 2024 Jan.

166. Ross L, Hansen D, Proudman S, Khanna D, Herrick AL, Stevens W; Australian Scleroderma Interest Group ASIG; Canadian Scleroderma Research Group (CSRG) incl. **Fortin P**; Baron M, Nikpour M; SCTC Activity Index Working Group. Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index. *Arthritis Rheumatol.* 2024 Jun 27. doi: 10.1002/art.42939. Online ahead of print.
167. Rouhi A, **Jamal S**, Arreola LG, Moon D, **Hudson M**, Roberts J, Ladouceur A, Ye C. Immune Checkpoint Inhibitor-Associated Remitting Seronegative Symmetrical Synovitis With Pitting Edema: Description of a New Entity by CanRIO. *J Rheumatol.* 2024 May 1;51(5):523-528. doi: 10.3899/jrheum.2023-0969.
168. Ruzycki SM, Roach P, Lithgow KC, McFadden CR, Chikwanha A, Holroyd-Leduc J, **Barnabe C**. A Logic Framework for Addressing Medical Racism in Academic Medicine: An Analysis of Qualitative Data. *BMC Medical Ethics* 2024 April 3.
169. Saffarzadeh M, Haydar SMA, **Shojania K**, Ouellette H, Nicolaou S, Murray N. Assessing tophaceous spinal gout treatment response using dual-energy CT as a point-of-care imaging modality: case report. *Skeletal Radiol.* 2023 Aug;52(8):1599-1604. doi: 10.1007/s00256-022-04260-w. Epub 2022 Dec 23.
170. Salma J, Au A, Ali S, Chamberlain S, Spence JC, **Jones A**, Kennedy M, Tong H, Meherali S, Mngomezulu P, Flynn R. Community Group-Based Physical Activity Programs for Immigrant Older Adults: A Systematic Realist Review. *J Aging Phys Act.* 2024 Jun 27:1-15. doi: 10.1123/japa.2023-0244. Online ahead of print.
171. Santos CS, Chen JP, Nikiphorou E, Tseng CW, Gutiérrez CET, Tan AL, Nune A, Kadam E, Kuwana M, Day J, Saha S, Velikova T, Lilleker JB, Caballero-Urbe CV, Sen P, Chinoy H, Aggarwal R, Agarwal V, Gupta L, Chen YM; COVAD study group (incl. **Hudson M**). Breakthrough SARS-CoV-2 infection and disease flares in patients with rheumatoid arthritis: result from COVAD e-survey study. *Rheumatol Int.* 2024 May;44(5):805-817. doi: 10.1007/s00296-024-05542-3. Epub 2024 Mar 12.
172. Sapir-Pichhadze R, Laprise C, Beauchamp ME, Kaouache M, Zhang X, Della Vecchia A, Azoulay L, Franco EL, **Abrahamowicz M**, Nicolau B. Immunosuppression and cancer risk in kidney transplant recipients: A retrospective cohort study. *Int J Cancer.* 2024 Feb 12. doi: 10.1002/ijc.34875. Online ahead of print.
173. Sehgal A, Scott S, Murry A, Henderson R, **Barnabe C**, Crowshoe LL. Critically examining health complexity experienced by urban Indigenous peoples in Canada by exploring the factors that allow health complexity to persist: a qualitative study of Indigenous patients in Calgary, Alberta. *BMJ Open.* 2023 Oct 30;13(10):e073184. doi: 10.1136/bmjopen-2023-073184.
174. Sehgal A, Henderson R, Murry A, Crowshoe L, **Barnabe C**. Advancing Health Equity for Indigenous Peoples in Canada: Development of a Patient Complexity Assessment Framework. *BMC Prim Care.* 2024 Apr 29;25(1):144. doi: 10.1186/s12875-024-02362-z.

175. Sheridan GA, Abdelmalek M, Howard LC, Neufeld ME, Masri BA, **Garbuz DS**. Navigated Versus Conventional Total Knee Arthroplasty: A Systematic Review and Meta-analysis of Prospective Randomized Controlled Trials. *J Orthop*. 2023 Dec 6;50:99-110. doi: 10.1016/j.jor.2023.11.070. eCollection 2024 Apr.
176. Sheridan GA, Howard LC, Neufeld ME, **Garbuz DS**, Masri BA. Factors Associated With Length of Stay for Hip and Knee Arthroplasty: A 20-Year Single-Province Population-Based Analysis of Longitudinal Temporal Trends. *Arthroplast Today*. 2023 Nov 23;24:101274. doi: 10.1016/j.artd.2023.101274. eCollection 2023 Dec.
177. Sheridan GA, Neufeld ME, Sidhu A, Kurmis AP, Kelly M, O'Byrne JM, Howard LC, Masri BA, **Garbuz DS**. The Diagnostic Utility of Serum Metal Ion Markers for High-Grade Aseptic Lymphocyte-Dominated Vasculitis-Associated Lesions (ALVALs) in Revision Hip and Knee Arthroplasty: An International Multicenter Study. *J Arthroplasty*. 2024 Jan;39(1):206-210. doi: 10.1016/j.arth.2023.06.024. Epub 2023 Jun 16.
178. Shoimer I, Kleiner O, Manion R, **Dutz J**, Philip A, Chan AW; Skin Investigation Network of Canada Priority Setting Collaborative. Top 10 research priorities for basal cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative. *Br J Dermatol*. 2024 Jan 23;190(2):276-277. doi: 10.1093/bjd/ljad391.
179. Shumnalieva R, Ravichandran N, Hannah J, Javaid M, Darooka N, Roy D, Gonzalez DE, Velikova T, Milchert M, Kuwana M, Joshi M, Gracia-Ramos AE, Boyd P, Yaadav P, Cheng K, Kobert L, Cavagna L, Sen P, Day J, Makol A, Gutiérrez CET, Caballero-Urbe CV, Saha S, Parodis I, Dey D, Nikiphorou E, Distler O, Kadam E, Tan AL, Shinjo SK, Ziade N, Knitza J, Chinoy H, Aggarwal R, Agarwal V, Gupta L; COVAD Study Group (incl. **Hudson M**). Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group. *Int J Rheum Dis*. 2024 May;27(5):e15178. doi: 10.1111/1756-185X.15178.
180. Silveira A, Lima C, Beaupre L, Chepeha J, **Jones A**. Shoulder specific exercise therapy is effective in reducing chronic shoulder pain: A network meta-analysis. *PLoS One*. 2024 Apr 29;19(4):e0294014. doi: 10.1371/journal.pone.0294014. eCollection 2024.
181. Subdar S, **Dhiman K**, Hartfeld NMS, **Hoens AM**, White K, Manske SL, **Hazlewood G**, **Lacaille D**, **Lopatina E**, **Barber MRW**, Mosher D, Fifi-Mah A, Twilt M, Luca N, Then KL, Crump T, **Zafar S**, Osinski K, **Barber CEH**. Investigating the influence of patient eligibility characteristics on the number of deferrable rheumatologist visits: planning for a patient-initiated follow-up (PIFU) strategy. *J Rheumatol*. June 2024, 51 (6) 587-595; DOI: <https://doi.org/10.3899/jrheum.2023-0891>.
182. Subdar S, **HoensAM**, White K, Spencer Hartfeld N, **Dhiman K**, **Duffey K**, Heath C, Lamoureux G, **Graveline C**, **Davidson E**, **Hazlewood G**, **Lacaille D**, **Lopatina E**, **Barber M**, Then K, Crump T, Zafar S, Manske S, Charlton A, Osinski K, Fifi-Mah A, Mosher D; **Barber C**. An environmental scan and appraisal of patient online resources for managing rheumatoid arthritis flares. *J Rheumatol*. June 2024, 51 (6) 577-586; DOI: <https://doi.org/10.3899/jrheum.2023-1025>

183. Tam ACT, Murphy RA, Conklin AI, **Zhang W**. Does Retirement and Work Stoppage Impact Body Weight and Waist Circumference Changes in Middle- and Older-Aged Women and Men? Results From the Canadian Longitudinal Study on Aging. *J Appl Gerontol*. 2024 Feb 27;7334648241230875. doi: 10.1177/07334648241230875. Online ahead of print.
184. Taplin JG, Bill L, Blanchard IE, **Barnabe CM**, Holroyd BR, Healy B, McLane P. Exploring paramedic care for First Nations in Alberta: a qualitative study. *CMAJ Open*. 2023 Dec 12;11(6):E1135-E1147. doi: 10.9778/cmajo.20230039. Print 2023 Nov-Dec.
185. Thomas M, **Marshall DA**, Sanchez AL, **Bartlett SJ**, Boonen A, Fraenkel L, Proulx L, Voshaar M, **Bansback N**, Buchbinder R, Guillemin F, Hiligsmann M, Richards DP, Richards P, Shea B, Tugwell P, Falahee M, **Hazlewood GS**. Exploring perceptions of using preference elicitation methods to inform clinical trial design in rheumatology: A qualitative study and OMERACT collaboration. *Seminars in arthritis and rheumatism*. 2023;58:152112. Epub 20221103. doi: 10.1016/j.semarthrit.2022.152112.
186. **Thomas M, Barnabe C, Kleissen T, Lacaille D, Hazlewood G**, Fifi-Mah A, **Hassen N**, Henry R, Kuluva M, **English K**, Koehn C, Lane T, Johnson N. Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Health Service Improvements. *Arthritis Care Res. (Hoboken)*. 2024 Apr;76(4):470-485. doi: 10.1002/acr.25278. Epub 2024 Jan 26.
187. **Thomas M**, Verma V, Gheshlaghi N, **Esdaile J, Avina-Zubieta A, Barnabe C, Harrison M, De Vera MA**. Reporting of determinants of health inequities and participant characteristics in randomized controlled trials of systemic lupus erythematosus in Canada: A scoping review. *Lupus*. 2024 Apr;33(5):462-469. doi: 10.1177/09612033241233032. Epub 2024 Feb 9.
188. Toulany A, Khodyakov D, Mooney S, Stromquist L, Bailey K, **Barber CEH**, Batthish M, Cleverley K, Dimitropoulos G, Gorter JW, Grahovac D, Grimes R, Guttman B, Hébert ML, John T, Lo L, Luong D, MacGreogor L, Mukerji G, Pidduck J, Senthilnathan V, Shulman R, Trbovich P, Munce SEP. Quality Indicators for Transition from Paediatric to Adult Care for Youth with Chronic Conditions: Protocol for an Online Modified Delphi Study. *JMIR Res Protoc*. 2024 Jun 18. doi: 10.2196/60860. Online ahead of print.
189. Toupin-April K, Gaboury I, Proulx L, Huber AM, Duffy CM, Morgan EM, **Li LC**, Stringer E, Connelly M, Weiss JE, Gibbon M, Sachs H, Sivakumar A, Sirois A, Siroich E, **Trehan N**, Abrahams N, Cohen JS, Cavallo S, Hindi TE, Ragusa M, Légaré F, Brinkman WB, **Fortin PR**, Décary S, Lee R, Gmuca S, Paterson G, Tugwell P, Stinson JN. "I'd like more options!": Interviews to explore young people and family decision-making needs for pain management in juvenile idiopathic arthritis. *Pediatr Rheumatol Online J*. 2023 Jul 26;21(1):74. doi: 10.1186/s12969-023-00849-0.
190. Trenaman L, Guh D, Law MR, Cheng L, **Harrison M**. Effect of a billing code to reimburse nurse-supported rheumatology care on health care costs and access: an

- interrupted time series analysis. *Arthritis Care Res (Hoboken)*. 2024 Feb 25. doi: 10.1002/acr.25317. Online ahead of print.
191. **Trenaman L**, Guh D, **Bansback N**, Sawatzky R, Sun H, Cuthbertson L, Whitehurst DGT. Quality of life of the Canadian population using the VR-12: population norms for health utility values, summary component scores and domain scores. *Qual Life Res*. 2023 Nov 8. doi: 10.1007/s11136-023-03536-5. Online ahead of print.
 192. Trenaman L, Kaal KJ, Laba TL, Safari A, Aguiar M, Burch T, Beckett J, Munro S, **Hudson M**, **Harrison M**. The financial burden of accessing care for people with scleroderma in Canada: a patient-oriented, cross-sectional survey. *CMAJ Open*. 2023 Jul 12;11(4):E630-E636. doi: 10.9778/cmajo.20220227. Print 2023 Jul-Aug.
 193. **Truong LK**, Mosewich AD, Miciak M, **Losciale JL**, **Li L**, **Whittaker JL**. Social support and therapeutic relationships intertwine to influence exercise behaviour in people with sport-related knee injuries. *Physiotherapy Theory and Practice*. Feb 19:1-14. doi: [10.1080/09593985.2024.2315520](https://doi.org/10.1080/09593985.2024.2315520).
 194. Tse JJ, **Contreras D**, Salat P, **Barber CEH**, **Hazlewood GS**, **Barnabe C**, Penney C, Ibrahim A, Mosher D, Manske SL. Evaluating High-Resolution Computed Tomography Derived 3-D Joint Space Metrics of the Metacarpophalangeal Joints Between Rheumatoid Arthritis and Age- and Sex-Matched Control Participants. *Front Med (Lausanne)*. 2024 May 9;11:1387532. doi: 10.3389/fmed.2024.1387532. eCollection 2024.
 195. van Til JA, Kip MMA, Schatorje EJ, Currie G, Twilt M, **Benseler SM**, Swart JF, Vastert SJ, Wulffraat N, Yeung RS, Groothuis-Oudshoorn CG, Warta S, **Marshall DA**, Ijzerman MJ, on behalf of the UCAN CAN-DU, UCAN CURE consortia. Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists? *Pediatric Rheumatology*. 2023 21(69):1-10. <https://doi.org/10.1186/s12969-023-00845-4>
 196. Vedadi A, Khairalla R, Che A, Nagee A, Saqib M, Ayub A, Wasim A, Macanovic S, Orchanian-Cheff A, Selzner-Malekkiani N, **Bartlett S**, Mucsi I. Patient-reported outcomes and patient-reported outcome measures in liver transplantation: a scoping review. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2023. Epub 20230406. doi: 10.1007/s11136-023-03405-1.
 197. Venerito V, Fornaro M, Sabbagh S, Ghosh S, Chinoy H, Gupta L; MyoLLM investigators (incl. **Leclair V**). Integrating Large Language Models in Medicine: A Study of Claude 2's Performance in MDAAT Scoring for idiopathic inflammatory myopathies. *Rheumatology (Oxford)*. 2024 Apr 22:keae233. doi: 10.1093/rheumatology/keae233. Online ahead of.
 198. Veyssiere M, Rodriguez Ordonez MDP, Chalabi S, **Michou L**, Cornelis F, Boland A, Olaso R, Deleuze JF, Petit-Teixeira E, Chaudru V. MYLK*FLNB and DOCK1*LAMA2 gene-gene interactions associated with rheumatoid arthritis in the focal adhesion pathway. *Front Genet*. 2024 May 13;15:1375036. doi: 10.3389/fgene.2024.1375036. eCollection 2024.

199. Wallace ZS, Miles G, Smolkina E, Petruski-Ivleva N, Madziva D, Cook C, Fu X, Zhang Y, Stone JH, **Choi HK**. Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults. *Ann Rheum Dis*. 2023 Jul;82(7):957-962. doi: 10.1136/ard-2023-223950. Epub 2023 May 3.
200. Wei J, **Choi HK**, Dalbeth N, Li X, Li C, Zeng C, Lei G, Zhang Y. Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes. *JAMA Netw Open*. 2023 Aug 1;6(8):e2330885. doi: 10.1001/jamanetworkopen.2023.30885.
201. Weinbrecht-Mischkewitz M, Kamal M, Asim F, Guillemin F, Goel N, Voshaar M, Boonen A, Berthelsen DB, Toupin-April K, Lopez-Olivo MA, Sloan VS, Boers M, **Jones CA**, van der Horst-Bruinsma I, Cashin AG, Sharma S, Leong A, Alten R, Shea B, March L, Tugwell P, Christensen R, Nielsen SM; Contextual Factors Working Group. Generating a list of potentially important contextual factors covering randomized trials, cohorts, and measurement property studies: An OMERACT initiative. *Semin Arthritis Rheum*. 2024 Jan 10;65:152370. doi: 10.1016/j.semarthrit.2024.152370. Online ahead of print.
202. Welzel T, Zapf B, Klotsche J, Satirer Ö, **Benseler SM**, Kuemmerle-Deschner JB. Optimized Treatment of Interleukin (IL-1)-Mediated Autoinflammatory Diseases: Impact of Disease Activity-Based Treatment Adjustments. *J Clin Med*. 2024 Apr 17;13(8):2319. doi: 10.3390/jcm13082319.
203. West TJ, Bruder AM, Crossley KM, Girdwood MA, Scholes MJ, To LK, **Couch JL**, Evans SCS, Haberfield MJ, Barton CJ, Roos EM, De Livera A, Culvenor AG. Does the one-leg rise test reflect quadriceps strength in individuals following anterior cruciate ligament reconstruction? *Phys Ther Sport*. 2023 Sep;63:104-111. doi: 10.1016/j.ptsp.2023.07.008. Epub 2023 Aug 2.
204. **Whittaker JL**, Kalsoum R, Bilzon J, Conaghan PG, Crossley K, Dodge GR, Detgood A, Li X, Losina E, Mason DJ, Pietrosimone, Risberg MA, Roemer F, Felson D, Culvenor A, Meuffels D, Gerwon N, Simon LS, Lohmander LS, Englund M Watt FE. Toward designing human intervention studies to prevent osteoarthritis after knee injury: A report from an interdisciplinary OARSI 2023 workshop Osteoarthritis and Cartilage Open Feb 23;6(2):100449 doi: 10.1016/j.ocarto.2024.100449 PMID 38440780
205. Wiens D, Smolik IA, MacKay D, Fowler-Woods A, Robinson DB, **Barnabe C**, El-Gabalawy HS, O'Neil LJ. Perceived Access to Health Care of Indigenous Peoples in Canada with Rheumatoid Arthritis and their First-Degree Relatives. *J Rheumatol*. 2024 Mar 1:jrheum.2023-1080. doi: 10.3899/jrheum.2023-1080. Online ahead of print.
206. Willett JDS, Gravel A, Dubuc I, Gudimard L, Dos Santos Pereira Andrade AC, Lacasse É, **Fortin P**, Liu JL, Cervantes JA, Galvez JH, Djambazian HHV, Zwaig M, Roy AM, Lee S, Chen SH, Ragoussis J, Flamand L. SARS-CoV-2 rapidly evolves lineage-specific phenotypic differences when passaged repeatedly in immune-naïve mice. *Commun Biol*. 2024 Feb 16;7(1):191. doi: 10.1038/s42003-024-05878-3.

207. Wojcick RK, Knisely MR, Bailey DE, Somers TJ, Kwakkenbos L, Carrier ME, Nielson WR, **Bartlett SJ**, Malcarne VL, **Hudson M**, Levis B, Benedetti A, Mouthon L, Thombs BD, Silva SG; SPIN Investigators. Patterns of patient-reported symptoms and association with sociodemographic and systemic sclerosis disease characteristics: a scleroderma Patient-centered Intervention Network (SPIN) Cohort cross-sectional study. *EClinicalMedicine*. 2023 Jul 20;62:102104. doi: 10.1016/j.eclinm.2023.102104. eCollection 2023 Aug.
208. Wu N, Wang SJ, Brazeau AS, Chan D, Mussa J, Nakhla M, Elkeraby M, Ell M, Prevost M, Lepine L, Panagiotopoulos C, Mukerji G, Butalia S, Henderson M, **Da Costa D**, Rahme E, Dasgupta K. Supporting and Incentivizing Peer Leaders for an Internet-Based Private Peer Community for Youths With Type 1 Diabetes: Social Network and Directed Content Analysis. *J Med Internet Res*. 2023 Dec 12;25:e48267. doi: 10.2196/48267.
209. Wurz A, Duchek D, Ellis K, Bansal M, Carrier ME, Tao L, Dyas L, Kwakkenbos L, Levis B, El-Baalbaki G, Rice DB, Wu Y, Henry RS, Bustamante L, Harb S, Hebblethwaite S, Patten SB, **Bartlett SJ**, Varga J, Mouthon L, Markham S, Thombs BD, Culos-Reed SN, Team S-CPA, Program F, Scleroderma Patient-centered Intervention Network I. A qualitative interview study exploring the psychological health impacts of the SPIN-CHAT program among people with systemic sclerosis at the onset of COVID-19: perceptions of trial participants and research team members. *Disability and rehabilitation*. 2023:1-13. Epub 20230128. doi: 10.1080/09638288.2023.2169775.
210. Wurz A, Ellis K, Duchek D, Bansal M, Carrier ME, Tao L, Dyas L, Kwakkenbos L, Levis B, El-Baalbaki G, Rice DB, Wu Y, Henry RS, Bustamante L, Harb S, Hebblethwaite S, Patten SB, **Bartlett SJ**, Varga J, Mouthon L, Markham S, Thombs BD, Culos-Reed SN, Team S-CPA, Program F. Exploring research team members' and trial participants' perceptions of acceptability and implementation within one videoconference-based supportive care program for individuals affected by systemic sclerosis during COVID-19: a qualitative interview study. *Transl Behav Med*. 2023. 2023 Jul 1;13(7):442-452. doi: 10.1093/tbm/ibac091.
211. Wurz A, Henry RS, Kwakkenbos L, Carrier ME, Patten SB, **Bartlett SJ**, Mouthon L, Varga J, Benedetti A, Culos-Reed SN, Thombs BD. Physical activity during COVID-19 in people with systemic sclerosis: A Scleroderma Patient-centred Intervention Network COVID-19 Cohort longitudinal study. *J Scleroderma Relat Disord*. 2024 Jun;9(2):110-116. doi: 10.1177/23971983241241593. Epub 2024 Apr 2.
212. Xiao ATY, Turk T, Deol K, Zhang S, Aref HAT, Campbell A, **Jones A**, Yamamoto SS, Dennett L, Kolewaski L, Sadowski CA, Yacyszyn EA. Evidence for the use of cannabis-based medicines in osteoarthritis: a scoping review. *Clin Rheumatol*. 2024 Jun 9. doi: 10.1007/s10067-024-07001-7. Online ahead of print.
213. Xu M, Harel D, Carrier ME, Kwakkenbos L, **Bartlett SJ**, Gottesman K, Guillot G, Hummers L, Malcarne VL, Richard M, Thombs BD; SPIN Investigators. Differential Item Functioning on the Cochin Hand Function Scale among People with Systemic Sclerosis by Language, Sex, and Disease Subtype: a Scleroderma Patient-centered

- Intervention Network (SPIN) Cohort Study. *Arthritis Care Res (Hoboken)*. 2023 Jul 24. doi: 10.1002/acr.25199. Online ahead of print.
214. Yanzhu X, Tan J, Kuusk U, Lee LH, **Amiri N**. Cystic Neutrophilic Granulomatous Mastitis (CNGM) with Erythema Nodosum and Polyarthritis, a Case Report. Vol.:(0123456789)SN *Comprehensive Clinical Medicine* (2023) 5:188 <https://doi.org/10.1007/s42399-023-01531-y>.
215. Yokose C, Eide SE, Huber FA, Simeone FJ, Ghoshhajra BB, **Shojania K**, Nicolaou S, Becce F, **Choi HK**. Frequently Encountered Artifacts in the Application of Dual-Energy CT to Cardiovascular Imaging for Urate Crystals in Gout: A Matched-Control Study. *Arthritis Care Res (Hoboken)*. 2024 Feb 5. doi: 10.1002/acr.25312. Online ahead of print.
216. Yoshida A, Li Y, Maroufy V, Kuwana M, Sazliyana Shaharir S, Makol A, Sen P, Lilleker JB, Agarwal V, Kadam E, Akawatcharangura Goo P, Day J, Milchert M, Chen YM, Dey D, Velikova T, Saha S, Edgar Gracia-Ramos A, Parodis I, Nikiphorou E, Tan AL, Nune A, Cavagna L, Toro Gutiérrez CE, Caballero-Urbe CV, Saavedra MA, Shinjo SK, Ziade N, El Kibbi L, Knitza J, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group (incl. **Hudson M**). Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey. *Rheumatol Adv Pract*. 2024 Mar 4;8(2):rkae028. doi: 10.1093/rap/rkae028. eCollection 2024.
217. Yu M, **Harrison M**, **Bansback N**. Can prediction models for hospital readmission be improved by incorporating patient-reported outcome measures? A systematic review and narrative synthesis. *Qual Life Res*. 2024 Jul;33(7):1767-1779. doi: 10.1007/s11136-024-03638-8. Epub 2024 Apr 30.
218. **Zafar S**, **Hazlewood GS**, Dhiman K, Charlton A, Then K, Dempsey E, Lester R, **Hoens A**, **Barnabe C**, **Lacaille D**, Rankin J, **Barber CEH**. "How are you?" Perspectives from patients and healthcare providers of text-messaging to support rheumatoid arthritis care, a thematic analysis. *ACR Open Rheumatol*. 2024 May;6(5):276-286. doi: 10.1002/acr2.11652. Epub 2024 Feb 20.
219. Zhan K, Buhler KA, Chen IY, Fritzler MJ, **Choi MY**. Systemic lupus in the era of machine learning medicine. *Lupus Sci Med*. 2024 Mar 4;11(1):e001140. doi: 10.1136/lupus-2023-001140.
220. Zhao K, Oualkacha K, Zeng Y, Shen C, Klein K, Lakhal-Chaieb L, Labbe A, Pastinen T, **Hudson M**, **Colmegna I**, Bernatsky S, Greenwood CMT. Addressing dispersion in mis-measured multivariate binomial outcomes: A novel statistical approach for detecting differentially methylated regions in bisulfite sequencing data. *Stat Med*. 2024 Jun 26. doi: 10.1002/sim.10149. Online ahead of print.
221. Zheng B, Eline E, Xu L, Huang K, Hermans G, Perch M, Samoukovic G, De Langhe E, Dastmalchi M, Christopher-Stine L, Diederichsen LP, **Leclair V**. Extracorporeal Membrane Oxygenation for Acute Lung Injury in Idiopathic Inflammatory Myopathies-A Potential Lifesaving Intervention. *Rheumatology (Oxford)*. 2024 May 25:keae311. doi: 10.1093/rheumatology/keae311. Online ahead of print.

ABSTRACTS

1. Ahmadzadeh Y, Magder L Ozdemir Z, Andrade D, **Barber MRW**, Tektonidou M, Sciascia S, Pengo V, Anunciación-Llunell A, Ruiz-Irastorza G, Aguirre MA, Belmont M, Nina K **Fortin PR**, Wahl D, Gerosa M, De Jesús G, Zhang Z, Atsuma T, Efthymiou M, Ware Branch D, Tincani A, Rodriguez Almaraz E, Pazzola G, Cervera R, Esen BA, Shi H, Knight J, Pons-Estel G, Willis R, Duarte-Garcia A, Bertolaccini ML, Cohen H, Petri M, Erkan D, and On Behalf Of APS ACTION. Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository “Registry”. Abstract #0097. *Arthritis & Rheumatology*. 2023;75(Suppl 9):157-160.
2. Amiable N, Benlarbi M, Dube M, Theriault S, Godbout A, Julien AS, Ortega-Delgado GG, Duchesne M, Cloutier R, JPerreault J, Gravel A, Fournier L, Alfonso G, Bourre-Tessier J, **Hudson M**, Richard N, Makhzoum JP, Mendel A, Bernatsky S, Dionne M, Libman M, De Serres G, Dieudé M, Flamand L, Kaufmann D, Finzi A, Bazin R, **Colmegna I, Fortin PR**. A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab. Abstract #0274. *Arthritis & Rheumatology*. 2023;75(Suppl 9):533-536.
3. **Andersen N, Lacaille D, McGuire E**, Savard J, **Fortin P**, Rahme E, **Da Costa D**. Cannabis Use Among People with Arthritis: Evaluating Disease and Psychosocial Factors Associated with Being a Cannabis User. *J Rheumatol*. In Press.
4. **Avina-Zubieta JA, Hoque R, Lacaille D, De Vera MA**, Qian Y, McCandless L, **Xie H, Esdaile JM**. Trajectories of Antimalarial Adherence among Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: A Population-based Cohort Study. *Lupus Science and Nature*. In Press.
5. Aydemir B, Schieir O, Valois MF, Muhammad L, Song J, Dunlop D, **Bartlett S**, Bessette L, Boire G, **Hazelwood G**, Hitchon C, Keystone E, Pope J, Thorne C, Tin D, Bykerk V, Lee Y and Canadian Early Arthritis Cohort (CATCH) Investigators. Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort. Abstract #0823. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1647-1649.
6. **Bansback N**, Law M, Clemons F, Tadrous M, Blitz S, **Harrison M**. How Did a Mandatory Switch Policy Influence the Uptake of Adalimumab Biosimilar and Other TNF Inhibitors? Abstract #1858. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3862-3863.
7. **Bansback N**, Tam A, Gladman D, Kulasingam V, Spackman E, Chandran V. What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment. Abstract #0168. *Arthritis & Rheumatology*. 2023;75(Suppl 9):308-310.
8. Barraclough M, Munoz-Grajales C, Erdman L, Diaz Martinez JP, Bingham K, Kakvan M, Kretzmann R, Tartaglia C, Ruttan L, **Choi M**, Appenzeller S, Marzouk S, Bonilla D, Katz P, Beaton D, Goldenberg A, Green R, Wither J, Touma Z.

Association of Serum Analytes with SLE Cognitive Impairment Phenotypes Formed by Machine Learning: MMP-9, S100A8/A9, IL-6, IL-10, and NGAL. Abstract #1461. *Arthritis & Rheumatology*. 2023;75(Suppl 9):2882-2883.

9. **Bartlett SJ**, Schieir O, Valois MF, Pope J, Bessette L, Boire G, Hitchon C, Keystone E, Thorne C, Tin D, **Hazlewood G**, Bykerk V. POS0584-HPR Pros and disease activity in year prior to COVID predict trajectories of depression in adults with RA in first 2 yers of pandemic. Data from thhe Canadian Early Arthritis Cohort. *Annals of the Rheumatic Diseases*. 2023;82(Suppl 1):561-2. doi: 10.1136/annrheumdis-2023-eular.6315.
10. **Bartlett SJ**, Bingham CO, Schieir O, Valois MF, Boire G, Pope J, Bessette L, Thorne C, Tin D, Hitchon C, **Hazlewood G**, Keystone E, Bykerk V. POS0471 specific symptom clusters at diagnosis signal a poorer early RA prognosis: Data from the Canadian Early Arthritis Cohort. *Annals of the Rheumatic Diseases*. 2023;82(Suppl 1):494-5. doi: 10.1136/annrheumdis-2023-eular.2819.
11. **Bartlett S, Bingham C**, Schier O, Valois MF, Boire G, Bessette L, Pope J, Tin D, Thorne C, **Hazlewood G**, Hitchon C, Keystone E, Bykerk V. PROMIS Symptom Clusters Predict Disease Activity in the First 6 Months in Newly Diagnosed RA Patients Starting MTX Therapy: Data from the Canadian Early Arthritis Cohort. Abstract #1285. *Arthritis & Rheumatology*. 2023;75(Suppl 9):2515-1517.
12. **Bartlett S**, Bingham C, Schieir O, Valois MF, Pope J, Bessette L, Boire G, Hitchon C, Kekystone E, Thorne C, Tin D, **Hazlewood G**, Bykerk V. Specific Symptom Clusters at Diagnosis Signal a Poorer Early RA Prognosis: Data from the Canadian Early Arthritis Cohort (CATCH). Abstract #2108. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4161-4163.
13. **Bartlett S**, Bingham C, Schieir O, Valois MF, Pope J, Bessette L, Boire G, Hitchon C, Keystone E, Thorne C, Tin D, Hazlewood G, Bykerk V, Canadian Early Arthritis Cohort (CATCH) Investigators. Specific Symptom Clusters at Diagnosis Signal a Poorer Early Ra Prognosis on Mtx Treatment: Results from The Canadian Early Arthritis Cohort (Catch). *J Rheumatol*. In Press.
14. **Bartlett S**, Schieir O, Valois MF, Boire G, Bessette L, Pope J, Tin D, Thorne C, **Hazlewood G**, Hitchon C, Keystone E, Bykerk V. Ra Symptom Clusters at Diagnosis Predict Disease Activity in The First 6 Months of Early Ra: Results from The Canadian Early Arthritis Cohort (Catch). *J Rheumatol*. In Press.
15. **Bartlett S**, Bingham CO, Schieir O, Valois MF, Pope J, Thorne C, Bessette L, Hitchon CA, Boire G, Tin D, Keystone E, **Hazlewood G**, Bykerk V, Catch Investigators, on behalf of CATCH Early Arthritis Investigators. Variability in Initial MTX Response in Newly Diagnosed RA Patients with Distinct PRO Symptom Clusters: A Longitudinal Analysis of the Canadian Early Arthritis Cohort. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 451. POST0031.
16. **Bayraktar D**, Sarac DC, Inanc I, Başkan F, Ugur E, Özkan A, Gucenmez S, Solmmaz D, Akar S. Pulmonary Functions and Respiratory Muscle Strength in Patients with Axial Spondyloarthritis. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 1180. POS1470-HPR.

17. Belce Erton Z, Thaler J, Andrade D, **Barber MRW**, Tektonidou M, Sciascia S, Pengo V, Pardos-Gea J, Ruiz-Irastorza G, Lopez-Pedreira C, Belmont HM, Nina K, **Fortin PR**, Zuily S, Chighizola C, Signorelli FV, Zhang Z, Atsuma T, Efthymiou M, Ware Branch D, Nalli C, Rodriguez Almaraz, Petri M, Pazzola G, Cervera R, Esen BA, Shi H, Zuo Y, Quintana RM, Willis R, Duarte-Garcia A, Bertolaccini ML, Cohen H, Erkan D, and On Behalf Of APS ACTION. Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). Abstract #0097. *Arthritis & Rheumatology*. 2023;75(Suppl 9):157-160
18. Bernatsky S, Ramsey-Goldman R, Urowitz M, Hanly JG, Gordon C, Petri M, Ginzler E, Wallace D, Bae SC, Romero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven R, Nived O, Kamen DL, Aranow C, Buyon J, Ruiz-Irastorza G, Sanchez-Guerrero F, Gladman D, **Fortin PR**, Lee JLF, Lukusa L, Alarcón GS, Merrill J, Kalunian K, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta M, Bruce I, Inanç M, **Clarke A**. Updated Analyses of Cancer Incidence and Risk Factors in a Large International SLE Cohort. Abstract #2588. *Arthritis & Rheumatology*. 2023;75(Suppl 9):5154-5158
19. Berthelsen DB, Nielsen SM, Rasmussen MU, Voshaar M, Richards P, **Bartlett SJ**, **Hazlewood G**, Shea B, Tugwell P, Ellingsen T, Jorgensen TS, Kristensen S, Simon L, Christensen R, Flurey C, on behalf of the OMERACT Safety Working Group. “I couldn’t carry on taking a drug like that”: a qualitative study of patient perspectives on side effects from drug treatment in rheumatology, from the OMERACT safety working group. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 593POS0744.
20. Birck M, Neville A, Storek J, Atkins H, **Hudson M**, **Colmegna I**, R. Lavoie J, Gao J, Bernatsky S. Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse? Abstract #0609. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1210-1212.
21. Birck M, Lukusa L, **Abrahamowicz M**, Boire G, Choquette D, Maksymowych WP, Bernatsky S. Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses. Abstract #1960. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3889-3890.
22. Birck MG, Neville A, Storek J, Atkins H, Hudson M, Colmegna I, Cotton T., Lavoie JR, Gao J, Bernatsky S. Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse? *J Rheumatol*. In Press.
23. Birck MG, Lukusa L, **Abrahamowicz M**, Choquette D, Boire G, Maksymowych, W, Bernatsky S. Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses. *J Rheumatol*. In Press.

24. Brizio M, Lora M, Moraes C, **Hudson M, Colmegna I**. Mesenchymal Stromal Cells in Scleroderma Have an Incomplete Myofibroblast-Like Phenotype with Preserved in Vitro Anti-Inflammatory and Anti-Fibrotic Effects. *J Rheumatol*. In Press.
25. Can Sarac D, Inanc I, Başkan E, Ozturk A, Gucenmez S, Şentürk B, Ugur E, Oksuz A, Konan E, Solmaz D, Akar S, **Bayraktar D**. Pulmonary Functions and Respiratory Muscle Strength in Rheumatoid Arthritis: A Case-Control Study. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 2143. AB1544-HPR.
26. Cardwell F, Elliot S, **Barber MRW**, Cheema K, George S, Boucher A, **Clarke AE**. Exploring Experiences and Perspectives of Canadian Patients with Lupus Nephritis Through Photovoice. Abstract #2020. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3999-4002.
27. Cardwell F, Kobza A, Elliot S, Gibson P, Soilman N, Skeith L, **Clarke AE, Barber MRW**. Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study. Abstract #1208 *Arthritis & Rheumatology*. 2023;75(Suppl 9):2363-2365.
28. Cardwell FS, Elliot SJ, **Barber MRW**, Cheema K, George S, Boucher A, **Clarke AE**. Exploring Experiences and Perspectives of Canadian Patients with Lupus Nephritis Through Photovoice. *J Rheumatol*. In Press.
29. Cardwell F, Kobza AO, Elliot SJ, Gibson PS, Soliman N, Skeith L. **Clarke AE, Barber MRW**. Exploring The Experiences and Perspectives of Patients Living with Antiphospholipid Antibodies: a Qualitative Study. *J Rheumatol*. In Press.
30. Challener G, Ma KSK, **McCormick N**, Yokose C, Tinianow A, **Choi H**. Risk of mortality in patients with tophaceous versus non-tophaceous gout. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 89. OP0170.
31. Challener G, Kohler MJ, Yokose C, Vinh J, **Choi H**. Safety and efficacy of sulfasalazine in treatment of immune checkpoint inhibitor-inflammatory arthritis. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 419. POS0139.
32. Challener G, Ma KSK, Kohler MJ, Yokose C, **Choi H**. Outcomes in patients with pre-existing autoimmune disease on immune checkpoint inhibitor therapy for treatment of cancer. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 55. OP0334.
33. Cho L, **Legge A**. Predictors of Adherence to Cervical Cancer Screening Guidelines Among Patients with Systemic Lupus Erythematosus. Abstract #2295. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4555-4556.
34. Cho L, Legge A. Predictors of Adherence to Cervical Cancer Screening Guidelines Among Patients with Systemic Lupus Erythematosus. *J Rheumatol*. In Press.
35. **Choi M**, Costenbader K, Fritzler M, St. Pierre Y, Urowitz M, Hanly JG, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Gladman D, Brucel, Petri M, Ginzler¹ E, Dooley MA, Ramsey-Goldman R, Manzi S, Jonsen A, Alarcón GS, van Vollenhoven R, Aranow C, MacKay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Buyon J, **Clarke A**. Direct Health Care Costs

- Differ by SLE Autoantibody Machine Learning Clusters in an International Inception. Abstract #2266. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4491-4495.
36. **Choi M**, Guan H, Yoshida K, Kargere B, Ellrodt J, Stevens E, Cai T, Everett B, Weber B, Costenbader K. Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus. Abstract #0744. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1484-1486.
 37. **Choi M**, Costenbader K, Fritzler M, **Clarke AE**, SLICC The Systemic Lupus Erythematosus International Collaborating Clinics. Direct Health Care Costs Differ by SLE Autoantibody Machine Learning Clusters in an International Inception. *J Rheumatol*. In Press.
 38. Chong DHY, Mattman A, Dou A, So A, Shi J, Cleve R, Lim HJ, Schaeffer DF, Telford JL, Chen LYC, **Carruthers MN**. Elevated serum CA19-9 in IgG4-related disease manifesting in the pancreas, liver and biliary tree not due to immunoassay interference. *J Rheumatol*. In Press.
 39. Chow A, Lau AN, Soucy E, Movahedi M, Li X, Mously C, Cesta A, Thorne C, Ahluwalia V, Chandran V, Boyle J, Dhillon R, **Chan J**, Joshi R, Bombardier C, Aydin S. Improving Outcomes of Patients Living with Psoriatic Arthritis: The Observational Best Practices Research Initiative (Obri-Psa). *J Rheumatol*. In Press.
 40. Crawford M, Bakowsky V, **Roberts J**, **Legge A**. Lyme Disease: an Emerging Mimic of Giant Cell Arteritis. *J Rheumatol*. In Press.
 41. **Davidson E**. You Can't Get This From a Doctor – The Role of a Support group for Young Adults with Rheumatic Diseases. Abstract #PP01. *Arthritis & Rheumatology*. 2023;75(Suppl 9):5240-5242.
 42. Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, Dourado E, Sambataro G, Bauer-Ventura I, Bae S, Lim D, Rivero Gallegos D, Yamano Y, Selva-O'callaghan A, Mammen A, Scirè CA, Montecucco C, Oddis CV, Fiorentino D, Bonella F, Miller F, I. Lundberg E, Schmidt J, Rojas-Serrano J, **Hudson M**, Kuwana M, González-Gay MA, Mchugh N, Corte TJ, Doyle T, Werth V, Aggarwal R, Cavagna L, on behalf of The CLASS Project. Clinical characteristics of anti-synthetase syndrome: analysis from the class project. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 617. POS1281.
 43. Fouad MH, Audet LA, Légaré MP, Costiniuk C, Pelaez S, Merry L, Légaré J, **Colmegna I**. Confidence in Covid-19 Vaccine Among At-Risk and Under-Vaccinated Groups: Migrants Living with Systemic Autoimmune Rheumatic Diseases. *J Rheumatol*. In Press.
 44. Ghiglieri C, Anderson RS, Wainwright E, Hollick R, **Lacaille D**, Macfarlane GJ, Morton L, on behalf of the Making it Work™ - Scotland study team. Making it work™ – Scotland: adaptation and development of the Canadian making it work programme to support people working with musculoskeletal conditions in the UK.
 45. **Gonzalez-Arreola L**, Ye C, **Hudson M**, **Roberts J**, Pope J, Appleton T, **Hoa S**, Fifi-Mah A, Maltex N, Saltman A, Himmel M, **Colmegna I**, Ladouceur A, **Obrzut A**, **Tan J**, Moon D, Nevskaya T, Schmidt E, Cho L, Toban N, **Jamal S**. Impact of

- Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO). Abstract #1075. *Arthritis & Rheumatology*. 2023;75(Suppl 9):2117-2120.
46. Gulati S, Lowe S, **Jones A**, Turk T, Yamamoto S, Gregg K, Kolewaski L, Olson J, Paul P, Sadowski C, Yacyshyn E. Investigating The Prevalence and Health Profiles Among Patients Using Cannabis Therapeutically for Management of Rheumatologic Diseases. *J Rheumatol*. In Press.
 47. Gulati S, Lowe S, **Jones A**, Turk T, Yamamoto S, Gregg K, Kolewaski L, Olson J, Paul P, Sadowski C, Yacyshyn E. Exploring The Personal Health Factors Associated with Cannabis Use for Rheumatic Disease Management Among Young and Middle-Aged Adults in Alberta, Canada. *J Rheumatol*. In Press.
 48. Gulati S, Hung W, Voaklander D, **Jones A**, Yacyshyn E. Evaluating The Distribution of Vasculitis Among Rural Farmers, Rural Non-Farmers and Urban Residents in Alberta. *J Rheumatol*. In Press.
 49. Hitchon C, Al Islam S, Fung DLX, Liu Q, Lac L, **Bartlett S**, Bessette L, Boire G, Bykerk V, **Hazlewood G**, Keystone E, Pope J, Schieir O, Thorne C, Tin D, Valois MF, van der Heijde D, Canadian Early Arthritis Cohort (CATCH) Investigators1, O'Neil L, Hu P.. Artificial Intelligence Models for Computer-Assisted Joint Detection and Sharp-van Der Heijde Score Prediction in Hand Radiographs from Patients with Rheumatoid Arthritis. Abstract #0745. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1487-1489.
 50. Hitchon C, Abdissa Adugna B, Akintayo R, Caldron P, **Colmegna I**, Dey I, McGill P, Ponce A, Scuccimarri R, Tikly M, Mody G, Meltzer M. Delivery of Rheumatology Education to Internal Medicine Residents in Rwanda: Evaluation of a New Virtual Rheumatology Course Supplemented by On-site Clinical Teaching. Abstract #2082. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4118-4119.
 51. Hitchon C, Islam S, Fung D, Liu Q, Lac L, **Bartlett S**, Bessette L, Boire G, **Hazlewood G**, Keystone E, Pope J, Schieir O, Thorne C, Tin D, Valois MF, Bykerk V; CATCH Canadian Early Arthritis Cohort (CATCH) Investigators, van der Heijde D, O'Neil L, Hu P. Artificial Intelligence Models for Computer-Assisted Joint Detection and Sharp-Van Der Heijde Score Prediction in Hand Radiographs from Patients with Rheumatoid Arthritis. *J Rheumatol*. In Press.
 52. Howe A, Li A, Jules K, Tan J, Sadek M, Kakvan M, Chattu B, Bani-Fatemi A, Bonilla D, Nielsen W, Anderson N, **Avina-Zubieta JA**, Fox M, Shaw W, Haaland D, Pope J, **Fortin PR**, Bingham K, Rozenbojm N, Peschken C, Su J, Reynolds J, Ivory C, Gladman D, Urowitz M, Zahi Touma F, Nowrouzi-Kia BB. Systemic Lupus Erythematosus and Functional Work Disability: A Qualitative Perspective Using a Work Disability Prevention Approach. Abstract #2286. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4536-4537.
 53. **Howren A, Avina-Zubieta JA**, Sayre EC, Puyat, J, **Da Costa D**, Gupta A, **Xie H, De Vera MA**. Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living

- with Inflammatory Arthritis. Abstract #1860. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3686-3688.
54. Inanc I, Solmaz D, Can Saraç D, Başkan E, Özkan A, Yucel K, Akar S, **Bayraktar D**. The Factors Related to Physical Performance in Female Patients with Psoriatic Arthritis. *Ann Rheum Dis*. Vol 83, supplement 1, year 2024, page 2143. AB1545-HPR.
 55. **Irwin K**, Huo R, Barber C, Barnabe C. All Cause Emergency Visits and Hospitalizations in Persons with Inflammatory Arthritis and Gout: a Systematic Review. *J Rheumatol*. In Press.
 56. Jorge A, Zhou B, **McCormick N**, Yokose C, Zhang Y, **Choi HK**. Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus. Abstract #1579. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3112-3114.
 57. **Karacabeyli D, Lacaille D, Lu N, Avina-Zubieta JA**. Incidence of Autoimmune Rheumatic Diseases Following Exposure to Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors: a Population-Based Study. *J Rheumatol*. In Press.
 58. **Karacabeyli D, Avina-Zubieta JA, Lu N, Xie H, Lacaille D**. Risk of acute myocardial infarction and ischemic stroke in adults with ankylosing spondylitis: a population-based study. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 1759. AB0906.
 59. Kavanaugh A, Soriano E, **Dutz J**, Selmi C, Rampakakis E, Shiff N, Nantel F, Lavie F, Coates L. Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bonaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study. Abstract #2238. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4421-4423.
 60. Kobza A, **Barber MRW**, Cardwell F, **Clarke AE**, Elliot S, Gibson P, Soliman N, Skeith L. Health Information Use by Patients Living with Antiphospholipid Antibodies and Antiphospholipid Syndrome. *J Rheumatol*. In Press.
 61. Kobza A, Cardwell F, Elliott S, Gibson P, Soliman N, Skeith L, **Clarke AE, Barber M**. Health information use by patients living with antiphospholipid antibodies and antiphospholipid syndrome. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 1226. AB0004.
 62. Koehn S, Klein D, **Jones CA, Barber C**, Jasper L, **Pham A**, Drummond N. Accessing care for Rheumatoid Arthritis: The role of family physicians. Presented at the Alberta Family Medicine Summit March 1, 2024.
 63. Koopman JJE, Buhler KA, **Choi MY**. From machine learning to clinical practice: phenotypic clusters of anti-MDA5 antibody-positive dermatomyositis. *Brief Bioinform*. 2024 May 23;25(4):bbae303. doi: 10.1093/bib/bbae303.

64. Kundacki B, **Barber M, Clarke AE**, Johnson S, Bruce I, and On behalf of the revised SLE organ damage index (SDI) collaborators. Lupus Damage Index Revision - Item Generation and Reduction Phase. Abstract #2265. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4489-4491.
65. Kundacki B, **Barber M, Clarke AE**, Johnson SR, Bruce IN, And on Behalf of The Revised Systemic Lupus Erythematosus Organ Damage Index Collaborators. Lupus Damage Index Revision – Item Generation and Reduction Phase. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 1009. POS1139.
66. Ladouceur A, **Hudson M**, Behloul H, Curtis J, Pilote L, Bernatsky S. Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data. Abstract #1056. *Arthritis & Rheumatology*. 2023;75(Suppl 9):2080-2082.
67. Ladouceur A, Ezdoglian A, Sparks JA, **Hudson M, Jamal S**, Clifford A, Roberts J, Ye C. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events. *Rheum Dis Clin North Am*. 2024 May;50(2):181-199. doi: 10.1016/j.rdc.2024.01.003. Epub 2024 Feb 22.
68. **Lacaille D, Avina-Zubieta JA, Zheng Y, Lu N, Xie H**. Comparison of Survival on Treatment and Severe Infection Among New Users of Biosimilar vs. Originator Biologics in Inflammatory Arthritis: Population-based Evidence from a Natural Experiment Due to a Policy Change. Abstract #0970. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1909-1910.
69. **Lacaille D, Moolooghy K, Avina-Zubieta JA, Zheng Y, Lu N, Xie H**. Survival on Treatment After Transition to a Biosimilar: Population-Based Evidence from a Natural Experiment Due to a Policy Change. *J Rheumatol*. In Press.
70. **Lacaille D, Moolooghy K, Avina-Zubieta JA, Zheng Y, Lu N, Xie H**. Comparable Safety Among New Users of Biosimilar Versus Originator Anti-Tnfs in Inflammatory Arthritis: Population-Based Evidence from a Natural Experiment Due to a Policy Change. *J Rheumatol*. In Press.
71. **Lacaille D, Moolooghy K, Avina-Zubieta JA, Zheng Y, Lu N, Xie H**. Comparable Safety and Effectiveness Among New Users of Biosimilar vs Originator Anti-TNFs in Inflammatory Arthritis: Population-based Evidence from a Policy Change. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 1331. POS0874.
72. **Lacaille D, Moolooghy K, Avina-Zubieta JA, Zheng Y, Lu N, Xie H**. Comparable Safety and Effectiveness After Transition to a Biosimilar Anti-TNF in Inflammatory Arthritis: Population-based Evidence From a Policy Change. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 1331. AB0192.
73. **Legge A, Lacaille D**. Prevalence of Frailty Among Individuals Living with Rheumatoid Arthritis: A Population-based Cohort Study. Abstract #1275. *Arthritis & Rheumatology*. 2023;75(Suppl 9):2494-2496.
74. **Legge A, Lacaille D**. The Prevalence of Frailty Among Individuals with Rheumatoid Arthritis: a Population-Based Cohort Study. *J Rheumatol*. In Press.

75. Li J, **Hudson M**, Ye C, **Roberts J**, Fifi-Mah A, **Choi M**, **Ho S**, Appleton T, Pope J, Maltez N, **Gonzalez-Arreola L**, **Obrzut A**, **Jamal S**. Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO). Abstract #1063. *Arthritis & Rheumatology*. 2023;75(Suppl 9):2092-2094.
76. Li J, **Hudson M**, Ye C, Fifi-Mah A, **Choi M**, **Ho S**, Appleton T, Pope J, Maltez N, Arreola L, Obrzut A, **Jamal S**. Impact of Aging on Rheumatic Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from The Canadian Research Group of Rheumatology in Immuno-Oncology (Canrio). *J Rheumatol*. In Press.
77. **Li LC**, **Xie H**, Feehan LM, Lu N, **Hoens AM**, **English K**, **Davidson E**, **Backman CL**, **Ramachandran S**, **Wang E**, **Therrien S**, **Mucha J**, Liu-Ambrose T, Shaw C, Miller K, **Lacaille D**. Effectiveness of a Technology-enabled Self-monitoring and Physical Therapist Counselling Program for Improving Self-management Ability in People with Rheumatoid Arthritis: A Randomized Controlled Trial. Abstract #0806. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1612-1614.
78. Loganathan A, Sambataro G, Yoshida A, Dourado E, Zanframundo G, Bozan F, Rivero Gallegos D, Bauer-Ventura I, Yamano Y, Bae S, Lim D, Faghihi-Kashani S, Bonella F, Corte TJ, Doyle T, Fiorentino D, González-Gay M Á, **Hudson M**, Kuwana M, Lundberg IE, Mammen A, Mchugh N, Miller F, Montecucco C, et al on behalf of Classification Criteria of Anti-Synthetase Syndrome (CLASS) project. Navigating complexities of multiple positive myositis autoantibodies: analysis from classification criteria of anti-synthetase syndrome (class) project. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 197. OP0005.
79. **Losciale JM**, **Truong LK**, **Zhang K**, **Silvester-Lee T**, Miciak M, Pajkic A, **Le CY**, **Xie H**, **Hoens AM**, Mosewich A, Hunt MA, Li LC, Roos EM, **Whittaker JL**. Assessing the efficacy of the Stop OsteARthritis (SOAR) program: A randomized delayed-controlled trial for persons at increased risk of early onset post-traumatic knee osteoarthritis. Presented at the Canadian Physiotherapy Association Congress, April 25 – 27, 2024, Vancouver, BC.
80. **Ma JK**, Hu DLK, Sisson M, Cheng J, **Collins JA**, **Davidson E**, **Duffey K**, **Harris L**, **Hoens AM**, **Jiwa S**, **Lacaille D**, **McQuitty S**, **Sequeira L**, **Tsui K**, Walker H, Westby M, **Li LC**. The development of an evidence-informed knowledge translation tool to guide shared decision-making in strength training prescriptions for people with rheumatoid arthritis. Presented at the Canadian Society for Exercise Physiologists Conference, October 11-14. Calgary, AB.
81. Marozoff S, **Lu N**, Loree JM, **Xie H**, **Lacaille D**, **Esdaile JM**, Corradetti B, Malone P, Koehn CL, **Mennell P**, **Hoens A**, **Avina-Zubieta JA**. Population-based analysis of the association between SARS-CoV-2 infection and incident autoimmune diseases. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 406. POS0574.
82. **Marshall DA**, Wen J, Currie GR, **Benseler SM**, Swart JF, Vastert SJ, Yeung RSO, Ohinmaa A. Responsiveness of the EQ-5D-Y-5L parent-proxy version among

children with juvenile idiopathic arthritis. Oral presentation at the International Society for Quality of Life Research (ISOQOL) Annual Conference, Calgary Alberta, Oct 18 – 21, 2023.

83. **McCormick N**, Yokose C, Wei J, Lu N, Wexler D, **De Vera MA**, **Aviña-Zubieta JA**, **Zhang Y**, **Choi HK**. Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study. Abstract #0811. *Arthritis & Rheumatology*. 2023;75(Suppl 9):31623-1626.
84. **McCormick N**, Yokose **C**, **Lu N**, **Choi HK**. Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes. Abstract #0742. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1480-1482.
85. **McCormick N**, Yokose C, Challener GJ, Joshi A, Tanikella S, **Choi HK**. Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients. Abstract #1120. *Arthritis & Rheumatology*. 2023;75(Suppl 9):2201-2203.
86. **McCormick N**, Link, Yokose C, **Lu N**, Zhang Y, **Choi HK**. Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors. Abstract #2428. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4808-4810.
87. **McCormick N**, Joshi A, Terkeltaub R, Merriman T, Yokose C, **Choi H**. Prediagnostic proteomics of gout: prospective cohort study of 48,898 men and women. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 4. OP0051
88. **McCormick N**, Yokose C, **Lu L**, Wexler D, **Avina-Zubieta JA**, **De Vera M**, McCoy R, **Choi H**. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors vs sulfonyleureas for primary and secondary gout prevention among patients with type 2 diabetes receiving metformin monotherapy: target trial emulation studies. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 90. OP0177.
89. **McCormick N**. Pre-diagnostic Immunomodulatory amino acid metabolites and risk of gout, accounting for serum urate: A prospective study of 249,677 individuals and Mendelian randomization analyses. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 308. POS0155.
90. **McCormick N**. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for the risk of kidney stone among gout patients with type 2 diabetes: target trial emulation studies. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 406. POS0251.
91. Meng C, Lee Y, Schieir O, Valois MF, Butler M, Boire G, **Hazelwood G**, Hitchon C, Keystone E, Tin D, Thorne C, Bessette L, Pope J, **Bartlett S**, Bykerk V. Having More Tender Than Swollen Joints Is Associated with Worse Functional Outcomes in Patients with Early RA in a Prospective Real-World Cohort. Abstract #1295. *Arthritis & Rheumatology*. 2023;75(Suppl 9):2533-2534.

92. Meng C, Lee Y, Schieir O, Valois MF, Butler M, Boire G, **Hazlewood G**, Hitchon CA, Keystone E, Tin D, Thorne C, Bessette L, Pope J, **Bartlett SJ**, Bykerk V. Characterizing prevalent non-articular pain at early RA diagnosis and evolution over the first year of RA treatment: results from the Canadian Early Arthritis Cohort study. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 191. OP0064.
93. **Michou L**, Gamache P, Dialahy IZ, Guertin JR, Tarride JE, Brown JP, Jean S. Temporal Trend of Mortality in Paget's Disease Over 20 years in Quebec, Canada. Presented at the Annual meeting of the American society for Bone and Mineral Research in October 15, 2023, Vancouver, Canada.
94. **Michou L**, Paré G, Gagnon E, Petit-Teixeira E, Fernandes MJ. Évolution de l'expression de SUPT20H au cours de la différenciation en macrophages et en ostéoclastes. **Proposed English title:** Evolution of the expression of SUPT20H during the differentiation into macrophages and osteoclasts. Presented at the 36e Congrès Français de Rhumatologie/ Annual Congress of the French Rheumatology Society, Paris, France, 10 au 12 décembre 2023.
95. **Michou L**, Gamache P, Zefania Dialahy I, Guertin JR, Tarride JE, Brown JP, Jean S. Secular trend in cause-specific mortality in Paget's disease of bone compared with the general population. Presented at the European Calcified Tissue Society annual meeting, May 23 - 28, 2024, Marseille, France.
96. Morand E, Arriens C, Geraldino-Pardilla L, **Clarke AE**, Pomponi S, Hobar C, Wegman T, Koti R, Banerjee S, Van Vollenhoven RF. Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (tyk2) inhibitor, in systemic lupus erythematosus (SLE): efficacy by baseline demographics and disease characteristics in the phase 2 paisley trial. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 945. POS0527.
97. Munoz-Grajales C, Barraclough M, Diaz Martinez JP, Su J, Bingham K, Kakvan M, Kretzmann R, Tartaglia C, Ruttan L, **Choi M**, Appenzeller S, Marzouk S, Bonilla D, Katz P, Beaton D, Green R, Wither J, Touma Z. Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment. Abstract #0558. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1098-1100.
98. Munoz-Grajales C, Barraclough M, Erdman L, Martinez JD, Bingham K, Kakvan MM, Pozzi Kretzmann R, Tartaglia C, Ruttan L, **Choi M**, Appenzeller S, Marzouk S, Bonilla D, Katz P, Beaton D, Goldenberg A, Green R, Gladman D, Wither J, Touma Z. Association of Serum Analytes with SLE Cognitive Impairment Phenotypes Formed by Machine Learning: Mmp-9, s100A8/a9, Il-6, Il-10, and Ng2. *J Rheumatol*. In Press.
99. Muñoz-Grajales C, Barraclough ML, Diaz-Martinez JP, Su J, Bingham K, Kakvan M, Kretzmann RP, Tartaglia MC, Ruttan L, **Choi MY**, Appenzeller S, Marzouk S, Bonilla D, Katz P, Beaton D, Green R, Gladman DD, Wither J, Touma Z. Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment. *Front Immunol*. 2024 Jan 25;14:1326751. doi: 10.3389/fimmu.2023.1326751. eCollection 2023.

100. Neyer MA, Henry RS, Carrier ME, Kwakkenbos L, Gottesman K, Guillot G, Lawrie-Jones A, Mayes MD, Mouthon L, Nielson WR, Richard M, Sauv  M, Malcarne VL, **Bartlett SJ**, Thombs BD. Coping with Chronic Illness – Is Resilience the Key? A Scleroderma Patient-Centered Intervention Network (SPIN) Cross-Sectional Study. International Convention of Psychological Science, Brussels, Belgium. March 2023.
101. Nguyen N, Bernatsky S, Colmegna I, Berger C, Carrier N, Allard-Chamard H, Liang P, Roux S, Boire G, **Hudson M**. Predicting Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis Using an Extended Set of Clinical and Laboratory Variables Remains Suboptimal. *J Rheumatol*. In Press.
102. Nikolic R, Krustev E, Fritzler M, **Choi M**, Moran Toro C. Knowledge Gaps in Treatment and Biomarkers for Melanoma Differentiation-Associated Gene 5 Dermatomyositis with Rapidly Progressive Interstitial Lung Disease. *J Rheumatol*. In Press.
103. Nikolic RPA, Virk MK, Buhler KA, Costenbader KH, **Choi MY**, Weber B. Hydroxychloroquine and Chloroquine-Induced Cardiac Arrhythmias and Sudden Cardiac Death in Patients with Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis. *J Cardiovasc Pharmacol*. 2024 May 8. doi: 10.1097/FJC.0000000000001589. Online ahead of print.
104. Nowrouzi-Kia B, Howe A, Li A, Jules K, Tan J, Sadek M, Kakvan M, Chattu VK, Bani-Fatemi A, Bonilla D, Nielsen W, **Anderson N**, **Avina-Zubieta JA**, Fox M, Shaw W, Haaland DA, Pope J, **Fortin P**, Bingham K, Peschken C, Rozenbojm N, Urowitz M, Reynolds J, Ivory C, Gladman D, Lim , Sanchez-Geuerrero J, Keeling S, Katz P, Touma Z. Work Disability in Patients with Systemic Lupus Erythematosus: a Pan-Canadian Qualitative Study. *J Rheumatol*. In Press.
105. Oakes EG, Buhler K, Adejorin I, Marks K, Dillon E, Ellrod J, Yee J, Rao D, **Choi M**, Costenbader K. Post-COVID-19 Autoimmune Serologies and Immunophenotypes. Abstract #0221. *Arthritis & Rheumatology*. 2023;75(Suppl 9):428-431.
106. Oakes EG, Ellrod J, **Choi M**, Yee J, Guan H, Costenbader K. Adverse Events Among Patients with and Without Autoimmune Rheumatic Disease Prescribed SGLT2 Inhibitors. Abstract #0741. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1477-1480.
107. Oganesyanyan A, Sharp R, O'Neill P, Aranow C, Arnaud L, Askanase A, Cheol Bae S, Bernatsky S, Bruce I, JBuyon J, Chatham W, **Clarke AE**, Costedoat-Chalumeau N, Dooley MA, **Fortin PR**, Ginzler E, Gladman D, Gordon C, Hanly JG, Inanç M, Isenberg D, Jacobsen S, Jonsen A, Kalunian K, Kamen DL, Lim SS, Mak A, Morand E, Peschken C, Petri M, Pons-Estel BA, Rahman A, Ramsey-Goldman R, Reynolds J, Romero-Diaz J, Ruiz-Iratorza G, Sanchez-Guerrero J, Steinsson K, Urowitz M, van Vollenhoven R, Vinet E, Voskuyl A, Wallace D, Manzi S, Jones KL, Boackle SA. Effect on Lupus Outcomes of the Protective Allele at rs1876453 in the Complement Receptor 2 Gene. Abstract #2311. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4582-4583.

108. Parastandehchehr G, Vinet E, Arnaud L, Costedoat-Chalumeau N, **Fortin PR**, Reynolds J, Thorne C, Touma Z, Wallace D, Werth V, Bernatsky S, Mendel A, on behalf of SLICC and CaNIOS investigators. Quinacrine in Systemic Lupus Erythematosus: An International and Canadian Survey of Availability, Effectiveness, and Safety. *J Rheumatol*. In Press.
109. Pianarosa E, Roach P, McLane P, Elliott M, Holroyd B, **McQuitty S**, Katz S, Russon N, Lin K, **Barber CEB**, **Barnabe C**. Identifying Inflammatory Arthritis Ambulatory Care Service Model Enhancements Needed to Reduce Avoidable Emergency Department Use. Abstract #1008. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1982-1984.
110. Pianarosa E, Roach P, McLane P, Elliott M, Holroyd B, **McQuitty S**, Katz S, Russon N, Lin K, **Barber C**, **Barnabe C**. Reducing Avoidable Care Use and Improving Care Experience: a Focus on Emergency Department Use by Persons with Inflammatory Arthritis. *J Rheumatol*. In Press.
111. Pianarosa E, Roach P, **Barber C**, Holroyd B, McLane P, Katz SJ, Elliott M, Russon N, Hildebrandt C, **Chomistek K**, **Davidson E**, Keeling S, **Barnabe C**. Inflammatory Arthritis Patient Decision Making to Attend, and Experience of, Emergency Department Use. *J Rheumatol*. 2024 Jun 1:jrheum.2024-0111. doi: 10.3899/jrheum.2024-0111. Online ahead of print.
112. Polley DJ, Latham P, **Choi MY**, Buhler KA, Fritzler MJ, Fritzler ML. Identification of novel clusters of co-expressing cytokines in a diagnostic cytokine multiplex test. *Front Immunol*. 2023 Jul 31;14:1223817. doi: 10.3389/fimmu.2023.1223817. eCollection 2023.
113. Poole J, Carandang K, Hill MT, Koch AM, **Rogers P**, **Lacaille D**. Adaptation of the Making it Work™ for People with Systemic Sclerosis. Abstract #2090. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4129-4130.
114. Poole JL, Carandang K, Thelander-Hill M, **Lacaille D**, Dionne T. Relationships between job self-efficacy and risk of work disability in people with systemic sclerosis enrolled in the making it work systemic sclerosis program. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 496. POS0153-HPR.
115. Powell M, Bykerk V, Schieir O, Valois MF, **Bartlett S**, Bessette L, Boire G, Hitchon C, Keystone E, Pope J, Thorne C, Tin D, **Hazlewood G** and Canadian Early Arthritis Cohort (CATCH) Investigators. Real World Patterns of Advanced Therapy Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort. Abstract #0428. *Arthritis & Rheumatology*. 2023;75(Suppl 9):829-830.
116. Powell M, Bykerk V, Schieir S, Valois MF, **Bartlett S**, Bessette L, Boire G, Hitchon C, Keystone E, Pope J, Thorne C, Tin D, **Hazlewood G**, CATCH Canadian Early Arthritis Cohort Investigators. Real World Patterns of Advanced Therapy Tapering in Early Rheumatoid Arthritis: Data from The Canadian Early Arthritis Cohort. *J Rheumatol*. In Press.
117. **Primeau C**, **Bayraktar D**, Kho M, Tong C, **Li LC**. What challenges and opportunities do physiotherapists encounter in integrating interventions to promote sleep in in

- individuals with rheumatoid arthritis? *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 502. POS0419-HPR,
118. **Prlic H**, Sayre EC, **Xie H**, **Ojo D**, **Tan J**, **Li LC**, **Lacaille D**, **Avina-Zubieta JA**, **Esdale JM**, **Cibere J**. Osteoarthritis and Cognitive Function: a Population-Based Cross-Sectional Study. *J Rheumatol*. In Press.
 119. Proulx L, Richards D, Coish J, Schieir O, Kern J, Keystone E, Pope J, Thorne C, Boire G, **Bartlett SJ**, **Hazlewood G**, Tin D, Hitchon CA, Veilleux ME, Beaulieu MC, Bykerk V. Getting research into the hands of people living with rheumatoid arthritis: a novel approach from the Canadian Early Arthritis Cohort (catch). *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 51. OPOS0083-PARE.
 120. Roberts N, Li J, **Bansback N**, Tseng CW, Shiboski S, Schmajuk G, Yazdany J. Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022. Abstract #1617. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3206-3207.
 121. Satirer Ö, **Benseler S**, Kuemmerle-Deschner JB. Pregnancy outcomes in caps patients on il-1 inhibition. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 552. POS1183.
 122. Satirer Ö, Henes H, Doering M, Lesk T, **Benseler S**, Kuemmerle-Deschner JB. Pediatric autologous hematopoietic stem cell transplantation in treatment-resistant autoimmune diseases: a real-life single-center experience. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 2037. AB1372.
 123. Savarimuthu V, Ladouceur A, Terry O, Roberts J, Pope J, Appleton T, **Hoa S**, Fifi-Mah A, Maltez N, Saltman A, Himmel M, **Colmegna I**, Cho L, Schmidt E, Berger C, Barnette T, **Gonzalez-Arreola L**, Ye C, **Jamal S**, **Hudson M**. Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort. Abstract #1055. *Arthritis & Rheumatology*. 2023;75(Suppl 9):2077-2080.
 124. Shapiro J, Choi F, Xu A, Duong T, Gingras AC, Bernatsky S, **Benseler S**, Yeung R. Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases. Abstract #2478. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4915-4918.
 125. Shen HC, Ivensky V, Troyanov Y, Bourre-Tessier J, Zarka F, **Hoa S**, Nehme J, Makhzoum JP, Mansour AM, Meunier RS, Mereniuk A, Lim D, Raynauld JP, Rich E, Goulet JR, Landry M, Bouchard-Marmen M, Leclair V, Allard-Chamard H, **Hudson M**, O'Ferrall E, Massie R, Karamchandani J, Ellezam B, Targoff IN, Satoh M, Fritzier M, J Senecal JL, Meyer A, Landon-Cardinal O. From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence. Abstract #1960. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3889-3890.

126. Suissa S, Comin E, Suissa K, **Hudson M**. Glucosamine and cancer incidence in patients with osteoarthritis: real-world observational study. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 391. POS0374.
127. Tam A, Badesha J, Guh D, **Bansback N**, Hollis A, Grootendorst P, Bae SC, **Anis A, Zhang W**. Do policies that improve biosimilar uptake also help achieve greater expenditure control? A cross-country policy analysis. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 534. POS0149.
128. **Tan J, Avina-Zubieta JA**, Lee JLF, **Fortin PR, Colmegna I, Gonzalez Arreola L**, Berger C, Larch M, Hitchon C, Richards D, Bernatsky S. When Should I Get My Next Booster? Active Surveillance of COVID-19 Breakthrough Infections in Canadian Patients with Immune-Mediated Inflammatory Diseases. Abstract #0213. *Arthritis & Rheumatology*. 2023;75(Suppl 9):410-412.
129. **Tan J, Avina-Zubieta JA**. Lee J LF, **Fortin PR, Colmegna I, Gonzalez Arreola L**, Berger C, Larché M, Hitchon C, Richards D, **Lalonde N**, Bernatsky S. When Should I Get My Next Booster? Active Surveillance of COVID-19 Breakthrough Infections in Canadian Patients with Immune-Mediated Inflammatory Diseases. *J Rheumatol*. In Press.
130. **Tan J**, Sergeant A, **De Vera M, Amiri N**. Expectant Anxiety: Impact of Medication Adjustments on Anxiety and Patient-Reported Outcomes in Pregnant Patients with Rheumatic Diseases. *J Rheumatol*. In Press.
131. **Tan J, De Vera M, Amiri N**. Back to the clinic? Evaluating pregnancy management outcomes in virtual and in-person care. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 2140. AB1538.
132. Thaler J, Ahmadzadeh Y, Andrade D, Skeith L, Tektonidou M, Sciascia S, Pengo V, Pardos-Gea J, Ruiz-Irastorza G, Lopez-Pedreria C, Belmont HM, Nina K, **Fortin PR**, Wahl D, Gerosa M, De Jesús G, Zhang Z, Atsuma T, Efthymiou M, Ware Branch D, Andreoli L, Rodriguez Almaraz E, Petri M, Pazzola G, Cervera R, Artim Esen B, Shi H, Knight J, Pons-Estel G, Willis R, Duarte-Garcia A, Bertolaccini ML, Cohen H, Erkan D, and On Behalf Of APS ACTION. First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). Abstract #1604. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3177-3179.
133. **Thomas M, Harrison M, Barnabe C, Avina-Zubieta A**, Ronquillo C, Kuluva M, Samson A, **Trehan N, De Vera M**. Equity, Diversity, and Inclusion in Canadian Rheumatology Research: a Qualitative Study Exploring Researcher Perspectives. *J Rheumatol*. In Press.
134. Toupin-April K, Stringer E, Proulx L, Trehan N, Sirotych E, Abrahams N, Sirois A, Huber N, Duffy C, Morgan E, Cohen J, Gaboury I, Li L, Cavallo S, Connelly M, Décary S, El Tal T, Guzman J, Ghio D, Knight A, Luca N, Martini R, Tugwell P, Stinson J. Going Beyond Pain: Consensus Meetings to Expand The Jia Option Map with Other Symptoms and Functional Activities. *J Rheumatol*. In Press.

135. **Trehan N**, Abrahams N. Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease. Abstract #PP14. *Arthritis & Rheumatology*. 2023;75(Suppl 9):5262-5263.
136. **Trehan N**, Proulx L, Dukes I. Voices Unheard: Unmasking the Hidden Challenges of Youth with Rheumatic Diseases. Abstract #1259. *Arthritis & Rheumatology*. 2023;75(Suppl 9):2463-2465.
137. Tsyruk O, Chandran V, Hitchon C, J. **Avina-Zubieta A, Colmegna I, Fortin PR**, Larche M, Boire G, Lukusa L, Bowish D, Kaplan GG, Pereira D, Dayam R, Lee JLF, Turnbull E, Valerio V, Proulx L, Gunderson J, Gingras AC, Bernatsky S. Safety & Immunogenicity of COVID-19 Vaccines in Systemic Immune Mediated Inflammatory Diseases (SUCCEED). Abstract #1796. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3565-3568.
138. Tsyruk O, Kaplan GG, **Fortin PR**, Hitchon C, Chandran V, Larché ML, **Avina-Zubieta JA**, Boire G, **Colmegna I, Lacaille D, Lalonde N**, Proulx L, Gunderson J, Richards DP, Allard-Chamard H, Roux S, Kirmani A, Lodhi S, Heesels L, Markovinovic A, Lukusa L, Pereira D, Lee J, Bernatsky S. Safety & Immunogenicity of Covid-19 Vaccines in Systemic Immune Mediated Inflammatory Diseases (Succeed): Preliminary Results on Severe Adverse Events. *J Rheumatol*. In Press.
139. Vedadi A, Khairalla R, Che A, Nagee A, Saqib M, Ayub A, Wasim A, Macanovic S, Orchanian-Cheff A, Selzner-Malekkiani N, **Bartlett S**, Mucsi I. Patient-reported outcomes and patient-reported outcome measures in liver transplantation: a scoping review. *Quality of life research, an international journal of quality of life aspects of treatment, care and rehabilitation*. 2023;32(9):2435-45. Epub 20230406. doi: 10.1007/s11136-023-03405-1.
140. **Wang E**, Chan A, Lendvoy K, Canesco M, Sayre EC, Koehn C, Fox TL. Health Literacy in Arthritis Care in Canada: The Perspective of BipoC Individuals Across Age Categories. *J Rheumatol*. In Press.
141. **Wang E**, Chan A, Lendvoy K, Canesco M, Sayre E, Koehn CL, Fox TL. Health literacy in arthritis care in Canada: the perspective of bipoC men. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 518. POS1436-PARE.
142. Wei J, Tarnopolsky M, **Hudson M**, Mitchell R, Buhler K, Dufour A, de Almeida L, **Fortin PR**, Boilard E, Becker Y, Hatcher E, Zhang MF, Fritzler M, **Choi M**. Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles. Abstract #2578. *Arthritis & Rheumatology*. 2023;75(Suppl 9):5131-5134.
143. Wiens D, Robinson D, Smolik I, **Barnabe C**, El-Gabalawy H, O'Neil L. Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives. Abstract #1015. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1996-1998.
144. Wilson T, **Fortin PR, Colmegna I**, Theriault S, Amiable N, Godbout A, **Hazlewood G**. Switch or Stay the Same? Preferences of People with Autoimmune Disease on

- Rituximab for Different Types of COVID-19 Vaccine Boosters. Abstract #2036. *Arthritis & Rheumatology*. 2023;75(Suppl 9):4032-4033.
145. Wojcek R, Knisely M, Bailey D, Somers T, Kwakkenbos L, Carrier ME, Nielson W, **Bartlett SJ**, Malcarne V, **Hudson M**, Levis B, Benedetti A, Mouthon L, Thombs B, Silva S. Patterns of patient-reported symptoms in systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) study. *Annals of the Rheumatic Diseases*. 2023;82(Suppl 1):182-3. doi: 10.1136/annrheumdis-2023-eular.4991.
 146. Yacyshyn E, Gulati S, Hung W, Voaklander D, **Jones A**. A Population-Based Study of Vasculitis Among Farmers and Urban Residents in Alberta.
 147. Yacyshyn E, Gulati S, Lowe S, **Jones A**, Turk T, Yamamoto S, Gregg K, Kolewaski L, Olson J, Paul P, Sadowski C. Exploring the health and cannabis use among young and middle-aged adults with rheumatologic conditions in Alberta, Canada. Abstract #1825. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3628-3629.
 148. Yacyshyn E, Gulati S, Lowe S, **Jones A**, Turk T, Yamamoto S, Gregg K, Kolewaski L, Olson J, Paul P, Sadowski C. Investigating the health profiles and the prevalence and correlates of cannabis use among patients accessing rheumatologic care in Alberta, Canada. Abstract #1826. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3629-3630.
 149. Yazdany J, Jorge A, **Barber C**, Barnado A, Bermas B, Duarte-Garcia A, Bennett A, Feldman C, Garg S, Haseley L, Jatwani S, Johansson T, Limanni A, Machua W, Rodgers W, Rovin B, Santiago-Casas Y, Suter L, Zell J, Katz P, Bartels CM. Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States. Abstract #1899. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3762-3764.
 150. Yee J, Feldman C, Oakes EG, Ellrodt J, **Choi M**, Karlson E, Costenbader K. Cost-related Medication Burden for Patients with and Without Systemic Autoimmune Rheumatic Diseases. Abstract #1016. *Arthritis & Rheumatology*. 2023;75(Suppl 9):1998-2000.
 151. Yee J, Oakes EG, **Choi M**, Feldman C, Karlson E, Costenbader K. Depression, Anxiety and Post-Traumatic Stress Disorder in Association with Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program. Abstract #0122. *Arthritis & Rheumatology*. 2023;75(Suppl 9):217-219.
 152. Yelnik C, Chaturvedi S, Labreuche J, Pan XP, Belmont HM, Nina K, **Fortin PR**, Ware Branch D, Zuo Y, Willis R, Brodsky R, Salmon J, Bertolaccini ML, Cohen H, Petri M, Erkan D and On Behalf Of APS ACTION. Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). Abstract #1605. *Arthritis & Rheumatology*. 2023;75(Suppl 9):3180-3182.
 153. Yelnik CM, Erton ZB, Drumez E, Cheildze D, de Andrade D, **Clarke A**, Tektonidou MG, Sciascia S, Pardos-Gea J, Pengo V, Ruiz-Irastorza G, Belmont HM, Pedrera

- CL, **Fortin PR**, Wahl D, Gerosa M, Kello N, Signorelli F, Atsumi T, Ji L, Efthymiou M, Branch DW, Nalli C, Rodriguez-Almaraz E, Petri M, Cervera R, Shi H, Zuo Y, Artim-Esen B, Pons-Estel G, Willis R, **Barber MRW**, Skeith L, Bertolaccini ML, Cohen H, Roubey R, Erkan D. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository ("Registry"). *Semin Arthritis Rheum.* 2023 Dec 20;65:152347. doi: 10.1016/j.semarthrit.2023.152347. Online ahead of print.
154. Yokose C, Challener G, Zhou B, **McCormick N**, Tanikella S, Panchot, K, Kohler MMJ, JYinh J, Zhang Y, Bates D, Januzzi J, Sise M, Wexler D, **Choi HK**. Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis. Abstract #1117. *Arthritis & Rheumatology.* 2023;75(Suppl 9):2195-2197.
 155. Yokose C, Zhou B, **McCormick N**, Tanikella S, Kohler MJ, Yinh J, Zhang Y, Wexler D, Choi HK. The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System. Abstract #1116. *Arthritis & Rheumatology.* 2023;75(Suppl 9):2193-2195.
 156. Yokose C, Eide SE, Huber FA, Simeone FJ, Ghoshhajra BB, **Shojania K**, Nicolaou S, Becce F, **Choi HK**. Frequently Encountered Artifacts in the Application of Dual-Energy CT to Cardiovascular Imaging for Urate Crystals in Gout: A Matched-Control Study. *Arthritis Care Res (Hoboken).* 2024 Feb 5. doi: 10.1002/acr.25312. Online ahead of print.
 157. Yokose C, **McCormick N**, **Lu N**, Abhishek A, Gaffo A, Zhang Y, **Choi H**. Cardiovascular safety of colchicine and nSAID prophylaxis with urate-lowering therapy initiation: target trial emulation (tte) analyses. *Ann Rheum Dis.* Vol. 83, supplement 1, year 2024, page 368.POS0053.
 158. Zanframundo G, Dourado E, Bauer-Ventura I, Faghihi-Kashani S, Yoshida A, Loganathan A, Rivero Gallegos D, Lim D, Bozan F, Sambataro G, Bae S, Yamano Y, Bonella FF, J. Corte T, Doyle T, Fiorentino D, González-Gay MA, **Hudson M**, Kuwana M, Lundberg IE, Mammen A, Mchugh N, Miller F, Montecucco C, et al on behalf of CLASS project working group and contributing centres. The role of multi-criteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the class project. *Ann Rheum Dis.* Vol. 83, supplement 1, year 2024, page 92. OP0015.
 159. **Zhao K, Xie H, Dehghan N, Esdaile JM, Avina-Zubieta JA**. Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis. Abstract #1544 *Arthritis & Rheumatology.* 2023;75(Suppl 9):3045-3046.
 160. **Zhao K, Dehghan N, Xie H, Esdaile JM, Avina-Zubieta JA**. Increased risk of severe infection in patients with antineutrophil cytoplasmic antibody-associated vasculitides: A population-based trend analysis. *Ann Rheum Dis.* Vol. 83, supplement 1, year 2024, page 182.

161. Zhang H, **Cibere J**, Jones CE, Wilson DR. Early Hip Cartilage Degeneration in Young Patients Meeting a Consensus Definition of Femoroacetabular Impingement Syndrome. Podium presentation, International Workshop on Osteoarthritis Imaging, Lausanne, Switzerland, June 28-30, 2023.
162. **Zhou Y, Lacaille D**, Zheng Y, Qian Y, Nosyk B, **Xie H**. The impact of biosimilar use on healthcare utilization among new users of etanercept for inflammatory arthritis: a population-based regression discontinuity analysis. *Ann Rheum Dis*. Vol. 83, supplement 1, year 2024, page 1349. AB0222.